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To improve detection of the misuse of erythropoietin (EPO) for performance 
enhancing purposes, this PhD examined ways to improve recovery and preanalysis 
concentration of EPO from urine. It also looked at ways to enhance the signal in 
liquid chromatography tandem mass spectrometry of the acidic glycopeptides from 
digested EPO, and at distinguishing between recombinant EPO and human urinary 
EPO based on differences in their glycosylation. Due to a shortage of supply of 
available analytical standards, model glycoproteins were frequently used in place of 
endogenous EPO.   
 
Immunoextraction with magnetic beads effectively recovered EPO from urine which 
had been filtered to remove large proteins, but was unsuccessful from unfiltered 
urine, suggesting more research into the right choice of antibody was needed. 
 
The specific and reversible binding of boronic acids to cis-diol groups found in the 
glycan groups of glycoproteins was investigated as a device for the selective binding 
of EPO. Attempts were made to functionalise mesoporous silica for use as a column 
packing material. Although there was evidence that at least one method of 
functionalisation was successful, the use of this silica to extract glycoproteins and 
glycopeptides was not. 
 
Signal enhancement through the introduction of ‘superchargers’ into LC solvents 
was investigated. This was effective with small molecules, and also improved 
detection of sialylated glycopeptides. The results do not fit entirely with current 
models of how superchargers exert their effect, suggesting they are incomplete. 
 
Finally, the cleavage, digestion and derivatisation of N-glycans to identify bisected 
and non-bisected structures as a way to discriminate between rEPO and huEPO was 
examined.  Samples were analysed using LC-MS and CE-LIF, and although much of 
the work was carried out using a model glycoprotein, there is some evidence that the 
approach may be capable of discriminating between artificial and endogenous EPO 
at the levels found in anti-doping samples. 
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1.1 Erythropoietin – a brief history 
 
Erythropoietin (EPO) is a glycoprotein hormone produced principally by the kidney 
(and in smaller amounts by the liver, spleen, brain, bone marrow and lungs) that 
regulates red-blood cell production, by binding to receptors on bone marrow cells 
and initiating an intracellular phosphorylation cascade which stimulates 
erythropoiesis. It also acts to protect red blood cells and other cell types from 
apoptosis (Elliott, Pham et al. 2008). Its existence was definitively shown in 1953 by 
Professor Allan Erslev, who demonstrated significant production of immature red 
blood cells in rabbits transfused with large amounts of plasma from anaemic rabbits 
(Erslev 1953).  
Attempts to isolate the protein proved problematic. Discussing the isolation of the 
protein, Goldwasser and Kung wrote in 1968 that to obtain 10 mg of EPO, 3250 L of 
human urine would be required, or ‘about 3 yr’s daily collection from a single 
patient, or one month’s collection from 36 patients, which does not seem to be an 
impossible goal’ (Goldwasser and Kung 1968). In 1977, nine years later, they were 
finally successful in doing so (Miyake, Kung et al. 1977). Their isolation of EPO 
was carried out from the urine of aplastic anaemia patients, who produce excess 
amounts of the hormone. Nonetheless, 1500 L of urine was required, and the 
extraction process involved seven steps, including ion exchange chromatography, 
ethanol precipitation, gel filtration and adsorption chromatography using 
hydroxylapatite. The final product had an activity of 70,400 units/mg, and enabled 
the development of a method for cloning the gene for EPO. 
In 1985, a method for the cloning of the human EPO gene and the expression of a 
cDNA clone in hybrid monkey cells to produce a synthetic product was published in 
Nature (Jacobs, Shoemaker et al. 1985); later that year a second paper was published 
(Lin, Suggs et al. 1985), demonstrating the cloning of the human EPO gene and its 
expression in Chinese hamster ovary (CHO) cells. This technique was patented by 
Amgen and used to produce their first commercial synthetic EPO product, Epogen, 
which received its first clinical trial in 1987 (Eschbach, Egrie et al. 1987). Since 
then, attempts to increase the efficacy of the drug have resulted in the production of 
other recombinant forms of the hormone including epoietin-beta, or betapoietin (also 
produced in Chinese hamster ovary cells) and Dynepo (produced in human cell 
cultures), as well as darbepoetin, commercially called Aranesp or NESP, a similar 
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erythropoeisis stimulating protein. More recently, since the expiration of the patent 
on recombinant EPO (rEPO), a number of biosimilar products have been produced in 
laboratories around the world (Schellekens 2009). Other products which act in a 
similar fashion include Hypoxia Inducible Factor (HIF) stabilisers, which act to 
increase endogenous EPO production; MIRCERA (known commonly as CERA), a 
pegylated beta EPO; and EPO mimetic peptides, such as Hematide, which act in the 
same way as EPO although they are structurally unrelated. 
 
1.2 EPO – regulation of production 
 
The role of EPO is to maintain red blood cell levels within the normal physiological 
range, and to restore them after haemorrhage or disease. However, EPO production 
is regulated entirely by tissue oxygen levels. Low levels of oxygen cause the 
production of proteins called Hypoxia Inducible Transcription factors (HIFs), which 
induce the expression of the EPO gene. As a result, athletes can induce the 
production of greater numbers of red blood cells by training at altitude, where 
oxygen levels are lower, and an increase in EPO levels has been demonstrated in 
people moved from sea level to higher altitudes (Faura, Ramos et al. 1969; Abbrecht 
and Littell 1972). These HIFs are hydroxylated in the presence of oxygen, causing 
them to be digested by proteosomes, and at the same time reducing their DNA 
binding capacity, stopping gene expression (Bruegge, Jelkmann et al. 2007). (See 
Figure 1.1). The levels of EPO found in serum can vary quite widely. One study by 
Jelkmann and Wiedemann found that the mean EPO level was 6 U/L, but the range 
was 2 to 25 U/L in 19 serum samples (Jelkmann and Wiedemann 1990). 
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Figure 1.1: Biochemical pathway resulting in EPO production in hypoxic conditions 
(LaManna, Chavez et al. 2004) (reproduced with permission) 
 
1.3 EPO – binding to receptors and signal transduction 
 
EPO is secreted into the blood stream, and binds to membrane-bound erythropoietin 
receptors, EPO-R, on its target cells (Chang, Sikkema et al. 1974). These are mainly 
found on the burst-forming units-erythroid (BFU-E) and the colony-forming units-
erythroid (CFU-E) cells of the bone marrow (Wu, Liu et al. 1995). The EPO-R is a 
glycoprotein consisting of 484 amino acids with one N-glycosylation site. This, 
along with phosphorylation, increases the size of the receptor from 52.6 kDa to about 
60 kDa. Two receptor molecules form a homodimer, binding one EPO molecule 
(Livnah, Stura et al. 1999). Binding induces a conformational change in the two 
receptor molecules, resulting in tighter binding between them. This in turn activates 
two Janus kinases (JAK2) on the cytoplasmic region of the receptor, initiating the 
phosphorylation cascade (Zhao, Dong et al. 2009). The effect of EPO is terminated 
by the action of the haematopoietic cell phosphatase (HCP) which catalyses JAK2 
de-phosphorylation (Klingmuller, Lorenz et al. 1995; Yi, Zhang et al. 1995) On de-
phosphorylation, the EPO/EPO-R complex is internalised and degraded by 
proteosomes and lysosomes (Verdier, Walrafen et al. 2000). 
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1.4 Pharmacokinetics of EPO 
 
Following intravenous (IV) administration, EPO shows bi-exponential elimination 
kinetics, with a rapid fall in the first hour, followed by a prolonged and slower loss 
afterwards. The initial fall is thought to be due to uptake and degradation by cells 
with EPO-R receptors, and this fits with evidence that the bimodal nature of the 
elimination is more prominent when small amounts are administered and can be 
absent when large amounts are given. This suggests that the mechanism of initial 
elimination is susceptible to saturation (Cheung, Goon et al. 1998; MacDougall, 
Gray et al. 1999) (see Figure 1.2). 
 
Figure 1.2: Mean serum erythropoietin (EPO) concentration-time profiles 
(uncorrected for baseline erythropoietin levels) for subjects receiving subcutaneous 
single- or multiple-dose regimens. From Cheung, Goon et al. 1998; reprinted with 
permission 
 
The half life of epoetin-alpha and beta is 6-9 hours after IV administration. That of 
darbepoietin is three to four times longer (25 h) (MacDougall, Gray et al. 1999), 
while that of CERA is longer still (130-140 h) (Macdougall, Robson et al. 2006). 
The longer life span of these newer epoetins means that dosing strategies can include 
fewer administrations, with weekly or even monthly injections. Darbepoietin has 
also been shown to be more potent in rats and mice, with a single dose of 
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darbepoietin given to mice once weekly seen to be as effective as the same dose of 
rEPO given three times a week (Egrie, Dwyer et al. 2003). This effect has not been 
seen in renal failure patients, however (Jacobs, Frei et al. 2005), where no difference 
in the effectiveness of darbepoietin compared to epoetin alpha or beta was detected. 
 
1.5 EPO structure 
 
Figure 1.3: Predicted structure of glycosylated human Erythropoietin. Erythropoietin 
exists as a mixture of glycosylated variants (glycoforms), and glycosylation is 
known to modulate its biological function. The three high-mannose N-linked 
oligosaccharides (Man_9 GlcNAc_2) are shown in purple, the single O-linked 
glycan (alpha-GalNAc) is shown in pink. The structure in the image represents a 
single glycoform that is the origin from which all others are generated. Figure made 
by the Woods group using Chimera. Reprinted with permission from 
http://glycam.ccrc.uga.edu/ccrc/ 
 
EPO is a class I cytokine glycoprotein which in its native state consists of four α-
helical bundles, creating a hydrophobic core (Figure 1.3). With the exception of 
darbepoietin, all erythropoietins share the same amino acid sequence (Figure 1.4), 
with 165 amino acids including three N-glycosylated asparagines (Asn24, Asn38 and 
Asn83) and one O-glycosylated serine (Ser126). The attached carbohydrates are 
responsible for about 40% of the approximate 30.4 kDa mass of EPO. Darbepoietin 
 25 
contains an extra two N-linked glycosylation sites (Asn30 and Asn88), which appears 
to extend the drug’s serum half-life and in vivo biological activity (Egrie and Browne 
2001), as mentioned above. They also increase the molecular mass, to about 38.5 
kDa. Glycan groups consist of bi, tri and tetra-antennary structures with differing 
degrees of sialylation and N-acetyl lactosamine repeats. Glycosylation of peptides 
and proteins, unlike amino acid sequence, is not coded for by DNA and is dependent 
on cellular conditions, including temperature, pH and physiological levels of 
biochemicals. As a result, it is not surprising that quantitative and qualitative 
differences appear to exist in the glycosylation of the different EPO forms, with a 
greater variation in those found in EPO alpha and beta compared with Dynepo (Llop, 
Gutierrez-Gallego et al. 2008). There is also evidence that sialic acid variants not 
produced endogenously in humans (due to a lack of the necessary enzyme) can be 
detected in preparations of synthetic EPO (Groleau, Desharnais et al. 2008). These 
differences, and the specific rEPOs in which they are found, will be discussed in 
greater detail below. 
 
1 APPRLICDSR VLERYLLEAK EAENITTGCA EHCSLNENIT 
41 VPDTKVNFYA WKRMEVGQQA VEVWQGLALL SEAVLRGQAL 
81 LVNSSQPWEP LQLHVDKAVS GLRSLTTLLR ALGAQKEAIS 




















Figure 1.4: Amino acid sequence of human EPO; active form cleaved from the 192 
amino acid precursor, the full sequence of which is available at 
http://www.uniprot.org/uniprot/B7ZKK5 
 
The peptide core of the hormone is responsible for its erythropoietic effects, while 
the presence of the glycan groups seems to be responsible for its in vivo lifespan. 
Rapid elimination of epoietins appears to be mediated by binding to receptors, which 
is inversely correlated with the extent of glycosylation (Darling, Kuchibhotla et al. 
2002; Elliott, Egrie et al. 2004). This would provide an explanation for the increased 
half-life of darbepoietin compared to rEPO, as darbepoietin contains two extra 
glycosylation sites. 
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The presence of a large number of sialic acid residues also appears to be linked to the 
longevity of the hormone in the blood, as glycoproteins with exposed galactose 
residues are rapidly cleared from the blood by binding to asialoglycoprotein 
receptors on hepatocytes (Fukuda, Sasaki et al. 1989), while rEPO also shows 
greater binding affinity for EPO-R after desialylation (Takeuchi, Takasaki et al. 
1990).  
The peptide backbone of CERA is also the same as other epoetins; however, it is 
modified by reacting the N-terminal amino group or the Є-amino group of any lysine 
residue with methoxy polyethylene glycol butanoic acid, producing a pegylated form 
which has a molecular mass of about 60 kDa. As mentioned above, it has a much 
longer half life than other epoetins, up to 6 times longer than darbepoetin and 20 
times longer than Epogen. 
 
1.6 Clinical use of rEPO and potential side effects 
 
Clinically, rEPO is most commonly used to treat patients suffering from anaemia 
caused by chronic kidney disease. It has also been used to treat anaemia in cancer 
sufferers caused by chemotherapy and radiotherapy. There is also evidence that 
erythropoietin could be beneficial in certain neurological disorders, including 
schizophrenia (Wustenberg, Begemann et al. 2011), depression (Miskowiak, Vinberg 
et al. 2010) and cerebral malaria (Casals-Pascual, Idro et al. 2008), although to date 
there have not been any full clinical trials. 
Side effects of rEPO include increased blood viscosity, with concomitant increased 
vascular resistance and the development of hypertension (Raine 1988). Possible 
reasons for this include elevated red cell mass, neurohormonal system disturbances 
and direct effects on the vascular smooth muscle (Zhu and Perazella 2006). Long 
term use of rEPO can also result in pure red cell aplasia, due to the induction of 
antibodies against the EPO molecule. This in turn causes a virtual absence of 
erythroid precursors in the bone marrow, and a very low red blood cell count 
(Casadevall, Eckardt et al. 2005). This is a rare condition, but saw a dramatic 
increase after 1998. The development of the disease in patients with chronic renal 
failure receiving rEPO seems to have been associated with subcutaneous 
administration, and possible reasons could be the use of polysorbate 80 as a stabiliser 
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or the use of uncoated rubber stoppers on syringes. Subsequent changes to the 
production method have resulted in a fall again in the number of cases (Wish 2011). 
Recent research has also suggested that the use of EPO to treat anaemia may impair 
disease control with certain cancers (Brian 2003; Henke, Laszig et al. 2003), can 
result in increased likelihood of venous thromboembolic events (Dicato and Plawny 
2010) and that interaction of rEPO with EPO-R in breast tissue may antagonise the 
effects of chemotherapy (Groner and Hynes 2010). 
 
1.7 Abuse of EPO in sports 
 
Epoetins have been abused in sports because of their potential to improve athletic 
performance, especially in endurance sports. This was demonstrated in studies which 
showed improved exercise tolerance in anaemic dialysis patients given rEPO 
(Muirhead, Keown et al. 2011). The administration of rEPO to healthy human 
subjects also resulted in an increase in blood haemoglobin concentration and an 
increase in maximal aerobic power (VO
2
max) from 4.52 to 4.88 l min
−1
, which was 
the same as resulted from an infusion of the equivalent amount of red blood cells 
(Ekblom and Berglund 1991). A second study found that administration of rEPO to 
male athletes resulted in increased VO
2
max, and greater time to exhaustion 
(Birkeland, Stray-Gundersen et al. 2000). These improvements would seem to be 
advantageous in sporting competitions, although actual athletic performance in terms 
of time trials was not investigated. 
As well as erythropoietic effects, EPO has been shown to depress plasma volume, 
probably through a down regulation of the rennin–angiotensin–aldosterone axis 
(Lundby, Thomsen et al. 2007). The relative contribution of a decrease in plasma 
volume to an increase in arterial oxygen content was calculated to be between 37.9 
and 53.9%, suggesting this seems to be as important as erythropoietic effects in 
increasing circulatory oxygenation.  
The use of rEPO has other advantages over autologous blood transfusions (an 
alternative method also abused for boosting the oxygen carrying capacity of the 
blood), namely the absence of a need for blood removal, storage, transportation and 
re-infusion. 
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The extent to which rEPO is abused is not clear. It is a suspect in the deaths of 20 
cyclists in 4 years, while in 1998 a team was ejected from the Tour de France for 
using the drug, and six other teams withdrew (Eichner 2007). There have been 
claims that its use is still widespread due to difficulties with testing, and in particular 
the short time frame for detection. rEPO is difficult to detect 3 days after use, and it 
has been claimed that if athletes follow a microdosing regime, the use of rEPO may 
be undetectable 12-18 hours after use, enabling even athletes facing daily testing 
potentially to escape being caught (Ashenden, Varlet-Marie et al. 2006). Floyd 
Landis, the 2006 Tour de France winner who was stripped of his title after he tested 
positive for elevated levels of testosterone, has since claimed that many other riders, 
including Lance Armstrong, were guilty of abusing EPO. Armstrong denied the 
claims, and has always tested negative in anti-doping tests, but was recently stripped 
of his seven Tour de France titles and banned for life from cycling by the U.S. Anti-
Doping Agency (USADA). 
As a result of both the potential for improved sporting performance and the health 
risks associated with its use, the International Olympic Committee placed rEPO on 
its list of banned drugs in 1990. 
Recombinant human EPO has also been detected in sporting animals; specifically, it 
has been detected in urine samples from greyhounds (Bartlett, Clancy et al. 2006), 
while cases of racing horses testing positive for rEPO or darbepoietin have also been 
reported (NYDailyNews.com 2008) 
 
1.8 Methods of detecting rEPO use: indirect methods 
 
Initial attempts to counter the use of rEPO were carried out by examining athletes’ 
haematocrits. In 1997, the International Union of Cycling introduced a regulation 
which banned any male athlete whose haematocrit was more than 50%, and any 
female athlete whose was more than 47%. However, they have always stated this 
was done on grounds of safety and that a failed result did not imply rEPO use; as a 
result, athletes were only banned from competition for two weeks after a failed test. 
Attempts to find a serological marker for rEPO meant levels of reticulocytes and 
macrocytes (production of both of which are increased after rEPO administration) 
were considered, as were concentrations of soluble transferrin receptor, a protein 
involved in iron metabolism which influences the production of haemoglobin. 
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Suggestions that rEPO may have fibrinolytic actions led to proposals to test for its 
use in urine by the measurement of urine total degradation products. Markedly 
higher levels of these products were found in 13% of top-level athletes tested by a 
study; since out-of-competition athletes and a control group of hockey players did 
not demonstrate similar results, the authors concluded the top-level athletes had 
taken rEPO (Gareau, Brisson et al. 1995). 
For the Olympic Games in Sydney in 2000, two methods were used to test for rEPO. 
One was an indirect method, based on changes in the haematological profile of 
blood. Specifically, it examined reticulocyte haematocrit, serum EPO, soluble 
transferrin receptor, haematocrit and per cent macrocytes. (Parisotto, Gore et al. 
2000) Two models were developed, to test for current rEPO use (‘ON-model’) and 
previous usage (‘OFF-model’). The ON-model was successful at identifying 94-
100% of rEPO users during the final 2 weeks of the administration phase, and 
produced only one false positive from a possible 189. The OFF-model was applied 
during the wash-out phase and, during the period of 12-21 days after the last rEPO 
injection, it identified 67-72% of recent users with no false positives. 
The indirect method can be further improved by comparing an athlete’s 
haematological profile against their own past history, rather than against values 
derived from the general population. Studies have suggested that between-individual 
variation is the largest source of variation in pooled data (Malcovati, Pascutto et al. 
2003). An approach has been developed which enables an athlete’s baseline profile 
to be estimated from just one prior blood test, eliminating this variability without 
imposing undue logistical constraints (Sharpe, Ashenden et al. 2006). Another 
indirect method uses measurements of haematocrit value, reticulocyte count, soluble 
transferrin receptor content, and concentration of β-globin mRNA in a 
multiparametric formula, and was successful in detecting rEPO abuse in 57.5% of 
the samples examined (Magnani, Corsi et al. 2001). 
These indirect methods are relatively successful in detecting rEPO abuse, and have 
the added advantage that they can also detect other forms of cheating to increase 
oxygen carrying capacity of the blood, including the use of other epoetins or agents 
which act in a similar way. The downside is that blood collection is logistically more 
difficult than urine collection, especially if multiple samples are needed over a 
period of time to develop a baseline for an individual athlete. It is also necessary to 
ensure correct pre-analytical procedures are followed, as it has also been 
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demonstrated that major plasma volume changes, especially those caused by 
dehydration due to exercise, can markedly affect the soluble transferrin receptor and 
the haemoglobin concentrations as well as the haematocrit level (Robinson, Saugy et 
al. 2003). 
In 2010 WADA published a guideline (WADA 2010) for the implementation of 
longitudinal monitoring of athletes’ haematological profiles. It says the following 
markers should be considered for the production of a profile: haematocrit, 
haemoglobin, red blood cells count, percentage of reticulocyte, reticulocytes count, 
mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular 
haemoglobin concentration and index of stimulation, which was generated by the 
OFF-model, and is a mathematical function of the haemoglobin and reticulocyte 
percentage. Samples which are flagged as abnormal with a probability of 99.9% are 
then considered by a panel of three experts, who will decide if a prohibited substance 
has been taken, or if further testing is mandated. 
 
1.9 Methods of detecting rEPO use: direct methods 
 
1.9.1 Isoelectric focusing/Immunoblotting 
 
The other process used to test for rEPO was a test on urine, and it is the one which 
has since been adopted by WADA as its standard method. It depends on detecting 
differences in the migration of isoforms of EPO on an isoelectric focusing gel, which 
it is thought is related to the glycan structure of the glycopeptides (Nimtz, Wray et 
al. 1995; Kawasaki, Haishima et al. 2001). Protein is extracted from urine by 
repeated ultrafiltration, reducing the sample size from 20 ml to 20 µl. These samples 
are heated at 80°C for 3 minutes to denature urinary aspartic proteases, then cooled 
back to room temperature, and supplemented with Tween 80.  
Samples are then applied to and separated on polyacrylamide slab gels containing 
ampholytes 2-4 and 4-6, with isoforms being separated according to their isoelectric 
point. A Western blot is used to transfer the isoforms to a nitrocellulose membrane. 
The membrane is incubated in a denaturing DTT buffer, then blocked with nonfat 
milk in phosphate buffered saline, before being blotted with an anti-EPO antibody 
(clone AE7A5, murine IgG2A). This is transferred to a separate membrane with a 
second blot under acidic semi-dry blotting conditions and this membrane blocked 
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again before being probed with a biotinylated anti-mouse antibody. This is then 
detected using a streptavidin linked chemiluminescent system (Lasne and de 




Figure 1.5: Isoelectric focusing/immunoblotting patterns of endogenous and artificial 
erythropoietins. Reprinted with permission (WADA 2009) 
 
 
Figure 1.6: Typical IEF gel, showing 1: rEPO (top) and darbepoietin standard and 2. 
typical pattern of a negative urine sample. Other lanes contain actual anti-doping 
samples and standards 
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The isoforms of rEPO are more basic (pI 4.4-5.1) than those of endogenous human 
urinary EPO (huEPO – pI 3.7-4.7), while those of darbepoietin are more acidic (pI 
3.7-4.0)(see Figures 1.5, 1.6) (Delanghe, Bollen et al. 2008). 
 
1.9.2 Definition of a positive result 
 
The WADA definition of a positive result has changed as new EPOs have been 
developed, with isoform patterns which differed from the original Epoetin-alpha and 
beta. The current identification criteria state that for a positive declaration of EPO-
alpha or beta, in the basic region there must be at least 3 acceptable, consecutive 
bands assigned as “1”, “2”, and “3” in the corresponding reference preparation (see 
Figure 1.5); the 2 most intense bands measured by densitometry must be in the basic 
area, shall be consecutive and shall be bands “1” and “2” or “2” and “3”; and each of 
the two most intense bands in the basic area must be more intense (approximately 
twice or more) than any band in the endogenous area, as measured by densitometry 
(WADA 2009). For other epoetins, the sum of the intensity of all bands in the basic 
area must account for approximately 85% or more of the total intensity of the bands 
in the lane. For darbepoietin, in the acidic area there must be at least 3 acceptable, 
consecutive bands assigned as “B”, “C” and “D” in the corresponding reference 
preparation, of which C or D must be most intense and must be approximately twice 
as intense as any endogenous band. For CERA, at least four bands must be present 
matching those of a reference sample. Band density measurement is carried out using 
a tailored piece of computer software, called GASepo. Alternative software packages 
are occasionally used, including AIDA 1D-Evaluation software from Fuji. 
 
1.9.3 Problems with isoelectric focusing/double immunoblotting method 
 
These processes are time consuming, requiring several incubations and blots of 
membranes, provide a subjective result, and as mentioned above are only effective 
within a short period of time after administration, potentially as little as 12-18 hours 
after injection. The requirement to compare band intensities in the different regions 
of the gel also mean that athletes abusing epoetins who naturally produce more 
endogenous EPO, or whose EPO production has been stimulated by hypoxia due to 
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altitude training or strenuous activity, would be more likely to produce a false 
negative result. This has prompted calls for the intensity requirement, at least in the 
case of samples positive for darbepoietin, to be scrapped (Lamon, Robinson et al. 
2007). 
Probably the most significant claims made against the standard method are related to 
the specificity of the monoclonal antibody used, antibody AE7A5. Khan et al. 
demonstrated that the antibody could react with other proteins in the pI range 3-5, 
which they identified as Tamm Horsfall glycoprotein, alpha-antichymotrypsin, 
alpha-2-thiol proteinase inhibitor and alpha-2-HS glycoprotein (Khan, Grinyer et al. 
2005). However, in response it was argued that this cross-reactivity was a result of a 
different extraction process (precipitation using acetonitrile) which denatures 
proteins and exposes buried domains, which then bind to the antibody. Under the 
standard extraction conditions, these domains are not available, and so non-specific 
binding does not occur (Rabin, Lasne et al. 2006).  
Non-specific binding of AE7A5 is also seen with several bacterial proteins, 
including those from Escherichia coli, which is found in human urine and on human 
skin in the uro–ano–genital region. Furthermore, it reacts with intracellular proteins, 
which could be released into the urine following urothelial damage. In fact, the 
generation of the antibody used an antigen which contains an amino acid sequence 
that occurs in more than 500 human and almost 185 E.coli proteins (Franke and Heid 
2006). 
In 2008, the protein responsible for commonly seen non-EPO bands on gels was 
identified as zinc-alpha-2-glycoprotein (Reichel 2008). This is abundant in urine, but 
binding was highly concentration dependent, and so extra bands were only seen in 
urine samples rich in the protein. Further, they were still outside the interpretative 
window of the gel, and so should not interfere with results. 
It has also been shown that human serum EPO contains isoforms with pIs in the 
same range as rEPO (Skibeli, Nissen-Lie et al. 2001), prompting suggestions that 
bleeding into the urine could cause  a false positive result. However, by adding an 
additional immunopurification step using another monoclonal anti human-EPO 
antibody (clone 9C21D11), a comparison of urine and serum samples was possible 
using isoelectric focusing (Lasne, Martin et al. 2007). It showed that although 
urinary profiles are more acidic than those from serum, serum EPO profiles (and, by 
extension, urinary profiles contaminated with blood) can still be distinguished from 
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those of rEPO. It also showed that the addition of a further immunopurification step 
did not affect any bands within the relevant pI window, but only removed proteins 
found outside it; this demonstrated again the sufficient specificity of the AE7A5 
antibody. 
 
1.9.4 Effort urines 
 
One possible cause of false positives with the direct test is post-exercise proteinuria. 
This has been shown to follow intense (rather than prolonged) exercise, and is of 
mixed glomerular-tubular type. It appears to be due to increased glomerular 
permeability, as well as reduced tubular reabsorption of proteins (Poortmans 1985), 
and it has been reported that it can lead to false positive detection of epoetin-beta in 
urine samples (Beullens, Delanghe et al. 2006). This has been disputed by Lasne 
with claims the quality of images obtained was too poor to allow proper 
interpretation, and counter claims that under the (then) current WADA guidelines, 
the athlete concerned would have wrongly tested positive (Lasne, Beullens et al. 
2006). 
A study carried out in 2009 attempted to determine what was responsible for these 
‘effort profiles’ (Lamon, Martin et al. 2009). Seven top cyclists performed periods of 
intense activity, separated by periods of active recovery. Urine samples were 
collected at the start of the day, at the start of exercise, half way through and 
immediately after. Blood samples were also taken, before and after exercise. In all 
subjects, a clear shift towards more basic pI was observed in urine profiles, although 
blood profiles remained unchanged (Figure 1.7). Total protein and EPO levels in 
urine rose 8.5 and 10-fold, while the greatest rise was in retinol-binding protein 
(RBP), which rose more than 300 times by the end of the exercise. Since the serum 
profile of EPO does not change, this suggested that effort urine profiles are indeed 
attributable to changes in kidney permeability or reuptake. The study also noted that 
despite the shift in patterns, none of the effort urines would have produced a positive 
result under WADA guidelines, and proposed that RBP levels could be used as a 





1.9.5 Active urines 
 
Some urine samples produce profiles with unusual patterns of banding, which appear 
to be shifted towards the basic region of the gel but which are still noticeably 
different from those produced by epoetin-alpha or beta. These are thought to be due 
to bacterial contamination of samples. Lasne reported that the occurrence of shifted 
profiles was much greater in samples in which bacterial proliferation had occurred 
(Lasne, 2009). Digestion of human urinary EPO (huEPO), rEPO and darbepoietin 
with sialidases and sulfatases produced IEF profiles similar to those seen in active 
urines (Belalcazar, Gutiérrez Gallego et al. 2006). Interestingly, whereas digestion of 
rEPO with sialidases resulted in proteins which migrated off the end of the gel, 
digestion of huEPO did not, suggesting that huEPO carries acidic groups other than 
the sialic acids. Freezing samples directly after collection has been recommended 
(Lasne 2009), as has the addition of sodium azide as a preservative (Belalcazar, 
Pascual et al 2005). The procedure for declaring a positive result has also been 
adjusted, to enable the possibility of active urines to be eliminated. A stability test 
has been introduced, whereby a sample of the urine is mixed with Complete and 
Peptstatin A protease inhibitors, adjusted to pH 5.5 using acetate buffer and then 
incubated overnight with rEPO and NESP. An active urine will result in the bands 
found in this sample shifting relative to a preparation of rEPO and NESP run 






Figure 1.7: IEF patterns of urine and serum EPO from 2 subjects participating in an 
intense exercise protocol: first morning sample (a), immediately before the warm-up 
training (b), middle (c), and end of exercise (d) and 3 hours after the end of the 
morning session (e) and end of the afternoon session (f). Lane r corresponds to BRP. 
There is an evident shift of the bands toward the cathode induced by exercise. 
Reprinted with permission from Lamon, Martin et al. 2009 
 
1.9.6 SDS-PAGE  
 
A demonstrable difference exists between huEPO and rEPO, darbepoietin and 
CERA in terms of molecular mass. This has been exploited to produce a method to 
distinguish between them using SDS-PAGE. Sodium dodecyl sulfate denatures 
proteins and wraps around the peptide backbone, in a constant weight ratio of 
1.4 g SDS/g of polypeptide. In doing so, it makes negligible the effects of the 
charged groups on the peptide itself. Thus, when exposed to an electric field, 
proteins migrate through a polyacrylamide gel at a rate relative only to their 
molecular size, with smaller proteins migrating faster than large ones. Typical 
apparent molecular masses for epoetins obtained by SDS-PAGE are listed in Table 





Table 1.1: Molecular weights of endogenous and artificial EPOs, as determined by 
SDS-PAGE (Reichel, Kulovics et al. 2009) 
Erythropoietin Molecular weight (KDa) 







Because of the various isoforms of EPO, the bands produced by SDS-PAGE are 
relatively broad. However, this is not true of Dynepo, which produces a narrow 
band, presumably because of the smaller range of glycosylations found (Llop, 
Gutiérrez-Gallego et al. 2008). As a result, bracketing suspect samples with Dynepo 
standards enables a line to be drawn, above which artificial EPOs are found, and 
below which bands for endogenous EPO lie (Figure 1.8). 
 
Figure 1.8: SDS-PAGE analysis of EPOs, showing the higher molecular mass of 
recombinant EPO compared to huEPO  (Reichel 2011) – reproduced with permission 
 
One exception to this appears to be Repotin, an epoetin produced in baby hamster 
kidney cells which appears to have a molecular mass even lower than huEPO. 
However, on IEF analysis it produced a profile which was even more basic than that 
of other epoetins tested. (Reichel, Kulovics et al. 2009). SDS-PAGE analysis has 
been shown to easily distinguish both ‘active’ and ‘effort’ urines. Enzymatic activity 
in ‘active’ urines is thought to cleave sialic acids, shifting the profile to a more basic 
(i.e. more rEPO-like) region; with SDS-PAGE, cleavage reduces the molecular mass, 
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moving the band away from the rEPO region (Reichel, Kulovics et al. 2009). The 
molecular mass of serum EPO is approximately the same as huEPO; it should not be 
surprising, then, that effort urines display virtually unchanged profiles (a slight 
increase in molecular mass only), and that they do not enter into the rEPO region of 




MIRCERA excretion in urine is very low, due to its large (60 kDA) molecular size, 
and as such its presence should be tested for in serum. The human sEPO profile is 
more basic than the urinary one, complicating profiles derived from blood and 
analysed using IEF. Unfortunately, SDS-PAGE analysis of samples containing 
MIRCERA showed reduced sensitivity compared to other epoetins (Reichel, 
Abzieher et al. 2009). It has been suggested that SDS binds to the PEGylation on 
MIRCERA, but is incapable of fully solubilising the molecule. As a result, 
MIRCERA migrates as a broad smeared band. Replacing SDS with Sodium 
N-lauroyl sarosinate (Sarcosyl), which has enhanced surfactant properties due to 
containing both carboxylate and amide functional groups, enabled MIRCERA to be 
resolved into a sharp band, without disturbing the resolution of huEPO and rEPOs. 
 
1.9.8 Capillary zone electrophoresis 
 
Capillary zone electrophoresis (CZE) is a commonly used tool for the separation of 
glycoprotein isoforms, including those with terminal sialic acids (Kinoshita, 
Murakami et al. 2000). Several CZE methods have been proposed for the separation 
of EPO isoforms (Watson and Yao 1993; Yu, Cong et al. 2005; Benavente, 
Hernández et al. 2007), using either UV absorbance or mass spectrometry as a 
detection system. Wang et al. used deep UV laser-induced fluorescence detection 
(deep UV-LIF) combined with an immunomagnetic bead extraction technique and 
capillary zone electrophoresis (Wang, Dou et al. 2012). They reported high 
resolution glycoform profiling with improved sensitivity. A further advantage was 
that the original glycoform distribution was preserved because no fluorescent 
derivatisation was required. The overall detection sensitivity was 1.5 × 10
−8
 mol/L, 
which was two orders of magnitude better than conventional CZE with UV 
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absorbance detection. This is suitable for pharmaceutical preparations, but is not 
sensitive enough for the anti-doping analysis of EPO in blood and urine. A method 
for separating N-linked oligosaccharides, including those derived from rEPO, was 
described by Ijiri et al. (Ijiri, Todoroki et al. 2011). After derivatisation using 
rhodamine 110 CE separations were performed using a fused-silica capillary and 
neutral pH buffer conditions enabling the separation of sialo-oligosaccharides 
according to the number of sialic acids. A second separation was then performed 
using the same capillary and acidic pH buffer conditions, enabling the separation of 
asialo-oligosaccharides according to their sizes. The method gave a limit of detection 
of maltose of about 10 amol. Structural identification of rEPO glycopeptides was 
possible, even when starting with just 10 µg of material. Capillary isoelectric 
focusing methods have also been developed, (Cifuentes, Moreno-Arribas et al. 1999; 
Lopez-Soto- arritu, D  ez-Masa et al. 2002), which show good reproducibility and 
run times of less than 15 minutes; however, sensitivity is poor, with samples often 
made up at concentrations of 1 mg/mL. As a result, these techniques are suitable to 
the analysis of pharmaceutical preparations for quality control purposes, but not yet 
for use in anti-doping efforts (Zhang, Chakraborty et al. 2009). Wang et al. 
combined a competitive immunoassay with capillary electrophoresis (Wang, Zhang 
et al. 2009). Recombinant EPO conjugated with horseradish peroxidase (HRP) was 
incubated with a known amount of anti-EPO antibodies and unconjugated EPO. CE 
was used to separate the rEPO-HRP from the antibody-rEPO-HRP complex, with 
silica dioxide nanoparticles used as a pseudostationary phase to improve analyte 
separation at neutral pH. Measurement of the signal from the two analytes allowed 
determination of the concentration of unmodifed rEPO in solution. The linear range 
for EPO was 1.8–158.0 ng/mL and the detection limit was 0.9 ng/mL. The approach 
was successfully used for the measurement of EPO levels in human sera samples; 
however, since it could not distinguish between hsEPO and rEPO, it would only be 




Efforts have been made to develop an immunoassay method for the detection of 
artificial erythropoietins, which could potentially be faster than testing through IEF 
or Sarcosyl-PAGE due to the removal of the ultrafiltration or immunoextraction step.  
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1.9.9.1 CERA: Lamon et al.  (Lamon, Giraud et al. 2009) developed a high 
throughput method for the detection of CERA in serum. Microtitre plates were 
coated with an anti-EPO antibody, while the detection antibody was a monoclonal 
anti-PEG antibody labeled with digoxigenin (DIG). After the secondary antibody 
incubation, an anti-DIG antibody labeled with horseradish peroxidase was bound, 
and then an ABTS (2,2′-azinobis[3-ethylbenzothiazoline-6-sulfonic acid] 
diammonium salt) substrate added and the colorimetric reaction produced detected. 
The lower limit of quantification (LLOQ) of the assay was 30 pg mL
−1
 and the lower 
limit of quality control (LLQC) 50 pg mL
−1
. The process is rapid, allowing 70 
samples to be processed by an operator per day, and by using a cut off of 100 
pg mL
−1
, the sensitivity of the assay over a 4-week period following 200 μg CERA 
injection was 80%. The authors recommended that their ELISA method be used to 
screen samples, which could then be confirmed by either IEF or Sarcosyl-PAGE. 
They have recently carried out work to compare the three techniques (Leuenberger, 
Lamon et al.), and have reported that the ELISA technique is more sensitive than 
IEF; following injection of 200 μg of CERA, the ELISA technique produced positive 
results until day 20, whereas it was almost undetectable by day 13 using IEF. In 
contrast, the presence of CERA could also be detected at day 20 through the use of 
Sarcosyl-PAGE, showing it is a more appropriate method to use when CERA use is 
suspected. 
An alternate method utilised polyethylene glycol precipitation, followed by a 
commercial homogeneous immunoassay (Van Maerken, Dhondt et al. 2010). Serum 
samples were incubated with an equal volume of 50% PEG-6000 solution or saline 
solution, vortexed, centrifuged and the EPO concentration of the supernatant 
measured using a paramagnetic-particle chemoluminescent immunoassay. The 
PEGylation of MIRCERA increases its solubility in water, so that the ratio of the 
measured EPO concentrations was significantly higher in serum samples taken from 
patients given CERA than in those not given it. 
 
1.9.9.2 rEPO: Mallorqui et al. (Mallorqui, Llop et al. 2010) bound anti-EPO 
antibodies (clone 9C21D11) to microtitre well plates. Polyvinylpyrrolidone (PVP) 
was used as a blocking agent, and the serum samples incubated overnight at 4°C, 
before elution with 0.4 M glycine, 6 M urea, pH 11.0 for analysis by isoelectric 
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focusing. Alternatively, elution was carried out with 0.7% acetic acid, pH 2.8, and 
then samples hydrolysed with 0.1 M TFA and derivatised with 7 mM DMB solution. 
DMB derivatives of sialic acids could then be analysed by reversed-phase capillary-
HPLC, allowing the identification of the non-human N-glycolyl-neuraminic acid 
(Neu5Gc), which is present as 1-2% of the sialic content of rEPO and so could 
provide additional proof of exogenous origin. Whilst carrying out this work, the 
authors noted that elution from the well plates with acidic solvents resulted in more 
effective elution of the basic isoforms of EPO. Consequently, they proposed a 
differential elution method for distinguishing between rEPO and huEPO (Mallorquí, 
Gutiérrez-Gallego et al. 2010). After incubating ultrafiltered urine samples in the 
well plates, elution was carried out firstly at pH 2.8; then, a second elution was 
carried out at pH 11.3. Both elutions were then concentrated through an ultrafilter, 
diluted with Immulite assay diluent and then analysed using an Immulite 1000. Table 
1.2 shows the relative amount eluted in the first elution for different EPO standards. 
 
Table 1.2: Recoveries of erythropoietins in acidic elutions, compared to recovery of 
huEPO 
Erythropoietin % eluted in acidic elution Ratio of % eluted to % 
eluted of huEPO (± s.d) 
huEPO 61.7 1 
rEPO 86.5 1.34 (±0.125) 
Dynepo 89.4 1.40 (±0.018) 
Darbepoietin 38.0 0.60 (±0.082) 
CERA 96.4 1.51 (±0.011) 
 
Carrying out the same process on blank urine samples produced a ratio of 0.86 
(±0.145), suggesting either matrix effects or differences in the endogenous EPO 
compared to the NIBSC standard. This provides greater certainty when dealing with 
rEPO or CERA; however, it reduces the discriminatory power of the test for 
darbepoietin. The authors proposed a cut off ratio of 1.15 for a positive test, and 
using this comparative analysis of urine samples spiked with rEPO found that 
analysis by differential elution was slightly more sensitive than analysis of the same 
samples by the standard IEF approach. The whole process is also much more rapid 
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than the IEF approach; however, more data is still needed to determine exactly where 
the cut-off for a positive test should lie. 
 
1.9.9.3 Darbepoietin: Wide et al. were the first to describe an ELISA method for the 
detection of darbepoetin in human serum (Wide, Wikstrom et al. 2003). Their 
method was based on an increase in immunoreactivity after treatment with 
neuramindase. Serum samples were incubated in acetate buffer pH 5.6, either with or 
without neuraminidase for 1 or 24 hours. EPO activity was then measured using kits 
from either R&D or medac GmbH. The mean relative increase in immunoactivity of 
endogenous EPO after enzymatic digestion was 42% with the medac-kit and 117% 
with R&D-kit. For darbepoetin the equivalent figures were 282% and 231% with 1 h 
and 299% and 256% with 24 h enzyme incubation, respectively. Both endogenous 
EPO and rEPO showed similar changes after enzymatic incubation. The method 
enabled detection of darbepoietin in samples taken 14 days after injection. 
Gimenez et al. (Gimenez, de Bolos et al. 2007) developed antibodies that were 
specific for either EPO or darbepoietin, by synthesising peptides which correspond 
to the regions of the peptide backbone which are different, coupling these to 
ovalbumin or keyhole limpet hemocyanin, and using these as antigens. The sera 
produced was then tested by ELISA against rEPO or darbepoietin. Antibodies raised 
against EPO (81–95) were able to recognize rHuEPO in its native state, but did not 
react with darbepoietin in either its native or reduced and alkylated form. In contrast, 
anti-darbepoietin (86–104) antibodies recognised both darbepoietin and rHuEPO, 
although rHuEPO was recognised to a lesser extent. Immunopurification using an 
immobilised darbepoietin (86–91) peptide column isolated the antibodies that 
specifically recognised the VNET sequence of darbepoietin, enabling QVNETL-
specific antibodies to be obtained. These antibodies are able to recognise 
darbepoietin in ELISA and Western blot assays without binding rEPO. However, to 
date the ability of these antibodies to discriminate between rEPO and darbepoietin 
has not been exploited in an anti-doping method. 
 
1.9.9.4 ESAs: A method for the detection of Peginesatide (also known as Hematide) 
has been described by Leuenberger et al. (Leuenberger, Saugy et al.). Microtitre 
wells are coated with an anti-PEG monoclonal antibody (clone 1A8); the detection 
antibody is a biotinylated monoclonal antibody directed against the peginesatide 
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peptidic moiety (clone 11F9-biotin). Incubation with a streptavidin-horseradish 
peroxidase conjugate, followed by a TMB substrate produces a colorimetric reaction, 
which is read at 450 nm, and samples above a predetermined threshold are then 
analysed by a confirmatory method, using an immuno-precipitation followed by a 
western blot. Both assays can detect 0.5 ng/mL concentrations of peginesatide in 
blood samples, enabling detection for up to 10 days after an injection of 0.1 mg/kg. 
 
1.9.9.5 Membrane assisted isoform immunoassay (MAIIA): MAIIA is a technique 
developed by Maria Lönnberg and Jan Carlsson (Lönnberg and Carlsson 2000), 
based on separation (by ion-exchange or affinity chromatography) and immunoassay 
detection of protein isoforms in the same lateral flow, assisted by capillary forces in 
a membrane device. The method has been applied to the detection of epoetins, using 
a strip which has a capture zone containing wheat germ agglutin (WGA), illustrated 
in Figure 1.9. This has been shown to bind to all isoforms of EPO, but shows greater 
affinity for rEPO isoforms (Franco Fraguas, Carlsson et al. 2008). As a result, it was 
possible to distinguish between endogenous and artificial EPO by eluting from the 
lectin using an increasing concentration of the competing sugar, 
N-acetylglucosamine (GlcNAc). This is exploited in the MAIIA system; following 
binding to the WGA region, bound EPO is eluted using either a high or low 
concentration of GlcNAc; this migrates along the membrane to the detection region, 
which contains an anti-EPO antibody. Visualisation is done using a second anti-EPO 
antibody labelled with carbon black nanostrings. A scanner then measures the 
intensity of the obtained grey to black band in the detection zone, which is directly 
proportional to the amount of bound EPO. Comparison of the results from the two 
different elutions produces the percentage of migrated isoforms (PMI), the amount 
eluted at the low concentration expressed as a percentage of the amount eluted at the 
high concentration. For huEPO, this is around 75%; for rEPOs, it varied from 25.1 to 
51.7%; for MIRCERA, it was about 90%, and for darbepoietin it was 7.7% (WADA 
2009). To date, this approach has not been validated for use on anti-doping samples. 
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Figure 1.9: Left - EPO WGA MAIIA column. Interaction with the wheat germ 
agglutinin (WGA) ligands reduces the migration rate for isoforms containing more 
WGA binding carbohydrate groups. Endogenous isoforms interact less with WGA 
than recombinant ones, enabling the two to be distinguished (right). Reprinted from 
http://www.maiiadiagnostics.com/research/epo_doping_test.htm, with permission 
 
1.10 Aptamer-based affinity detection 
 
An alternative to the use of antibodies in affinity-based detection relies on the use of 
aptamers. These are single stranded DNA or RNA molecules, selected for their 
binding properties by repeated rounds of in vitro selection or Systematic Evolution 
of Ligands by Exponential Enrichment (SELEX) (Ellington and Szostak 1990; Tuerk 
and Gold 1990). As well as having binding properties which rival those of 
antibodies, aptamers possess other significant advantages which antibodies do not: 
they can be engineered completely in a test tube, are easy to label and are very 
stable. They have been used for the specific detection of proteins including IgE 
(German, Buchanan et al. 1998), thrombin (Li, Guo et al. 2008) and ricin (Haes, 
Giordano et al. 2006).  Zhang et al. developed an aptameric molecular beacon (MB) 
based probe for the detection of rEPO-α in physiological buffer (Zhang, Guo et al. 
2009). It involved a fluorescent aptamer and a short complementary quencher 
sequence, binding to which was disrupted by the specific binding between the 
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aptamer and rEPO.  They reported a linear range of 1–10 nM for the detection of 
rEPO, and a calculated limit of detection of 0.4 nM. The same authors also 
developed an aptamer based capillary electrophoresis method with laser-induced 
fluorescence detection for quantifying rEPO (Shen, Guo et al. 2010). In this method, 
the complex of aptamer-rEPO and free aptamer can be separated and identified by 
their migration times. The presence of sodium cations in the sample buffer and 
running buffer was found to be crucial in stabilising the complex and improving the 
separation efficiency. They attempted to quantify rEPO-α in physiological buffer, 
artificial urine and human serum. The linear range for rEPO-α was from 0.2 to 
100 nM and the limit of detection was 0.2 nM (i.e. 7.4 ng/mL). Binding experiments 
using fluorescein isothiocyanate-labeled rEPO-α (F-rEPO-α) and N-deglycosylated 
F-rEPO-α demonstrated that the glycosylation of rEPO-α was of importance in the 
specific interaction between it and its aptamer. In comparison, aptamers specific for 
the peptide backbone of rEPO were isolated by first immobilising rEPO molecules 
through their glycans on a lectin (Wheat germ agglutin) activated sepharose gel 
before incubation with an ssDNA library (Zhang, Guo et al. 2010).  
 
 
1.11 Structural analysis of EPOs 
 
Mass spectrometry is commonly regarded as the gold standard for the identification 
and detection of biological molecules, due to its sensitivity and specificity.  Due to 
the lack of endogenous, purified material available, there have not been many 
attempts to determine the structure of the glycans found in huEPO. Takeuchi et al. 
(Takeuchi, Takasaki et al. 1988) compared huEPO and rEPO produced in Chinese 
hamster ovary cells. They liberated glycans by hydrazinolysis and separated them by 
paper electrophoresis, lectin affinity chromatography, and Bio-Gel P-4 column 
chromatography. They concluded that there were three N-linked sugar chains in each 
molecule all of which were complex and acidic. The major sugar chains were of 
fucosylated tetraantennary complex type with and without N-acetyllactosamine 
repeating units, and small amounts of 2,4- and 2,6-branched triantennary and 
biantennary sugar chains were detected. Repeat units were particularly prominent in 
the rEPO, where they were found in 34.5% of glycans, compared to just 7.5% of 
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the huEPO. Sialic acid linkage in huEPO was of the NeuAc α2 - 6Gal and 
NeuAc α2 - 3Gal type, while that in rEPO was solely of the NeuAc α2 - 3Gal type.  
In the same year, Tsuda et al. (Tsuda, Goto et al. 1988) compared the structures of 
glycans from EPO from the urine of aplastic anaemic patients, with that of rEPO 
produced in baby hamster kidney cells. Desialylated glycans were released using 
N-oligosaccharide glycopeptidase, aminated with a fluorescent reagent and then 
separated using HPLC. The structure of each oligosaccharide thus isolated was 
analysed by a combination of sequential exoglycosidase digestion and further HPLC 
separation with an amide-silica column. They also used high resolution proton 
nuclear magnetic resonance spectroscopy to analyse the structure of rEPO. They 
reported significantly different glycan profiles in huEPO isolated from different 
individuals, whereas different rEPO preparations showed great similarity. They also 
confirmed Takeuchi’s findings, that tetraantennary structures are the most common, 
and were only able to detect N-acetyllactosamine repeat units in rEPO. 
Site-specific glycosylation of huEPO has been investigated using MALDI (Rahbek-
Nielsen, Roepstorff et al. 1997). huEPO was reduced, alkylated and digested using 
Endoproteinase Lys-C, before being separated into fractions using HPLC and a C8 
column. Fractions were desialylated using neuraminidase before being spotted using 
a 4HCCA matrix and analysed using MALDI-TOF mass spectrometry. They 
concluded that the single O-glycosylation at Ser126 consisted of a Hex-HexNAc core 
with either one or two sialic acids attached.  The distribution of bi-, tri- and 
tetraantennary glycans varied significantly between the three N-glycosylation sites. 
Those found at Asn24 are the most heterogeneous, and biantennary structures are only 
found here. The glycans at Asn38 and Asn83 consisted of tri and tetraantennary 
structures, and all sites were found to contain small amounts of tetraantennary 
structures with N-acetyllactosamine repeats. These results matched well with those 
of Takeuchi et al., and with one of the profiles reported by Tsuda et al. However, 
they differ significantly from another of the profiles recorded by Tsuda; Rahbek-
Nielsen et al. have suggested this may be due to the different sources of huEPO, or 
the purification steps involved. 
There has been a great deal more work done in determining the structures of the 
glycans found in rEPOs, darbepoietin and CERA, since these are more readily 
available in purer form and in larger amounts.  
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Rush et al. (Rush, Derby et al. 1995) found that rEPO produced in Chinese hamster 
ovary cells featured Asn24 glycans of mostly biantennary and triantennary forms, 
with varying levels of Neu5Ac residues that are differentially O-acetylated. As with 
huEPO, glycans at Asn38 and Asn83 consisted of tri and tetraantennary structures, 
with or without N-acetyllactosamine repeating units, with the greater heterogeneity 
found in Asn83 glycans. Di-O-acetylations were also found on glycans at Asn83. The 
Ser126 oligosaccharide is composed of GalGalNAc and either one or two Neu5Ac 
residues, which also exhibit varying levels of O-acetylation. O-acetylation was 
predominantly 9-O linked, although O-acetyl groups are known to migrate to other 
positions when hydrolysed. 52 different N-linked glycan structures were identified in 
total. Fucosylation of rEPO glycans has been shown to be almost complete on the 
innermost GlcNAc residues through an α1–6 linkage (Nimtz, Martin et al. 1993). 
The presence of N-glycolylneuraminic acid has been demonstrated in rEPO from 
Chinese hamster ovary cells (Hokke, Bergwerff et al. 1990; Hokke, Bergwerff et al. 
1995), and in rEPO produced in baby hamster kidney cells (Nimtz, Martin et al. 
1993) at about 1-2% of the sialic acids present. Since humans lack the enzyme 
necessary for the production of N-glycolylneuraminic acid (CMP-Neu5Ac 
hydroxylase) (Varki 2001), this has been proposed as a method for the identification 
of rEPO.  However, since the presence of Neu5Gc has been demonstrated in fetal 
tissue and in human carcinomas (Higashi, Hirabayashi et al. 1985), and it has also 
been suggested that it could be taken up in the diet and incorporated into 
some glycoproteins (Tangvoranuntakul, Gagneux et al. 2003), other confirmatory 
steps may still be needed. Derivatisation of sialic acids with 
1,2-diamino-4,5-methylenedioxy-benzene (DMB) after immunoaffinity purification 
of EPO enabled the detection of Neu5Gc in plasma samples taken from athletes 
suspected of taking rEPO (Mallorquí, Llop et al. 2010). Takegawa et al. (Takegawa, 
Ito et al. 2008) used capillary zwitterionic-type hydrophilic interaction 
chromatography (ZIC-HILIC) to separate glycopeptides produced by GluC digestion 
of rEPO. They found that 105 N-glycopeptides and 8 O-glycopeptides could be 
detected in a single run of a 150 ng injection (Figures 1.10, 1.11). These included 
partially acetylated sialic acids, and some which were replaced with 
N-glycoylneuraminic acid. However, their method involved highly concentrated 
digests (1 mg/mL), and their mass accuracy was only 0.1 m/z. 
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Figure 1.10: ZIC-HILIC separation of glycopeptides from rEPO. TIC and extracted 
mass chromatogram (MC) of m/z 290.1 corresponding to in-source fragment ions of 




Figure 1.11: MS spectra accumulated in the time periods (A: 20–30 min) and 
(B: 30-80 min), from the chromatogram in Figure 1.10.  
 
Nanoflow LC-MS/MS has been used to characterise the glycans of rEPO as well, 
with a view to reducing the limit of detection towards that needed for antidoping 
analysis. Groleau et al. (Groleau, Desharnais et al. 2008) used Endoproteinase GluC 
to digest BRP rEPO (mixture of EPO α and EPO β) to give singly glyosylated 
fragments. Analysis was carried out using the Agilent HPLC-Chip/MS and 6330 ion 
trap XCT Ultra mass spectrometer. Digested rEPO was injected onto a Zorbax chip 
with a 40 nL enrichment column and C18 analytical column. Detection and 
identification of the three most prominent glycoforms of Asn24 and Asn38 was 
possible using 100 ng of rEPO after desialylation, at a concentration of 500 μg/mL. 
Assignment of the glycan structures on these glycopeptides was possible to an 
extent, with the identification of N-acetyl lactosamine repeat units possible. With the 
fully sialylated glycopeptides, detection of the three most abundant isoforms of 
Asn24 was possible with 100 ng of material, but identification of repeat units and 
therefore structural assignment was not. With sialylated material, identification of 
acetylations on the O-glycopeptide was simplistic. They suggested that this, or the 
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presence of repeat units on Asn24 and Asn38, may be targets for distinguishing 
between rEPO and huEPO, although huEPO was not available in sufficient quantity 
for them to try the approach. This remains a problem in developing an antidoping 
method, and to date further work has not been published by this group. 
The differences in glycosylation of different artificial EPOs has been investigated as 
well. Shahrokh et al. compared the glycosylation of Dynepo, Eprex, NeoRecormon 
and darbepoietin and found significant differences between them (Shahrokh, Royle 
et al. 2011). Protein-N-glycosidase F was used to remove glycans from the 
glycoprotein. These were then extracted and fluorescently labelled. They were then 
separated using HILIC and WAX chromatography, and detected using fluorescence 
detectors set with excitation and emission wavelengths of 330 and 420 nm 
respectively. They found that darbepoietin had up to six O-acetyl groups attached to 
the sialic acids. Eprex and NeoRecormon had only minor amounts of O-acetylation 
while Dynepo had none. Dynepo, produced in human cell lines, had no Neu5Gc, and 
contained the lowest amount of disialylated glycans, while darbepoietin contained 
the highest amount of tetrasialylated glycans. NeoRecormon and Eprex contained 
more trisialylated, but less tetrasialylated glycans than Dynepo and darbepoietin.  
The highest amount of tetraantennary glycans was found in Dynepo, as was the 
lowest amounts of triantennary glycans with a β 1-6-GlcNAc linkage. All the 
epoetins were found to contain N-acetyl-lactosamine repeat units, although Dynepo 
had the least. In Dynepo and darbepoietin, these repeat units were mostly found on 
biantennary glycans, whereas in NeoRecomon and Eprex they were on triantennary 
glycans. The sLe(x) epitope was only detected in Dynepo. Recent work by Bones et 
al. (Bones, McLoughlin et al. 2011) used a 2D LC approach, with a shallow weak 
anion exchange gradient in the first dimension followed by further separation of each 
obtained peak using a HILIC column. Analysing the European Pharmacopeia 
Biological Reference Preparation (BRP) 3 erythropoietin standard, a mix of 
recombinant epoetin alpha and epoetin beta expressed in CHO cells, they found 
tetra-antennary glycans to be the primary glycosylation on Asn24 and Asn83. A novel 
finding was that up to five poly-N-acetyl lactosamine repeats were observed on a 
tetrasialylated glycan present at Asn83, although this made up less than 0.1% of the 
total glycan pool. In contrast, biantennary glycans were the major structure detected 
at Asn38. 
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Capillary zone electrophoresis coupled with ESI-TOF-MS was used by Balaguer et 
al. (Balaguer, Demelbauer et al. 2006) to characterise intact rEPO and enzymatically 
released glycans. Effective separation of glycoforms is necessary to avoid a broad 
unresolved signal. Balaguer et al. used a novel acrylamide-based capillary coating to 
suppress electroosmotic flow, and an orthogonal accelerated TOF mass spectrometer 
for detection. They were able to get baseline resolution of rEPO molecules 
containing different numbers of sialic acids, and some separation of rEPO molecules 
containing different numbers of N-acetyl lactosamine repeat units. Analysis of 
N-glycans released by PNGase digestion identified 19 different glycans, including 
ones with 5 sialic acids attached, and sulfated glycans. Distinguishing between 
glycans with repeat units and those with multiple antennae was not possible, due to 
the single MS method used. As with the previous CZE techniques, the main 
drawback of this method was the need for highly concentrated (1 mg/mL to 2.5 
mg/mL) solutions. Intact mass spectrometry of rEPO was also attempted by 
Giménez et al., who used CE separation with physically adsorbed capillary coatings 
from UltraTol™ Pre-Coats on the capillaries, and an ion trap as an analyser 
(Giménez, Benavente et al. 2008). They were able to identify a total of 17 different 
glycoforms, including ones with different numbers of sialic acids and different 
numbers of N-acetyl-lactosamine repeat units. However, a lack of stability and 
bleeding of the capillary coating caused problems with MS detection, such as a 
significant loss of sensitivity and the presence of peaks in the mass spectra 
corresponding to molecular ions from the coating. An orthogonal accelerating time-
of-flight mass spectrometer, combined with CE-MS was also used in a paper 
published by Giménez et al. in 2012 (Giménez, Ramos-Hernan et al. 2012). In this 
paper, they examined tryptic and Endoproteinase Glu-C digests of rEPO either with 
or without digests with neuraminidase. Twelve sialoforms corresponding to 5 
different glycoforms were detected at Asn83, and they also reported for the first time 
a sulfated sialoform of this glycopeptide. Different sialoforms were also detected on 
the O-glycosylation, and an estimate of the different amounts of acetylated sialic 
acids and N-glycolylneuraminic acid was produced. As previously however, highly 
concentrated solutions were needed. 
If the presence or absence of sialic acid groups was the only difference between 
isoforms of EPO, then a maximum of 14 isoforms would be detectable using IEF 
(with the maximum sialylation occurring when three tetraantennary, fully sialylated 
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N-glycans and one doubly sialylated O-glycan are found).  However, as mentioned 
above, digestion of huEPO with sialidase did not result in a product which was too 
basic to be detected in the IEF window, suggesting charges are carried elsewhere in 
the molecule as well. Other structural features of rEPO which have been reported 
include the presence of mannose-6-phosphate (Nimtz, Wray et al. 1995) and the 
sulfation of GlcNAc (Kawasaki, Haishima et al. 2001; Balaguer, Demelbauer et al. 
2006). Cointe et al. (Cointe, Béliard et al. 2000) attempted to produce a rEPO as 
close as possible to huEPO, by expressing the EPO gene in a human lymphoblastoid 
cell line, named RPMI 1788. This resulted in unusual glycosylation patterns: 80% of 
N-glycans possessed a bisecting GlcNAc residue, 25% bore a second fucose residue 
which was largely present in a sialyl Le
x
 motif, and 13% contained more than three 
LacNAc repeats (up to five per molecule). 
 
Recently, Christian Reichel suggested that there may be a structural difference 
between all rEPOs and endogenous EPO (Reichel 2011). Sequential digestion of 
recombinant and huEPO with exoglycosidases and subsequent analysis by 
SDS-PAGE showed that both responded the same to digestion with Arthrobacter 
ureafaciens α-sialidase and Steptococcus pneumoniae β-D-galactosidase. However, 
further digestion with N-acetyl-β-D-glucosaminidase from Steptococcus pneumoniae 
was partly inhibited in endogenous but not recombinant erythropoietins. Subsequent 
digestion with Jack bean α-D-mannosidase and Helix pomatia β-D-mannosidase led 
to only very limited further deglycosylation of endogenous EPO, while rEPO 
glycans continued to be degraded. Reichel proposed that this could be due to tissue 
specific glycosylation, such as the existence of a bisecting GlcNAc residue in 
endogenous EPO, sterically hindering the exoglycosidases. IEF analysis of sialidase 
treated rEPO and huEPO found that it resulted in the disappearance of most isoforms 
of rEPO, suggesting charge on them lies solely in sialic acid residues. However, 
with huEPO it resulted in the appearance of more than ten additional 
basic isoforms, suggesting additional charges (e.g. sulfates) are present. 
This remained after subsequent deglycosylation with β-D-galactosidase and 
N-acetyl-β-D-glucosaminidase, suggesting the charges must either be present on the 
core sugars or on the non-cleavable residues of the glycan arms. The presence of 
these charges could also be responsible for steric hindrance of the deglycosylating 
enzymes. 
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The structures of the component saccharides of EPO glycans are illustrated in Figure 
1.12. Summary diagrams of the range of structures found are shown in Figure 1.13 
(for N-glycans) and Figure 1.14 (for O-glycans). 
 
 





Figure 1.13: Summary diagram of N-glycans found on rEPO and endogenous EPO, 
including possible positions of sulfate and bisecting N-acetylglucosamine moieties. 





Figure 1.14: O-glycans found on rEPO and endogenous EPO; same key as in Figure 
1.13. 
 
1.12 Sample preparation 
 
Extraction of EPO from urine and especially serum faces the same challenge; 
extraction of EPO, which is present at low concentrations, coupled with the removal 
of interfering matrix components which may be present at (much) higher 
concentrations. In serum, the concentration of albumin in particular is in the region 
of 40 g/L, compared to 50 ng/L for EPO. Ultrafiltration through 30 kDa centrifugal 
filters is the standard approach for urine samples, as mentioned above, where EPO is 
typically present at a concentration of about 10 ng/L (Emslie, Howe et al. 1999). 
However, this does not remove abundant urine proteins, which can cause 
interference either inside (Khan, Grinyer et al. 2005) or outside (Lasne, Martin et al. 
2007) the pI range of EPO. Immunoaffinity approaches can theoretically result in 
more specific sample clean up. In demonstrating that huEPO and hsEPO profiles are 
different, Lasne et al. (Lasne, Martin et al. 2007) used an immunoaffinity column to 
extract EPO from serum, consisting of monoclonal antibody 9C21D11 coupled to an 
Affi-Gel Hz hydrazide gel. Elution was carried out using a buffer at pH 11, 
containing 6 M urea, and samples were then subject to ultrafiltration, before being 
analysed by isoelectric focusing. Paramagnetic beads (Guan, Uboh et al. 2007; Guan, 
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Uboh et al. 2008) have also been used to extract EPO and darbepoietin from equine 
plasma, and from human serum (Skibeli, Nissen-Lie et al. 2001). Tosyl activated 
beads were used to bind polyclonal rabbit anti-EPO antibodies, which were then 
incubated overnight with samples. Elution was then carried out using a pH 2 buffer 
containing PEG 6000. As mentioned above, Wang et al. (Wang, Dou et al. 2012) 
also developed a technique using antibody-functionalised paramagnetic beads. They 
used Protein A coated beads, functionalised using a rabbit polyclonal antibody, 
incubated them with the sample for 3.5 hours and eluted using 10 M urea for 
2 hours. Although they demonstrated that extraction from albumin-containing 
pharmaceutical preparations was possible, they were unable to replicate this result in 
urine samples. After filtering urine through a 50 kDa filter, recovery was improved 
although still low. They concluded that large molecules were interfering with the 
antibody binding, and proposed Tamm Horsfall glycoprotein (Mr, 69,000) and 
alpha-2-thiol proteinase inhibitor (Mr, 72,000) as two possible candidates.  
These processes all take a relatively long time; either long incubations are required, 
or immunoaffinity extraction is followed by ultrafiltration, a lengthy process on its 
own. Immunoaffinity extraction using these processes is also costly, if beads or 
columns are disposed of after use. In 2006, Mi et al. (Mi, Wang et al. 2006) 
produced an immunoaffinity column for extracting EPO from urine, which used 
polyclonal rabbit antibodies. It had a binding capacity of 2 μg of EPO, and recovery 
from urine samples was measured at 86 ± 9%. However, elution was carried out with 
8 mL of glycine-HCl buffer, so very little preconcentration occurred, and a 
subsequent lack of IEF data meant that possible isoform selectivity was not 
addressed. Furthermore, the authors claim the column can be used up to 30 times. 
However, no data is presented to demonstrate the existence or absence of carryover 
between extractions. Attempts to repeatedly use extraction materials risks carryover 
between samples and false positives or negatives as a result. 
Validation has however taken place for another kit developed by the producers of the 
MAIIA method (Lönnberg, Dehnes et al. 2010); this uses disposable anti-EPO 
monolithic columns for extraction of EPO from blood or urine samples, as an 
alternative to ultrafiltration or immunoaffinity extraction using ELISA plates. These 
are much smaller than traditional monoliths, being only 0.15 mm long with a volume 
of 6 µL, meaning that much less antibody is required and that the columns can be 
disposable and (relatively) low cost. Each column used in the study had 
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approximately 20 to 40 µg of anti-EPO (clone 3F6) immobilised on it. Recovery of 
huEPO was 65 ± 17% (mean ± SD), which compared to a mean of 51% from 
ultrafiltration, in line with earlier estimations of recovery by this method (Lasne 
2002). Mircera recovery is lower (mean of 57%), as the pegylation reduces its 
affinity for the antibody used; recovery is enhanced by the use of an ‘Exposure aid’, 
which presumably partially denatures the molecule and exposes binding sites. 
Isoform distribution was retained, and background noise was reduced compared to 
extraction by ultrafiltration (Figure 1.15).  
 
 
Figure 1.15: IEF (pH 2–6) analysis of isoform distribution for endogenous EPO. 
Endogenous EPO from a 20 mL urine sample was obtained by either ultrafiltration 
(UF) or affinity purification using MAIIA cartridges (AP). C1, C2 and C3 represent 
three different urine samples with an estimated original concentration in urine of 4, 7 
and 60 ng EPO/L. Affinity purification of the urine sample removed the background 
staining and made the interpretation of band intensity, intensity ratio calculation and 
estimation of position much more reliable. From Lönnberg, Dehnes et al. 2010; 
reprinted with permission 
 
 
1.13 Mass spectrometry for anti-doping analysis 
 
To date, no mass spectrometric method has been developed for the detection of 
artificial EPOs in anti-doping samples from humans. The problem is one of 
sensitivity; where the artificial and endogenous form share the same peptide 
backbone, differences are due to the glycosylation patterns found. One key 
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difference between endogenous and recombinant EPOs appears to be the number of 
sialic acids detected; these groups are notoriously labile in both MALDI and ESI 
sources.  
However, mass spectrometric methods have been developed for cases where the 
peptide sequence is not the same for the natural and artificial EPOs being considered, 
i.e. in humans with the example of darbepoietin, or in animals injected with rEPO. 
Guan et al. (Guan, Uboh et al. 2007) developed a method to detect the presence of 
rEPO and darbepoietin in horse plasma. It involved extraction using 
immunomagnetic beads, digestion by trypsin and then analysis using LC-MS/MS. 








 from rEPO and 
darbepoietin were used for confirmation. The limit of confirmation reported was 
0.2 ng/mL, and the limit of detection was 0.1 ng/mL for rEPO and darbepoietin. A 
modified method was also proposed (Guan, Uboh et al. 2008), which enabled 









 (T9) from darbepoietin, produced after 
digestion with both trypsin and PNGaseF. The limit of identification was 0.1 ng/mL 
for darbepoietin and 0.2 ng/mL for rEPO in equine plasma, and the limit of detection 
was 0.05 ng/mL for darbepoietin and 0.1 ng/mL for rEPO. The same approach has 
also been applied to human plasma (Guan, Uboh et al. 2009), where the limit of 
detection for darbepoietin was 0.1 ng/mL, and that of identification was 0.2 ng/mL. 
However, as mentioned above, this method cannot distinguish between rEPO and 
hsEPO.  
Yu et al. produced a slightly modified version, which also involved immunoaffinity 
extraction using anti-rEPO antibody-coated Dynabeads followed by trypsin digestion 
(Yu, Ho et al. 2010). They used a nano-flow reversed phase LC system, with a 
peptide trapping column and a C18 analytical column. Monitoring four transitions in 
SRM mode for the peptide VNFYAWK for the detection of rEPO, darbepoietin and 
CERA in equine plasma, they reported limits of detection of 0.1, 0.2 and 1.0 ng/mL, 
respectively. 
The method was further improved (Guan, Uboh et al. 2010) through switching to a 




), common to 
rEPO, darbepoietin and CERA, and extracting analyte from plasma samples that had 
been pretreated with polyethylene glycol (PEG) 6000, to precipitate plasma proteins. 
 59 
The limit of identification was 0.5 ng/mL for CERA, 0.2 ng/mL for rEPO, and 
0.1 ng/mL for darbepoietin in equine plasma; the limit of detection was 0.3 ng/mL 




Since the expiration of the patent on EPO, a number of biosimilar EPOs have been 
produced as well as a number of cheaper-production "copy" epoetins. It has been 
estimated that up to 80 such products may already be available in countries with 
more relaxed pharmaceutical standards (Macdougall and Ashenden 2009). Since the 
glycosylation of EPO is dependent on the specific cell conditions, these would be 
expected to show variation in their isoforms from those already available. Park et al. 
(Park, Park et al. 2009) compared Epogen produced by Amgen with a number of 
biosimilar products produced in Korea, China and India. They found a high degree 
of variability of isoforms. Analysis by IEF showed four isoforms to be present in the 
Epogen samples. Those from rEPOs made by Jia Lin Hao, Ji Mai Xin, and Huan Er 
Bo, all in China, showed approximately nine isoforms; additionally, the isoform 
patterns of rEPO from Huan Er Bo differed between samples, demonstrating 
variability in the manufacturing process. Eporon (from Korea) also contained more 
isoforms than Epogen, and again differed between batches. Samples from India also 
showed multiple isoforms. In particular, Zyrop, manufactured in Argentina and sold 
in India and Wepox, which is manufactured in India, demonstrated a great range of 
isoforms (Figure 1.16). Similar variability and differences from Epogen has also 
been described in other Korean rEPOs (Kang, Sang et al. 2010), and in biosimilars 
from Brazil, South Africa, Ukraine and Russia (Reichel, Kulovics et al. 2009). 
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Figure 1.16: IEF/Immunoblotting gel of rEPO samples (A) samples from China 
(lanes 2–9) and Korea (lanes 10–13) and (B) samples from India (lanes 1–5). 
Reprinted with permission from Park, Park et al. 2009 
 
1.15 Aim of this PhD 
 
The current methods for identification of the misuse of erythropoietins and related 
drugs, IEF and SDS/Sarcosyl-PAGE, are both time and labour intensive. The results 
they produce are subjective, as different gels cannot be compared; it is also suspected 
that they result in a large number of false negatives, as their lack of specificity means 
that the criteria for a positive test need to be set more tightly than is perhaps 
desirable. Alternative methods developed with the intention of tackling this problem 
either fail to identify all the isoforms, lack sufficient sensitivity to be used in anti-
doping tests or have not been validated with real antidoping samples (see Table 1.3 
for a summary of the approaches attempted with EPO). The aim of this PhD was to 
develop a mass spectrometric method for the identification of recombinant EPOs in 
anti-doping samples. To this end, Chapter 2 details the attempt to develop an 
immunoaffinity approach to EPO extraction from urine as an alternative to 
ultrafiltration. Chapter 3 concerns attempts to produce a boronic acid functionalised 
silica, for the extraction and concentration of rEPO glycopeptides, with a view to 
using the modified silica in a trapping column. Chapter 4 is about the use of 
so-called ‘superchargers’ to improve the signal from compounds which are typically 
difficult to detect using mass spectrometry, such as acidic glycoproteins; and Chapter 
5 considers an approach to distinguish between recombinant and endogenous EPO 
based on the proposed  presence of a bisecting N-acetylglucosamine in glycans from 
endogenous EPO only.  
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Chapter 2: Extraction of EPO from urine using antibody 


























Aim: to use antibody activated paramagnetic beads to extract EPO from urine 





Extraction of EPO from urinary samples has generally been performed using 
ultrafiltration using successive 30 kDa filters. In this way, EPO is retained in the 
sample, while the sample volume is reduced from 20 mL to about 20 µL, a 1000 fold 
increase in concentration. This is a time consuming process, requiring multiple 
centrifugation steps and producing a final sample which will also contain any other 
large urinary compounds. Their presence means that the extract is often thick and 
viscous, making it difficult to apply to an isoelectric focusing gel and unsuitable for 
analysis, for example, by LC-MS. The presence of high amounts of protein in the 
retentate can also result in distortion of the EPO bands on the IEF gel, while the 
retention of urinary proteases means that an additional heating and cooling step is 
required before the samples can be run. 
Immunoaffinity extraction uses antibodies to bind analytes of interest specifically. 
Extraction using an immunoaffinity approach would seem to be a more desirable 
approach than ultrafiltration, as it could mean the removal of interfering and 
unwanted proteins and produce a product more amenable to analysis by LC-MS, 
with or without initial digestion.  
Antibody modified extraction columns have been shown to be effective (Mi, Wang 
et al. 2006). However, they are expensive and time consuming to produce, and the 
issue of carryover, which would prevent their use in anti-doping work, was not 
addressed. Extraction from blood using antibody modified paramagnetic beads has 
been demonstrated (Skibeli, Nissen-Lie et al. 2001). However, these used polyclonal 
antibodies, and tosyl-activated beads. Tosyl groups will bind to any amino group on 
the antibody; use of Protein G coated beads should improve antibody orientation (as 
shown in figure 2.1), potentially improving recovery, whilst correct selection of 
monoclonal antibody should improve specificity of EPO extraction. Since blood 
samples are less desirable than urine samples in anti-doping (due to the increased 
difficulty of collection and the more invasive nature of sampling),  the aim of this 
work was to develop a method for the successful extraction of EPO from urinary 
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Figure 2.1: Theoretical improved antibody orientation on Protein G coated beads 





2.2.1 Materials and equipment 
 
Dynabeads Protein G paramagnetic beads were purchased from Invitrogen (Paisley, 
UK). Streptavidin coated LodeStar paramagnetic beads were a generous gift 
from Varian, Inc. (Oxford, UK). Bis(sulfosuccinimidyl) suberate (BS3), 
Sulfo-NHS-LC-biotin, goat anti-mouse antibodies and HRP-Streptavidin conjugate 
were bought from Pierce Protein Research Products, a division of Thermo Fisher 
Scientific. Recombinant EPO standard (88/574) was purchased from NIBSC 
(Hertfordshire, UK). Eprex rEPO was from Janssen-Cilag (High Wycombe, UK). 
Complete protease inhibitor was bought from Roche (Welwyn Garden City, UK). 
Hydrochloric acid and acetonitrile (HPLC gradient grade) were purchased from 
Fisher Scientific (Loughborough, UK). Formic acid was from VWR International 
(Pennsylvania, USA). Immulite EPO quantification test kits (Immulite 1000 EPO 
assay) were purchased from Siemens (Frimley, UK). Anti-EPO antibodies (clones 
AE7A5 and 9C21D11) were purchased from R&D Systems (Abingdon, UK). Tris 
was bought from Amersham Biosciences (Buckinghamshire, UK). Trypsin was from 
Promega (Southampton, UK). Amicon and Microcon centrifugal filters, Steriflip 
filters, Durapore membranes and Immobilon membranes were from Millipore 
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(Watford, UK). ChemiGlow West Chemiluminescence Substrate Kit was from 
ProteinSimple (Ringmer, UK). Non-fat milk powder was from Marvel (St Albans, 
UK). Servalyt ampholytes were from Serva Electrophoresis (Heidelberg, Germany). 
Black ink was from Winsor & Newton (London, UK). MAIIA monolithic cartridges 
were from MAIIA Diagnostics (Uppsala, Sweden). All other chemicals were of 
analytical grade and were purchased from Sigma Aldrich (Poole, UK). 
 
Quantification of rEPO in samples was carried out using the Immulite immunoassay 
system. 
 
Separation of Dynabeads was carried out using a magnetic separator from New 
England Biolabs (Ipswich, Massachusetts, USA). 
 
LC-MS/MS was carried out using a Waters (Manchester, UK) nanoAcquity UPLC 
system, combined with a Waters Premier Quattro triple-quadrupole mass 
spectrometer with Waters nanospray source.  
 
 
2.2.2 Dynabead Protein G preparation 
 
Dynabeads were prepared as in manufacturer’s instructions. Briefly, 50 µL was 
washed twice with 0.1 M phosphate buffer (pH 7.0) with 0.01% Tween 20, (wash 
and bind, W&B, buffer) each time separating the beads out on a magnet. Ten 
microlitres (1 mg/mL) anti-EPO AE7A5 was added to 200 µL W&B buffer and this 
added to the beads. These were incubated at room temperature on a multi-tube vortex 
for ten minutes then washed using 0.01 M phosphate buffered saline (PBS) twice. 
 
 
2.2.3 Cross linking of beads  
 
BS3 solution was made up fresh, and incubated for 30 minutes with the modified 
Dynabeads to cross link antibodies to their surface. Beads were then incubated in 
200 µL 50 mM Tris-HCl buffer to quench the reaction, then washed twice more 
using PBS to produce Dynabeads ready for extraction. Modified and cross linked 
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beads were stored in PBS with 0.01% Tween 20. Volume used to store beads was the 
same as the initial volume of beads.  
 
 
2.2.4 EPO extraction (direct method) 
 
The direct and indirect methods of extraction are illustrated in figure 2.2. For the 
direct method, 50 µL beads were incubated with 20 mL of 10 mIU/mL aqueous 
rEPO solution with gentle shaking. Aliquots (250 µL) were taken every half hour, 
for analysis using Immulite. 
 
 
2.2.5 EPO extraction (indirect method) 
 
Anti-EPO (10 µg) was incubated with 20 mL of 10 mIU/mL rEPO solution, pH 7.4, 
0.01% Tween 20 overnight. Dynabeads Protein G (50 µL) were then added, and the 
tubes incubated at room temperature with aliquots taken for analysis at 1, 3, 7 and 24 
hours and frozen for later analysis with Immulite. A control sample with no addition 
of beads was run at the same time. 
 
 
2.2.6 Effect of presence of antibodies on Immulite results 
 
To check if the presence of antibodies to EPO could prevent the Immulite detection 
of the glycoprotein, 1 mL of 20 mIU/mL rEPO was added to 10 µg anti-EPO, 
vortexed and a 250 µL sample taken, then incubated on a plate shaker with further 
samples taken at 2 and 4 hours. The EPO concentration was then compared to that 
measured in a tube without antibody added. 
 
 
2.2.7 Biotinylation of antibodies 
 
Ultrapure water (360 µL) was added to 2 mg of sulfo-NHS-LC-biotin. 6.5 µL of 
solution was immediately added to 200 µg anti-EPO and the mixture placed on ice 
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for two hours. The solution was then transferred to a 30 kDa Microcon and 
centrifuged to remove unreacted biotin. The membrane of the filter was then washed 




Figure 2.2: Direct and indirect method for extraction of analytes using paramagnetic 
Protein G coated Dynabeads. The direct method can theoretically allow the reuse of 
beads, but the indirect method may be better if the concentration of the target analyte 
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2.2.8 Steptavidin coated LodeStar bead preparation 
 
LodeStar beads (100 µL) were washed once with tris buffered saline (TBS) then 
incubated for 1 hour with 10 µL biotinylated anti-EPO. Beads were washed gently 
three times with 300 µL TBS.  
 
 
2.2.9 Streptavidin coated LodeStar bead extraction of EPO 
 
1.5 mL of 100 mIU/mL rEPO was added to the beads produced in 2.2.8 and the 
sample incubated for 21 hours, with 250 µL aliquots taken at intervals and analysed 
using Immulite. A control sample without beads was incubated and sampled 
simultaneously. Beads were then washed in 200 µL TBS, transferred to a new tube 
and 25 µL glycine buffer (pH 2.4) added. The sample was incubated for 2 minutes 
then magnetically separated and the supernatant added to 225 µL of 1 M Tris-HCl 
buffer, before being analysed again using Immulite. 
 
 
2.2.10 Extraction using biotinylated goat anti-mouse antibodies 
 
Lodestar beads (100 µL) were washed as in 2.2.8, then incubated with 10 µL 
biotinylated goat anti-mouse antibodies in 300 µL TBS for 1 hour at room 
temperature with shaking. Beads were gently washed three times with TBS, then 
incubated with mouse anti-EPO (clone AE7A5) for two hours. The beads were then 
washed gently again with TBS, twice. 
 
rEPO (60 mIU/mL) was made up in 0.01 M PBS, with 0.05% sodium azide as a 
preservative. Beads were gently washed twice with TBS, then resuspended in 50 µL 
TBS and added to 1.5 mL of EPO solution. 250 µL aliquots were taken at hourly 
intervals and frozen overnight, then defrosted and analysed using Immulite. A 





2.2.11 Effect of Thimerosal/Complete/Sodium azide 
 
To ensure that breakdown of rEPO in solution by bacteria was minimised, 
antibacterials were added to the solution. To see if these had any effect on the 
binding of rEPO to beads, the experiment in 2.2.10 was repeated using 20 mIU/mL 
rEPO solution, without the addition of any preservative, and with the replacement of 
sodium azide with 0.05% thimerosal or Complete protease inhibitor (1 tablet 
dissolved in 50 mL 0.01 PBS). 
 
 
2.2.12 Effect of heating urine before extraction 
 
To see if binding of AE7A5 antibody to EPO is to domains only exposed after 
denaturation of the hormone, 20 mL urine samples were buffered with 3.75 M 
Tris-HCl to approximately pH 7. They were heated at 90 °C for 10 minutes, then 
allowed to cool, and then incubated with 50 µL Dynabeads made up as in 2.2.2 and 
2.2.3 for 30 minutes. Beads were removed using a magnetic separator, and urine 
samples then analysed using the standard isoelectric focusing/immunoblotting 
method. Control urine samples were heated then incubated with unmodified 
Dynabeads, before being analysed in the same way. 
 
 
2.2.13 Modification of Dynabeads using antibody 9C21D11 
 
Protein G coated Dynabeads were modified in the same way as in 2.2.2 and 2.2.3, 
using anti-EPO antibody 9C21D11. Recombinant EPO solution (50 mIU/mL) was 
made up in PBS + 0.02% sodium azide. Fifty microlitres of beads were added to 
20 mL of the solution and incubated on a blood spinner for 24 hours, with aliquots 
taken at intervals, frozen and then analysed using Immulite. A control solution with 






2.2.14 Effect of cross linking 
 
Dynabeads modified with antibody 9C21D11 and cross linked as in 2.2.3 were 
incubated with rEPO solution (50 mIU/mL), made up as in 2.2.13, for 1 hour. An 
aliquot was then taken and analysed using Immulite. Dynabeads modified with the 
same antibody but not cross linked were incubated and analysed at the same time. 
 
 
2.2.15 Necessity of cross-linking 
 
It was hoped that it would be possible to reuse modified Dynabeads more than once. 
To investigate if cross-linking of antibodies to Dynabeads was necessary, the ability 
of Dynabeads to bind rEPO after several incubation/wash/elution steps was 
investigated. Dynabeads were modified as in 2.2.13, and either cross-linked or not. 
Recombinant EPO solution was made up as in 2.2.13. 50 µL of Dynabeads were 
added to either 20 mL of rEPO solution, or 20 mL of a PBS + 0.02% sodium azide 
blank. Samples were incubated for 1 hour at room temperature, with rotation. 
Aliquots were then taken from the rEPO solution and frozen, before being defrosted 
and analysed using Immulite. Beads from the blank solution were removed using a 
magnetic separator, and washed once using 250 µL 0.01 M PBS. Elution was carried 
out using 50 µL phosphate buffer, pH 2.2, + 0.01% PEG 6000. Beads were 
incubated for 30 minutes at room temperature with gentle shaking, then removed 
using a magnetic separator, and washed twice using 250 µL 0.01 M PBS + 0.02 % 
Tween 20. This process was repeated twice more, so that for both crosslinked and 
non-crosslinked beads, the efficacy of extraction could be measured after no, one and 
two elution cycles. 
 
 
2.2.16 Dynabead extraction from spiked urine samples 
 
Attempts to quantify rEPO spiked into urine samples using Immulite proved 
unsuccessful, with significant differences in the measured values of repeats of rEPO 
standards. This occurred despite the use of 3.75 M Tris-HCl, pH 7.4 to ensure urine 
pH was theoretically suitable and the addition of human serum albumin. As a result, 
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extraction from urine samples was measured using LC-MS/MS instead. To improve 
accuracy, endogenous urinary EPO was removed from urine by ultrafiltering it 
through a 30 kDa filter. Filtered urine was pooled, then measured into 20 mL 
aliquots. 
 
Table 2.1: Theoretical tryptic fragments of rEPO 
 
Tryptic Fragment Start-End Sequence 
T1 1-4 APPR 
T2 5-10 LICDSR 
T3 11-14 VLER 
T4 15-20 YLLEAK 
T5 21-45 EAENITTGCAEHCSLNENITVPDTK 
T6 46-52 VNFYAWK 
T7 53-53 R 
T8 54-76 MEVGQQAVEVWQGLALLSEAVLR 
T9 77-97 GQALLVNSSQPWEPLQLHVDK 
T10 98-103 AVSGLR 
T11 104-110 SLTTLLR 
T12 111-116 ALGAQK 
T13 117-131 EAISPPDAASAAPLR 
T14 132-139 TITADTFR 
T15 140-140 K 
T16 141-143 LFR 
T17 144-150  VYSNFLR 
T18 151-152 GK 
T19 153-154 LK 
T20 155-162 LYTGEACR 
T21 163-165 TGD 
 
Digests of rEPO were carried out by making up standards in 100 mM glycine 
buffers, pH 1.8 and pH 11. Standards were made up so that 70 µL pH 11 buffer 
added to 30 µL pH 1.8 buffer gave a neutral (pH 7.4) solution. Standards were made 
up at 50, 100, 250, 500, 750 and 1000 ng/mL rEPO. Separate pH standards were 
incubated at room temperature for 30 minutes before being mixed together. Mixed 
standards or samples were heated at 80 °C for ten minutes, then allowed to cool to 
room temperature. 10 µL trypsin solution (10 µg/mL, in 50 mM ammonium 
bicarbonate, pH 7.4) was added and samples were incubated overnight at 37 °C. 
 
Concentration of rEPO was determined by measuring the peak area of three 
transitions for a peptide from the rEPO digest characteristic of human EPO. The 
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 (Table 2.1, T17 fragment), chosen because as 
well as being characteristic of EPO, repeated overnight digests of EPO demonstrated 
that the fragment was a reliable indicator of total EPO concentration. 
 
Chromatographic separation was carried out using a Waters nanoAcquity Symmetry 
C18, 180 µm x 20 mm trapping column, and a Waters nanoAcquity BEH C18, 
100 µm x 150 mm separation column. Solvent A was ultrapure water, with 0.1% 
formic acid. Solvent B was acetonitrile with 0.1% formic acid. Samples were moved 
onto the trapping column by running 99.5% A at 15 µL/min for 1 minute. LC run 
conditions were: 0.4 µL/min flow rate; 99% A at start, decreasing linearly to 57% A 
at 20 minutes. Decrease linearly to 20% A at 21 minutes, hold to 25 minutes, raise 
linearly to 99% A at 26 minutes, hold to 30 minutes. Column temperature was set at 
35 °C, sample tray temperature at 4 °C. 
 
Mass spectrometer was operated in positive ionisation SIM mode, for transitions 
450.0 → 235.2, 636.4, 799.4. Mass spectrometer conditions were: 
 
Capillary: 3.20 kV, Cone: 32 V, Extractor: 3 V, RF Lens: 0.6 V 
 
Quadrupole 1: Low mass resolution: 14.0, High mass resolution: 14.0,  
Ion energy: 0.5 
 
Collision cell: Entrance: -1, Collision: 20, Exit: 2.0 
 
Quadrupole 2: Low mass resolution: 14.0, High mass resolution: 14.0,  
Ion energy: 1.0 
 
Mutiplier: 650 
Collision gas flow: 0.18 mL/min 
  
Two injections (5 µL) were made for each standard concentration and the mean peak 
area for each transition measured. These were then summed to give a total area for 
the three transitions. 
 
 86 
Linearity for the standard curve produced by this method was better if the 
measurements for 50 ng/mL were disregarded. As a result, it was decided to spike 
samples at a concentration that would produce a solution of concentration 500 ng/mL 
if recovery was 100%. With 20 mL urine samples, this meant spiking at 2.5 ng/mL, 
i.e. 50 ng in total. 
 
Four spiked urine samples were incubated with Dynabeads modified as in 2.2.13. 
50 µL of Dynabeads were added to 20 mL of urine, which had been ultrafiltered to 
remove endogenous EPO then spiked with 50 ng Eprex rEPO. Urine had 2 mL of 
3.75 M Tris-HCl, pH 7.4 added, with further Tris-HCl added dropwise to ensure 
urine pH was between 7 and 8. Dynabeads were incubated in urine for 2 hours, then 
removed using a magnetic separator and washed with 250 µL PBS. The first elution 
was carried out using 70 µL 100 mM glycine-NaOH, pH 11, for 30 minutes at room 
temperature with shaking. A second elution was carried out using 30 µL 100 mM 
glycine-HCl, pH 1.8. The two elutions were mixed, and digestion and LC-MS/MS 
analysis carried out as above. Standard digests of 100, 500 and 1000 ng/mL rEPO 
were carried out at the same time. Recovery by Dynabeads was calculated by 
dividing the observed total peak area of the transitions by the theoretical total peak 
area of the transitions at 500 ng/mL obtained from the generated standard curve. 
 
 
2.2.17 Isoform selectivity of Dynabeads extractions 
 
To examine if extraction by Dynabeads modified with antibody 9C21D11 showed 
selectivity for some isoforms over others, ultrafiltered urine was spiked with either 
huEPO or rEPO (NIBSC) at a concentration of approximately 1 mIU/mL. 20 mL 
urine samples were incubated with Dynabeads and elutions carried out as in 2.2.16. 
After elution and mixing, eluates were dried down under vacuum, then reconstituted 
in 20 µL 50 mM Tris-HCl, pH 7.4, containing 1% (w/v) bovine serum albumin. 
Samples were then analysed using the standard isoelectric focusing/immunoblotting 




2.2.18 Extraction of EPO from unfiltered urine in comparison with MAIIA 
monolithic cartridges 
 
Extraction of huEPO using Dynabeads was compared to that of identical samples 
using MAIIA immunoaffinity monolithic cartridges. It has been reported that MAIIA 
cartridges showed slightly poorer recovery of EPO from urine samples compared to 
ultrafiltration, but that isoelectric focusing profiles were improved due to reduced 
background and band distortion (Lönnberg, Dehnes et al. 2010). To examine if the 
same was true of Dynabeads, two (non-filtered) urine samples were split into three 
20 mL aliquots. One was extracted using ultrafiltration, one with MAIIA cartridges 
and one with Dynabeads. Briefly, ultrafiltration involved addition of Complete 
protease inhibitor and buffering to approximately pH 7, followed by ultrafiltration 
through a 30 kDa centrifugal filter, to obtain a final retentate with a volume of 20 to 
40 µL. MAIIA extraction involved passing the urine samples through a MAIIA 
antibody monolithic cartridge, followed by a wash step and elution from the 
cartridge in 55 µL of elution buffer. Dynabead extraction was carried out as in 




2.2.19 Extraction of EPO by sequential Dynabeads/ultrafiltration 
 
A single urine sample was split into four 20 mL aliquots, and extracted either by 
ultrafiltration or with Dynabeads as in 2.2.16. Urine samples extracted using 
Dynabeads were kept and remaining EPO was extracted using ultrafiltration as in 




2.2.20 Extraction of EPO from buffer, ultrafiltered urine and whole urine 
 
To demonstrate the differing capability of Dynabeads as an extraction process from 
different matrices, 20 mL solutions of EPO were made up using NIBSC huEPO 
standard at 1 mIU/mL in either 50 mM Tris-HCl, pH 7.4 or urine which had been 
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filtered using a 30 kDa filter. Two 20 mL aliquots of a sample of urine were 
ultrafiltered until their volume was below 200 µL, a 6 µL  aliquot taken and made up 
to 250 µL with 50 mM Tris-HCl, pH 7.4, then their EPO concentrations measured 
using Immulite. The mean concentration was then used to adjust the concentration of 
the original urine sample (using ultrafiltered urine) to 1 mIU/mL. All three types of 
solution were then extracted using Dynabeads as in 2.2.16, and samples analysed 





2.3.1 EPO Extraction (direct method) 
 
Table 2.2 Direct Dynabead extraction of rEPO from aqueous solution 
 







As can be seen from Table 2.2 above, there was no apparent extraction of rEPO from 
solution using the direct method, as mean rEPO concentration did not fall over time. 
If anything, the concentration of EPO in solution appeared to increase post 
incubation with the beads, although this is likely to be due to a lack of accuracy in 








2.3.2 EPO extraction (indirect method) 
 
Table 2.3. Indirect method extraction of rEPO using Dynabeads 
 
Incubation time (hours) Mean Control rEPO 
concentration (mIU/mL) 
(n=2) 









1 5.1 5.2 
3 5.2 5.6 
7 5.0 5.2 
24 4.7 6.1 
 
a
 At start of incubation with anti-EPO antibodies 
b
 At start of incubation with Dynabeads 
 
As can be seen from Table 2.3 above, using the indirect method for extraction there 
was again no extraction of rEPO seen. A fall in EPO concentration in samples 
incubated with Dynabeads was observed, but this was also seen in the control sample 
and was therefore likely to be due to degradation of rEPO in the samples, possibly 
due to bacterial action. 
 
2.3.3 Effect of presence of antibodies on Immulite results 
 
Table 2.4. Effect of the addition of anti-EPO antibodies on apparent Immulite results 
 
Incubation time (hours) rEPO concentration – 
control (mIU/mL) 
rEPO concentration – 
antibodies added 
(mIU/mL) 
0 19.6 16.5 
2 18.9 16.1 
4 18.5 16.1 
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The addition of antibodies against EPO to a solution of EPO did appear to reduce 
slightly the apparent level of EPO in solution as measured using Immulite (see Table 
2.4) presumably because binding of the Immulite antibodies to EPO was reduced 
because the initial antibodies either bind all or part of the same epitope, or because 
they sterically hinder the binding of further antibodies to a different epitope. 
However, the difference was not large, and would only affect results if an indirect 
method of extraction was used. 
 
 
2.3.4 Use of biotinylated goat anti-mouse antibodies 
 
Table 2.5. Extraction using biotinylated goat anti-mouse antibodies 
 
Incubation time (hours) Mean EPO conc. – control 
(mIU/mL) (n=2) 
Mean EPO conc.  - with 
beads (mIU/mL) (n=2) 
0 60.3 60.3 
0.25 64.5 62.4 
1 60.2 61.6 
3 66.2 58.7 
5 61.5 61.2 
24 66.7 66.8 
 
Again, Table 2.5 shows that no obvious extraction of EPO from solution was seen, 
with the mean EPO concentrations in both the control and Dynabead incubations 
remaining approximately the same throughout the incubation. It is possible that there 
was a decrease in concentration after 3 hours incubation with the beads, and that this 
was due to binding which later broke down, possibly due to degradation of the 
antibody. However, the decrease (and therefore the degree of binding of EPO to the 
beads) was very small from the starting concentration, and within the range that 





2.3.5 Extraction using biotinylated anti-EPO 
 
Table 2.6. Extraction of rEPO using biotinylated anti-EPO activated beads 
 
Incubation time (hours) rEPO concentration (mIU/mL) 
Control + activated beads 
0 103 103 
0.25 97.0 102 
1 101 83.4 
3 102 93.2 
5 95.0 102 
21 102 94.3 
Eluate  1.1 
 
Once more, Table 2.6 shows there is no clear pattern of extraction of rEPO from 
solution. Variability in the concentration detected in the control sample, and in 
particular its fall and subsequent rise, suggest a degree of error in the accuracy of 

















2.3.6 Effect of Thimerosal/Complete/Sodium azide on rEPO extraction 
 
Table 2.7. Effect of different preservatives (PRES) on extraction of rEPO using 























0 23.1 19.4 20.1 22.4 20.1 22.5 21.5 
1 18.7 16.2 20.8 21.9 21.5 20.5 19.4 
2 16.5 12.9 20.5 22.6 20.0 19.1 19.2 
3 14.6 9.8 19.6 20.7 22.1 20.0 21.0 
4 14.1 9.7 20.4 19.4 20.5 20.4 20.4 
 
SA = sodium azide, T = thimerosal, C = Complete solution 
 
Table 2.7 above shows that in the absence of a preservative or beads, there is a fall in 
the EPO concentration in solution, presumably due to degradation of EPO by 
microorganisms. There is a similar sized fall when beads are present, which could 
mean that there is no binding by the beads of EPO, or that any binding is being 
masked by degradation of the EPO. The use of anti-bacterials and a protease 
inhibitor demonstrate that when degradation is prevented, there is no apparent 
binding of EPO to the beads. 
 
 
2.3.7 Effect of heating urine samples before extraction 
 
Profiles of urine samples heated, then ultrafiltered and analysed by 
IEF/immunoblotting after incubation with Dynabeads modified with antibody 
AE7A5 did not differ from those heated then incubated with non-modified 
Dynabeads. In all, EPO was clearly detected, demonstrating that heating of urine 
samples did not result in binding of EPO to Dynabeads. 
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2.3.8 Modification of Dynabeads with antibody 9C21D11 
 
The concentration of rEPO in solution dropped rapidly when incubated with 
Dynabeads modified with antibody 9C21D11, as shown in Table 2.8 and figure 2.3. 
 
Table 2.8: Effect on rEPO concentration of incubation with Dynabeads modified 
with antibody 9C21D11 
 
Time (hours) Mean EPO concentration (mIU/mL) (n=2) 
Control Dynabeads 
0 52.4 54.0 
0.5 47.1 17.5 
1 51.6 15.9 
2 53.7 15.4 
4 50.3 14.6 


























Figure 2.3: Effect on rEPO concentration of incubation with Dynabeads modified 
with antibody 9C21D11 
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2.3.9 Effect of crosslinking 
 
As shown in Table 2.9, cross-linking the antibodies to the beads did not affect their 
ability to bind rEPO. 
 
Table 2.9: Effect of cross-linking antibody-modified Dynabeads on the ability of 
these beads to bind rEPO 
 












51.4 13.7 13.2 
 
 
2.3.10 Necessity of cross-linking 
 
Initial binding capacity of the Dynabeads was largely unaffected by the cross linking 
procedure; in Table 2.9, the fall in rEPO concentration was slightly larger with the 
cross-linked beads; in Table 2.10, the fall was slightly less. However, the binding 
capacity of the non-cross-linked beads fell off significantly after multiple elution 
cycles, whereas that of the cross-linked beads remained approximately the same 
(standard deviation of fall in EPO concentration after incubation of 0.66 for cross-
linked beads, compared with 6.81 for non-cross-linked). This, presumably, was due 
to loss of antibodies from the surface of the beads, with the binding of the Protein G 
coating to the antibodies being disrupted in the same way as the binding of the 
antibodies to rEPO would be. This loss is of course prevented when the antibodies 
are covalently attached. 
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Table 2.10: Effect of multiple binding/wash/elution cycles on the binding capacity of 












0 0 49.0 50.0 
0 1 14.8 13.0 
1 0 48.9 48.9 
1 1 13.4 19.2 
2 0 51.9 50.4 
2 1 17.2 27.0 
 
 
2.3.11 Dynabead extraction from spiked urine samples 
 
The spectrum obtained by fragmenting the doubly charged T17 peptide is shown in 
figure 2.4. From this it was decided to use transitions m/z 450.0 to 236.2 (a2), 636.4 
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The data points generated by measuring the total peak area of this peptide are shown 
in Figure 2.5. The R
2 
value for the linear regression line plotted using all points was 
0.9967. If the values for the 50 ng/mL digest were ignored as shown in Figure 2.6, 
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Figure 2.5: Relationship of EPO concentration to total peak area of fragment ions 
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Figure 2.6: Relationship of EPO concentration to total peak area of fragment ions 
from peptide T17 (50 ng/mL digest excluded) 
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As a result, it was decided to spike samples such that 100 per cent recovery would 
give concentrations of 500 ng/mL, and to bracket the samples with standards at 100 
and 1000 ng/mL. 
 
Comparison of the measured peak areas from Dynabead extractions with the 
expected value from standards run at the same time (and digested for the same length 
of time) gave percentage recovery. Each sample was injected twice, and the mean 
peak area used. 
 
From the standards run simultaneously, the expected mean peak area for the 
Dynabead extractions was 2156 (arbitrary units). The obtained values are shown in 
Table 2.11. 
 
Table 2.11: Recovery of rEPO from urine by Dynabead extraction, as measured by 
LC-MS/MS 
 




1 1854 0.86 
2 1186 0.55 
3 1897 0.88 
4 1035 0.48 
 Mean O/E (± s.d.) 0.69 ± 0.21 
 
The mean recovery from Dynabead extractions was 69%. This compares well to 
extraction by ultrafiltration, which has been reported to be in the region of 50% 
(Lönnberg, Dehnes et al. 2010) However, the standard deviation is quite large, 
indicating that the method is not especially robust. The Dynabeads from these 
extractions were retained and subjected to repeat elutions. These elutions showed the 
presence of more EPO, unsurprisingly especially from samples 2 and 4 (mean O/E 
for the two of 18%). This suggests that binding of rEPO to the beads is not the 
problem, but that elution of rEPO from them is. Carryover is therefore a problem 
with this method. This could be reduced by repeated elutions (or possibly by eluting 
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in a larger volume). However, for anti-doping practices, where carryover could 
potentially result in a false positive result, each batch of magnetic beads would only 
be able to be used once. Repeated elutions may also improve overall recovery of 
EPO, but as less EPO would be recovered each time in the same volume of eluent, 
this would reduce the concentration of EPO in eluate; since sensitivity is a major 
issue in anti-doping testing, a further concentration step would then be desirable (or 
necessary), increasing further the time and effort needed by this extraction method. 
 
2.3.12 Isoform selectivity of Dynabeads 
 
The gel obtained by running ultrafiltered samples next to identical Dynabead 
extracted samples is shown in figure 2.7. There appears to be a slight variation in 
isoform density between the two samples. However, this is only small, and could be 
due to experimental variation. Importantly, by both methods both the positive and 




Figure 2.7: Ultrafiltration versus Dynabead extractions of EPO from ultrafiltered and 
spiked urine. Samples are: A- urine spiked with huEPO, ultrafiltration extraction; B- 
urine spiked with huEPO, Dynabead extraction; C- urine spiked with rEPO, 








Figure 2.8: IEF gel demonstrating efficacy of extraction of huEPO from urine 
samples by different methods. Lanes are: 1 - huEPO standard (NIBSC); 
2, 3 - extraction by ultrafiltration; 4, 5 - extraction with Dynabeads; 6, 7 - extraction 
using MAIIA monolithic cartridges. 
 
As shown in figure 2.8, as expected the bands produced by extraction using MAIIA 
cartridges are clearer, with slightly less background noise and significantly less 
distortion. There is also no obvious difference in selectivity for isoforms seen 
between the two methods. However, the extractions carried out using Dynabeads 
were not successful. Despite the apparent recovery measured using LC-MS/MS 
being around 70%, similar recovery was not observed in these extractions. This 
could be due to a difference in the suitability of the elution buffer for analysis by 
IEF/immunoblotting, but this had not been observed when checking for isoform 
selectivity in 2.3.12. However, isoform selectivity was checked using spiked, 
ultrafiltered urine. It is possible that other large compounds (probably proteins) 
1 2 3 4 5 6 7 
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removed from urine by this same filtration procedure interfere in the binding or 
elution of EPO to or from Dynabeads. 
 
 




Figure 2.9: IEF gel of urine samples sequentially extracted by 
ultrafiltration/Dynabeads. From left, lanes are: 1, 2 - Ultrafiltration extraction; 
3, 4 - Dynabead extraction; 5, 6 - Dynabead extraction then ultrafiltration; 7- huEPO 
standard (NIBSC) 
 
Figure 2.9 shows the gel obtained from samples ultrafiltered, extracted with 
Dynabeads and extracted with Dynabeads and then ultrafiltered. As in 2.3.13, the 
extractions with Dynabeads were (comparatively) unsuccessful (with very faint 
bands only being visible). When these samples were then extracted using 
ultrafiltration, bands similar in intensity to those directly extracted by ultrafiltration 
were observed. This would indicate that the failure of Dynabeads as an extraction 
method in 2.3.13 was due to the failure of the beads to bind EPO from whole urine, 
rather than a failure to elute it from the beads afterwards. 
1 2 3 4 5 6 7 
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2.3.15 Extraction of EPO from buffer, ultrafiltered urine and whole urine 
 
 
Figure 2.10: Recovery of EPO using Dynabeads from buffer, ultrafiltered urine and 
whole urine. From left, samples are: 1 - huEPO standard (NIBSC); 2- blank lane; 
3, 4 - extraction from buffer; 5, 6 - extraction from ultrafiltered urine; 
7, 8 - extraction from whole urine 
 
The difficulty in extracting EPO from whole urine is further illustrated in Figure 
2.10. When solutions of EPO are made up at physiological concentrations in a 
neutral buffer, recovery of EPO is successful. The isoform distribution is the same in 
the extraction as in the huEPO standard, and the relative intensity of the three most 
intense bands in the standard compared to the same bands in the extractions suggests 
a recovery of about 58%. Recovery of EPO from ultrafiltered urine which was then 
spiked at the same concentration with huEPO was somewhat more than in buffer. 
Measurement of the three most intense bands this time suggested a recovery of about 
80%. It is unclear if this is a ‘real’ effect, or if as with the mass spectrometric 
analysis, it suggests a lack of robustness in the extraction method. One explanation 
may be that ultrafiltration of urine fails to remove all EPO, so that the concentration 
in the ultrafiltered and spiked urine samples was higher than was thought. Extraction 
from whole urine adjusted to the same EPO concentration was poor. Bands are only 
faintly visible on the gel; analysis using GASepo, which can enhance band visibility, 
suggested a recovery of around 8%. 




Attempts to extract EPO from solution were not successful using the anti-EPO 
antibody AE7A5, despite this being a key element of the standard 
IEF/immunoblotting procedure for EPO detection. However, the standard procedure 
involves the membrane with the EPO attached being incubated in a solution of DTT 
for one hour, before it is incubated with the antibody. The antibody binds to an 
epitope in the first 26 residues of the protein, and it is likely that the exposure of this 
epitope is improved by the breaking of the disulphide bond between the cysteine 
residues at positions 7 and 161. Attempts to denature EPO by the addition of DTT to 
urine failed, with the formation of (presumably proteinaceous) solids observed, 
preventing effective incubation with Dynabeads. Attempts to expose the epitope 
simply by heating urine previous to extraction were also unsuccessful. This is 
perhaps not surprising, given the different denaturation mechanisms involved. 
Furthermore, the standard procedure for extraction of EPO also involves a heating 
step to denature urinary proteases, which EPO is resistant to, suggesting that 
attempts to denature EPO in this manner may not be effective. It is also known that 
AE7A5 binds to other urinary components, especially zinc-alpha-2-glycoprotein. 
These run at a different pI on an IEF gel, and so do not interfere with EPO detection. 
However, it is possible that its presence in urine at a comparatively high 
concentration inhibits binding of EPO to the antibody, and that this was responsible 
for preventing binding of EPO from urine samples. 
Extraction from solution using anti-EPO antibody 9C21D11 was successful in 
buffer, with relatively rapid falls in EPO concentration when incubated with 
Dynabeads modified with this antibody. Measurement using LC-MS/MS from 
ultrafiltered and then spiked urine suggested recovery in the region of 70%, although 
solutions were made up above physiological concentrations to enable detection 
within a linear response range. Tryptic digestion of extracts was simple, 
demonstrating the viability of this extraction process for analysis by alternative 
methods to IEF/immunoblotting. Analysis of similar samples made up at 
physiological concentrations demonstrated a lack of isoform selectivity, at least 
compared to ultrafiltration. However, attempts to extract EPO from whole urine 
using this method were not successful. Analysis of whole urine samples after 
incubation with antibody-modified Dynabeads indicated that binding of EPO to the 
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beads was inhibited in whole urine. This was not seen in ultrafiltered and spiked 
urine, suggesting that the inhibitory factor is the presence of large (>30 kDa) 
components.  Although the component(s) responsible have not been identified, as 
mentioned above antibody AE7A5 is known to bind to other urinary proteins; it is 
quite possible that antibody 9C21D11 also does so, preventing the binding of EPO. 
Since the binding epitope of 9C21D11 is not known, it is difficult to predict which 
urinary proteins might affect it.  
That this problem is not observed with MAIIA cartridges, which both bind and 
release EPO rapidly from urine and serum without being excessively affected by the 
presence of other proteins, demonstrates the importance of obtaining an antibody 
with optimal binding characteristics. In the case of MAIIA, this antibody is mouse 
monoclonal antibody 3F6. It is possible that use of this antibody would enable 
successful extraction of EPO from whole urine samples using modified Dynabeads. 
Alternatively, a new antibody could be sought, which could in theory have better 
specificity and more optimal affinity for EPO. However, due to reasons of cost and 
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Chapter 3: The production and comparison of boronic acid 
functionalised silica and polymeric materials for the 





























Aim: To produce boronic acid functionalised silica that could be used to extract and 
concentrate glycopeptides from solution, with the ultimate intention of improving 




3.1.1 Boronic acid – cis-diol complexes 
 
Boronic acids are alkyl or aryl substituted boric acids, which are capable of reacting 
with compounds containing cis-diol groups to form reversible covalent complexes 




Figure 3.1: Relationship between phenylboronic acid and its diol ester. Due to the 
involvement of protons, the relationship is pH dependent. Reproduced with 
permission (Springsteen and Wang 2002) 
 
Cis-diol containing biomolecules make up some of those of most interest to 
researchers, including glycoproteins, nucleosides and saccharides. The binding of 
boronic acids to saccharides is affected by the specific sugar involved. In aqueous 
solution, saccharides exist in different conformations, the open chain structure and 
the α and β ring forms. Ketohexoses such as fructose or aldopentoses such as ribose 
can form five-membered (furanose) rings, or six-membered (pyranose) rings. In a 
process known as ring-flipping, the conformation can change, resulting in axial 
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substituents becoming equatorial, and vice versa. The binding of boronic acids is 
affected by this. Reactivity is affected, as axially located OH groups are less electron 
withdrawing than equatorial OH groups. Furthermore, boron-oxygen bonds are quite 
short, and so in the absence of rotational freedom of the C-C bonds, boronic ester 
formation will require the reacting hydroxy groups to have small dihedral angles in a 
synperiplanar arrangement to ease ring strain.  
 
3.1.2 pH dependence of boronic acid binding  
 
The affinity of boronic acids for cis-diol containing molecules has also been shown 
to be dependent on the concentration of buffer and importantly highly dependent on 
the pH of the solution (See tables 3.1 and 3.2) (Springsteen and Wang 2002). In 
Figure 3.1, an increase in acidity moves the equilibria to the left. As Keq-tet is much 
greater than Keq-trig, this leads to greater hydrolysis of the ester bond. For some time 
it was generally assumed that stronger binding occurred at higher pH. However, Yan 
et al. (Yan, Springsteen et al. 2004) examined the binding of 25 arylboronic acids 
with a series of diols at a series of pH values, and demonstrated that the optimal 
binding pH is not always above the pKa of the boronic acid.  
The reversible, pH dependent nature of the binding, combined with the high 
equilibrium constants of the formation of the boronic esters (for example, the 
binding of phenylboronic acid with catechol has an equilibrium constant of 830 M
-1 
at pH 7.4) is the reason why the reactions have been used in the construction of 
sensors for saccharides (Zhao, Fyles et al. 2004; Das, Kim et al. 2011), nucleotide 
and carbohydrate transporters (Westmark and Smith 1996; Draffin, Duggan et al. 
2003) and in binding and separating carbohydrates chromatographically (Adamek, 








Table 3.1: Association constants (Keq) of the ester formed by saccharides with 
phenylboronic acid at various pHs, in 0.1 M phosphate buffer. Reproduced with 




Table 3.2: Association constants (Keq) of saccharides with phenylboronic acid at pH 





3.1.3 Different approaches for glycopeptide/glycoprotein extraction 
 
Recently there has been increasing interest in the use of boronic acid functionalised 
materials for the capture or separation of larger biomolecules. A quick search of the 
Web of Science database found 83 papers or patents about boronic acids and 
glycoproteins published between 2008 and 2012; 54 were published between 2003 
and 2007, and 53 were published in all years previously. For oligosaccharides and 
boronic acids, the equivalent figures were 30, 30 and 14. A number of different 
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materials with boronic acid functionality have been produced to capture 
glycoproteins and glycopeptides. Alternatives for the extraction or enrichment of 
glycosylated molecules are available, but all have drawbacks. Lectin 
chromatography is most commonly carried out using concanavalin A, but this is only 
very good for high mannose and hybrid N-glycans, shows less affinity for complex 
biantennary glycans, and little or no affinity for complex tri and tetra-antennary 
N-glycans (Cummings and Kornfeld 1982); HILIC chromatography is simple but 
can also enrich particularly hydrophilic non-glycosylated molecules; and oxidation 
and hydrazine chemistry is successful but the additional oxidation step increases 
method time and complexity. 
A comparison of three different approaches for glycoprotein/glycopeptide 
enrichment by SPE (Ozohanics, Turiák et al. 2012), specifically wheat germ 
agglutinin lectin, phenylboronic acid (PBA) and strong anion exchange, analysed 
samples by nano-HPLC-MS(MS). Quantification of peptides was based on the 
sum (or average) intensity of the three most abundant peptide peaks corresponding 
to a given protein. Quantification of glycopeptides was done in an 
analogous manner, using the intensity of three product ions 
(m/z 366.14, 512.19 and 657.23) characteristic of glycopeptides (respectively, 
the oxonium ions of N-acetyl-lactosamine, fucosyl-N-acetyl-lactosamine and 
sialyl-N-acetyl-lactosamine). Enrichment at the peptide level was found to be more 
effective than at that of the protein. It was also found that lectin extraction was 
disappointing for peptides, but that both anion exchange and PBA Solid Phase 
Extraction (SPE) materials significantly enriched glycopeptides compared to non-
glycosylated peptides. Recovery of glycopeptides was lower (about 50 %) with PBA 
SPE compared to anion exchange (about 60 % recovery), but the ratio to non-
glycosylated peptides was better. 
 
3.1.4 Surface modification with boronic acid 
 
Boronic acid functionality has generally been introduced in two ways; either through 
the modification of the surface of a material, such as silica or a polymeric material, 
or through the direct production of polymers from boronic acid containing 
monomers. The limitation with a flat surface is the lower surface area; however, with 
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porous materials such as silica or polymeric monoliths, pore size can limit the extent 
of boronic acid conjugation due to steric and diffusive barriers. 
Gold is often used as a structure to which boronic acids can be attached when 
MALDI is the analysis method, as gold can also adsorb UV laser to help desorption 
and ionisation of trapped molecules. Tang et al. (Tang, Liu et al. 2009) used gold 
nanoparticles spotted and sintered onto a steel plate, before being modified with 
4-mercaptophenylboronic acid to produce a porous substrate with large surface area. 
This was capable of selectively binding glycopeptides from solution, which could 
then be analysed by MALDI after the deposition of 2,5-dihydroxybenzoic acid 
matrix. The boronic acid functionalised plates exhibited high sensitivity and 
selectivity to glycopeptides. Furthermore, the enrichment and detection steps were 
rapid and simple. 
On plate enrichment for analysis by MALDI was also demonstrated by Xu et al. (Xu, 
Zhang et al. 2010). Gold-coated silicon wafers were immersed in 
11-mercaptoundecanol (MUD) to produce a MUD monolayer. Hydroxyl groups on 
the end of the organic chain were converted to carboxylic acids and activated, before 
being reacted with 3-aminophenylboronic acid. Wafers were immersed in samples to 
bind glycopeptides, before being analysed using MALDI. Analysis of tryptic digests 
of three glycoproteins showed that the limit of detection was increased by 93-248 
times compared to direct analysis of the digest, while recovery of glycopeptides from 
tryptic asialofetuin averaged 65.8 %. 
Reduction of non-specific adsorption/adhesion to structures on which 
aminophenylboronic acid (APB) has been immobilised can be obtained through the 
introduction of a spacer arm between the material and the APB. Jang et al. (Jang, 
Kim et al. 2009) designed a self-assembled monolayer (SAM)-based MALDI plate, 
which contained a oligo(ethylene glycol) (OEG) spacer group to reduce the 
nonspecific adsorption/adhesion, allowing direct detection of glycoproteins after 
affinity-capture on the plate. The specificity of the APB-functionalised SAMs was 
demonstrated by the selective capture of model glycoproteins such as RNase B (15 
kDa) and transferrin (80 kDa). 
Sepharose gel has been activated by binding to it 3-aminophenylboronic acid, and 
the gel then added to agarose gel on MALDI chips, to produce a high-capacity 
affinity layer (Gontarev, Shmanai et al. 2007). Calculations show that the maximum 




molecules per cm. This corresponds to about 10 ng/mm
2
, which is not sufficient for 
all purposes. The agarose gel has the advantage of porosity, and can bind 1-10 
µg/mm
2
. The affinity MALDI chips produced were capable of directly and 
specifically binding glycosylated molecules from samples, allowing their immediate 
analysis by MALDI mass spectrometry. 
Zhang et al. (Zhang, Xu et al. 2009) produced a hybrid material consisting of a silica 
coated ferrite core with numerous “satellites” of gold nanoparticles with lots of 
“anchors”. The anchors were 3-aminophenylboronic acid molecules, which were 
attached to the gold surface through long organic chains, to reduce steric hindrance. 
The grafting of the gold particles to the magnetic core increased the surface area, 
such that the adsorption capacity of the material was greater than 79 mg/g of 
material, three times higher than that of commercially available magnetic beads. 
Extraction of tryptically digested horseradish peroxidase showed that the beads 
successfully and specifically bound glycosylated peptides and not those without 
sugars attached. Recovery of glycopeptides from the composite nanoparticles of up 
to 85.9% was recorded. The nanoparticles could also be used to extract 
glycoproteins; with intact HRP, recovery of 71.6% was recorded. It was suggested 
that steric hindrance could be responsible for the reduced recovery compared to 
glycopeptides. 
Aminophenylboronic acid has also been immobilised on magnetic beads for the 
purposes of direct analysis by MALDI. Lee et al. (Lee, Kim et al. 2005) used 
carboxylic acid terminated magnetic beads which were activated by a carbodiimide 
and subsequently reacted with N-hydroxysuccinimide moiety to provide a site for the 
attachment of aminophenylboronic acid through the amino group. Extraction of 
glycoproteins was carried out in deionised water, and the same solvent used to wash 
the magnetic beads several times. Glycoproteins were shown to be significantly 
enriched by the process, whereas non-glycosylated proteins were not. Since 
ionisation of glycoproteins using MALDI is suppressed in the presence of non-
glycosylated proteins, this resulted in an increase in signal intensity of the 
glycoproteins. 
Magnetic nanoparticles were also produced by Lin et al. (Lin, Zheng et al. 2012) 
with boronic acid functionality. Amine-functionalised Fe3O4 nanoparticles were 
prepared via a solvothermal method. A homogeneous silica coating was formed by 
hydrolysis and polycondensation of tetramethyloxysilane (TMOS) and 
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3-methacryloxypropyl trimethoxysilane (γ-MAPS) on the surface of the 
nanoparticles, which were then functionalised using vinylphenylboronic acid. 
Saturation binding of the nanoparticles was 320 mg g
-1
 for the glycosylated protein 
ovalbumin, 4–7 times higher than the values obtained for the non-glycosylated BSA 
and Lysozyme, which were 45 and 70 mg g
-1
, respectively. The binding capacity of 
mucin, another glycosylated protein, was 2 times less than that of ovalbumin, 
indicating the effect of steric hindrance due to its larger molecular weight. Extraction 
of IgG from protein solution showed that both heavy chain and light chain 
polypeptides were bound by the nanoparticles. However, enrichment of the light 
chain was greater than that of the (glycosylated) heavy chain, suggesting that 
disruption of the binding between heavy and light chains was easier than that 
between the heavy chain and the boronic acid group. 
Boronic acid functionalised silica was demonstrated by Li et al. (Li, Zhao et al. 
2006). They used γ-glycidoxypropyltrimethoxysilane (GLYMO) to modify silica and 
introduce an epoxy group. This was then reacted with APB to produce the boronic 
acid functionalised silica. A similar approach was taken by Xu et al. (Xu, Wu et al. 
2008), except that they reacted the GLYMO and APB together first, then reacted the 
resulting compound with the silica. Xu et al. used mesoporous silica that they 
manufactured themselves, and reported 2 orders of magnitude improvement in the 
detection limit of glycopeptides. They also said that the method was applicable to all 
kinds of glycopeptides regardless of their sizes, structures, and hydrophilicities. 
A similar approach was used by Zhang et al. (Zhang, Yao et al. 2011) to produce 
aminophenylboronic acid (APB) functionalised magnetic mesoporous silica. 
Magnetic mesoporous silica nanocomposites were first produced. These were reacted 
with GLYMO in methylbenzene under reflux for 12 hours. The resultant 
GLYMO-functionalised mesoporous silica nanocomposites were then incubated in 
chloroform containing APB for 6 h under gentle rotation, to produce the boronic acid 
functionalised magnetic nanoparticles. The magnetic mesoporous silica 
nanocomposites were successfully used to selectively enrich glycopeptides. APB 
functionalised magnetic mesoporous silica also showed high selectivity for 
glycopeptides in a digest containing a 10-fold excess of bovine serum albumin 
(BSA) over horseradish peroxidase (HRP). 
Recently, boronic acid-functionalised core–shell polymer nanoparticles were 
successfully synthesised for enriching glycosylated peptides (Qu, Liu et al. 2012). 
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The nanoparticles were composed of a hydrophilic polymer core manufactured by 
distillation precipitation polymerisation (DPP) with a boronic acid-functionalised 
shell. Using the nanoparticles to capture glycopeptides from a tryptic digest of HRP 
prior to analysis by MALDI-TOF, the authors found that 18 glycopeptides were 
captured compared to eight glycopeptides enriched by using commercially available 
3-aminophenylboronic acid agarose under the same conditions. Glycopeptides could 
still be selectively isolated by the prepared nanoparticles at concentrations as low as 
5 nmol. 
 
3.1.5 Boronic acid solid phase microextraction 
 
Boronate affinity has also been used in solid phase microextraction (SPME) (He, Liu 
et al. 2009). Here, it was used because the pH dependent change in affinity of 
boronic acids for compounds containing 1,2 and 1,3 cis-diols allows desorption of 
bound analytes for analysis by HPLC or CE without harsh conditions such as 
elevated temperature which may cause degradation of analytes. He et al. 
electrochemically deposited poly-3-APBA onto a silver wire. Extraction of 
riboflavin was carried out at pH 9, with elution at pH 3.5. Binding equilibrium was 
reached after about 30 minutes, although desorption continued to increase up to 60 
minutes. 
 
3.1.6 Boronic acid chromatography 
 
Separation phases involving immobilised boronic acids include affinity 
chromatography supports, where phenylboronic acid is immobilised on dextranes 
(Hjertén and Li 1990) or co-polymerised with methacrylates (Lei, Liu et al. 2001). 
Separation and detection of N-acetylneuraminic acid and N-glycolylneuraminic acid 
has also been carried out using HPLC coupled to ESI-MS, with separation on a C18 
column modified using decylboronic acid (Allevi, Femia et al. 2008). This may be of 
relevance in the detection of rEPO usage, as N-glycolylneuraminic acid is found in 
rEPO but not endogenous EPO. In this study, the limit of detection was 100 ng/mL, 
with 2 ng on column. This was whilst using an ion trap as opposed to a triple 
quadrupole mass spectrometer, and working with a 2.1 mm diameter column. As 
such it is likely that improvements in sensitivity could be reasonably easily obtained. 
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Elution was carried out using aqueous formic acid (0.04%). With this weakly acidic 
mobile phase, other carbohydrates present in the sample were unretained and eluted 
with the solvent front. Both sialic acids, however, were retained sufficiently to allow 
baseline separation. 
Boronic acid affinity chromatography has also been combined with lectin affinity 
chromatography (Monzo, Bonn et al. 2007). Agarose beads with bound lectins 
(Con A or WGA) or bound 3-aminophenylboronic acid were mixed together, packed 
into spin columns and a protein test mixture added. Binding was carried out using a 
50 mM taurine buffer, at pH 8.7. Elution was carried out from the boronic acid 
functionalised beads using a solution consisting of 50 mM Tris, 0.5 M NaCl, 
0.05% NaN3, pH 7.2. Despite the surprisingly high pH of the elution buffer, they 
were able to successfully elute bound glycopeptides from the boronic acid agarose 
beads. This was attributed to the high NaCl concentration of the solution, while it 
has also been reported that the steric configuration of the hydroxy groups in Tris can 
interfere with binding of glycopeptides to boronic acids (Li, Larsson et al. 2001). 
 
3.1.7 Adjusting the pH of ester formation 
 
The need for a basic pH for conventional phenylboronic acids to bind cis-diols is 
inconvenient and increases the risk of degradation of labile compounds. Four 
approaches have been proposed to solve this problem. The first involves the 
incorporation of a carbonyl or sulfonyl group into the phenyl ring with electron 
withdrawing effects. Alternatively, an amine group can be incorporated next to the 
boronic acid, to form an intramolecular boron–nitrogen coordination. Li et al. (Li, 
Liu et al. 2011) produced a Wulff-type boronate (3-(dimethylaminomethyl)-aniline-
4-pinacol boronate) and immobilised it onto a polymeric macroporous monolith. The 
boronate affinity monolith produced demonstrated enhanced affinity to cis-diol 
biomolecules such as adenosine at pH as low as 5.5. 
Thirdly, the boron-nitrogen coordination can be replaced by a boron-oxygen one. A 
fourth alternative was proposed by Liu et al. (Ren, Liu et al. 2009), who produced a 
monolith with a boronic acid and amine group in the same neighbourhood. The 
amine coordinates with the boronic acid, functioning as a Wulff-type boronic acid, 
and producing enhanced affinity at neutral pH. Although this monolith exhibited 
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excellent specificity to small cis-diol containing molecules, it failed to bind 
glycoproteins, possibly due to steric inhibition. 
More recently, Liu et al. (Liu, Ren et al. 2011) produced a sulfonyl substituted 
boronic acid functionalised monolithic capillary with both a strong boronate affinity 
at neutral pH and also secondary separation capability to cis-diol biomolecules. As a 
result, it had two dimensional (2D) separation capability, firstly separating cis-diol 
compounds from non-cis-diol ones, and then further separating cis-diol compounds 
according to differential hydrogen bonding interactions with the monolith. 
 
3.1.8 Boronic acid functionalised monolithic materials 
 
Other monolithic materials with boronate functionality have also been produced. 
Bossi et al. (Bossi, Castelletti et al. 2004) produced polymers from 
3-aminophenylboronic acid monomers. This proved capable of separating 
diastereoisomers of ascorbic acid using capillary zone electrophoresis. Normally, the 
two diastereoisomers are separated in CZE only in the presence of borate buffer at 
high molarities (200 mM). The capillaries were also tested for the discrimination of 
haemoglobin and glycated haemoglobin and showed a fairly high selectivity towards 
the sugar-modified protein. 
Chen et al. (Chen, Lu et al. 2009) manufactured a poly(3-acrylamidophenylboronic 
acid-co-ethylene dimethacrylate) (AAPBA-co-EDMA) monolith in a 530 mm long 
capillary by a one-step in situ polymerisation procedure. Extraction of tryptic digests 
of HRP and mixtures of intact HRP/BSA was carried out. Ten glycopeptides from 
tryptic HRP peptides were selectively captured, as well as HRP protein from the 
HRP/BSA mixture, demonstrating both a high extraction capacity and specificity. 
Boronate functionalised monolithic capillary columns were also synthesised by in 
situ free radical polymerisation by Ren et al. (Ren, Liu et al. 2009). They used 
4-vinylphenylboronic acid as one of the monomers for the reaction, with ethylene 
glycol and diethylene glycol as porogens. The column displayed reversed-phase 
retention due to the hydrophobic nature of the monolith skeleton, requiring high 
concentrations of acetonitrile in the solvent to avoid this interaction. At pH 8.5, 
cis-diol containing catechol was completely retained, whereas quinol (without the 
cis-diol group) was unretained. At pH 2.7, catechol was completely eluted.  The 
presence of a Lewis base such as fluoride aids the formation of the boronic ester. The 
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fluoride ion has a lone pair of electrons which can form a complex with a boronic 
acid. This can then form a cyclic ester with a cis-diol group in a less basic media. It 
has been observed that the presence of fluoride enhances the complexation of 
saccharides with boronate ions under less basic conditions, facilitating the formation 
of an anionic ester (Westmark, Valencia et al. 1994; Deore, Yu et al. 2003). Ren et 
al. found that increasing the concentration of sodium fluoride in their mobile phase 
increased retention of catechol.  
Ren et al. did not look at retention or separation of large molecules such as 
glycopeptides or glycoproteins using their monolithic column, due to the problems 
of denaturation caused by the need for a high concentration of organic solvent in the 
eluent. However, in another paper (Ren, Liu et al. 2009) they synthesised a 
hydrophilic boronate functionalised polymeric monolithic column by free radical 
polymerisation through substituting the hydrophobic cross-linker EDMA with a 
hydrophilic one, N, N-methylenebisacrylamide (MBAA). This significantly reduced 
the hydrophobicity of the column, enabling retention of the glycosylated proteins 
HRP and lactoferrin, while non-glycosylated proteins were unretained. 
Boronate affinity monoliths have also been produced using metal-organic gels 
(MOGs) as a porogenic template (Yang, Lin et al. 2011). These proved to be a more 
convenient method for the formation of macropores in contrast to traditional 
porogenic methods. HRP and transferrin were selected as model glycoproteins and 
were completely bound by the boronate monolith at pH 8.5, whereas BSA and 
Cytochrome C were not. Both HRP and transferrin were eluted after switching to an 
acidic mobile phase (pH 2.5). The authors also successfully extracted transferrin 
from a bovine serum sample, demonstrating its application in complex biological 
samples. 
Boronic functionalised materials have also been used as an alternative to Protein A 
for the specific capture of IgG (Liu, Lu et al. 2012). The easier disruption of boronic 
acid bonding means that less harsh conditions can be used than with Protein A. The 
binding of boronic acids should also be to glycan groups located on the Fc region of 
antibodies, not the important epitope binding region. By locating the boronic acid 
ligand within mesopores of an optimised size, a monolith was produced such that 
glycan groups on IgG were able to bind to the boronic acid group while the rest of 
the antibody was left outside the pore. Other glycoproteins with glycans which could 
not reach the boronic acid ligand were excluded. Comparison of the binding of 
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antibodies with other glycoproteins found that all eight tested antibodies were 
captured by the monolith, whereas only two out of seven non-antibody glycoproteins 
were retarded. Since the binding affinity between the boronic acid and glycans on the 
different glycoproteins should have been similar, this demonstrates the importance of 
correct optimisation of pore size. 
The selectivity of polymer-based monoliths is not ideal, due to non-specific 
adsorption. Hybrid monoliths combine the merits of silica with those of organic 
polymer monoliths and have gained in popularity recently in the separation field. Lin 
et al. (Lin, Pang et al. 2011b) described a method for one-pot synthesis of organic–
inorganic hybrid affinity monoliths,  using hydrolysed tetramethyl orthosilicate 
(TMOS) and methacryloxypropyltrimethoxysilane (γ-MAPS) as co-precursors and 
4-vinylphenylboronic acid (VPBA) as a functionalised organic monomer. The 
resultant hybrid affinity monoliths specifically bound cis-diol-containing 
biomolecules and glycoproteins. Extraction of glycoproteins from egg white 
demonstrated the effectiveness of the hybrid affinity monolith for the specific 
capture of glycoproteins from complex biological samples. 
The same authors (Lin, Pang et al. 2011a) also produced boronic acid functionalised 
monoliths using VPBA and ethylene dimethacrylate as monomers, with the resultant 
material demonstrating similar selectivity for glycoproteins. 
 
3.1.9 Choice of approach 
 
Due to the simplicity of the reactions and the availability of materials and equipment, 
it was decided to attempt to replicate the production of boronic acid functionalised 
silica as carried out by Xu et al. (Xu, Wu et al. 2008), using commercially available 
silica. Despite the obvious advantages of using silica (easier control of pore size and 
simplicity of manufacture), there has been no apparent work in this area since their 
publication. Their work used their own ‘home-made’ mesoporous silica. Since 
production of this silica was beyond the scope of this work, it was decided to try and 
replicate it using commercially available silica. This would have the added 
advantage of demonstrating that the functionalised material could be easily and 
cheaply reproduced. The hope was that this would provide a material which could be 
used to pack a trapping column, helping concentrate glycopeptides from EPO and 
improve LC-MS. As a comparison, functionalisation with boronic acid groups would 
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also be carried out on commercially available polymeric beads, and commercially 
available boronic acid SPE materials would also be tested to examine their ability to 





3.2.1 Materials and equipment 
 
All water used was purified using an Elgastat Option 3 water purification unit and 
had 18.2 MΩ resisitivity. HPLC bulk packing silica (5 µm particle size, 300 Å pore 
size) was purchased from Varian (Oxford, UK). Azobisisobutyronitrile (AIBN) was 
purchased from BDH (Leicestershire, UK). Hydrofluoric acid (48%, analytical 
grade) was purchased from Fisher Scientific (Leicestershire, UK). Trypsin 
(sequencing grade) was purchased from Promega (Southampton, UK). Horseradish 
peroxidase (HRP) was a kind gift from Dr. Martyn G. Boutelle, of Imperial College, 
London. Polymeric beads (PL-CMS) were a gift from Varian. Phenylboronic acid 
functionalised SPE cartridges (Bond Elut PBA) were purchased from Agilent 
(Wokingham, UK). All other chemicals were of analytical grade and were purchased 
from Sigma Aldrich (Poole, UK). 
 
Infrared spectroscopy was carried out using a Perkin-Elmer Spectrum One FTIR 
Spectrophotometer, with a Durasampler II Diamond ATR attachment. 
 
ICP-MS was carried out using a Perkin-Elmer Elan DRC Plus. Conditions are set out 
below: 
 
rf power 1.1 kW, frequency 40 MHz 
torch Quartz torch using alumina injector tube 
plasma Ar flow rate 15 L/min 
auxiliary Ar flow rate 0.8 L/min 




Nebulizer and Spray Chamber 
  
nebulizer cross-flow type, gemtip type - ruby (argon) & sapphire (sample) 
spray chamber Scott Double Pass, room temp. 
made of Ryton 




sampling orifice 1.1 mm (made of Pt) 
skimming orifice 0.9 mm (made of Pt) 
  




B, peak hopping mode. 
  
50 sweeps per replicate at 200 ms per sweep. 
5 replicates averaged to give the final result, thus sample measurement took ~51 sec. 
Background measured in the first sample of the run and subtracted from all other 
results 
 
A Hypersil Gold C18 column from Thermo Fisher (Loughborough, UK), 200 mm 
length and 2.1 mm internal diameter with 1.9 µm particles was used for 
chromatographic separations, except where otherwise specified. LC-MS/MS was 
carried out using a Thermo Accela HPLC pump and autosampler, and a Thermo 
LTQ linear ion trap mass spectrometer, again unless otherwise specified. 
 
3.2.2 Production of boronic acid functionalised silica – method one 
 
Silica was modified using the method developed by Xu et al. (Figure 3.2). Fifty 
milligrams 3-aminophenylboronic acid monohydrate (APB) was dissolved in 20 mL 
deionised water, and the solution adjusted to pH 9.18 by addition of aqueous NaOH. 
Forty microlitres of 3-glycidyloxypropyltrimethoxysilane (GLYMO) was added 
slowly while stirring, with the flask sitting in an ice bath. The flask was then put in a 
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water bath on a stirrer for 6 hours at 40 ºC. Then, it was returned to an ice bath for 
five minutes, before a further 40 µL of GLYMO was added, and the flask stirred for 
6 more hours at 65 ºC. The resulting solution (boronic acid bonded GLYMO, GA) 
was transferred to a new vial and kept refrigerated overnight. Twenty milligrams of 
silica was then weighed into a centrifuge tube, and 5 mL of the solution added to it. 
This was heated at 75 ºC for two hours, then the tube was centrifuged, the 
supernatant removed and 5 mL more GA added. This was repeated twice more until 
all the 20 mL of GA had been used. The resulting silica was washed twice with 3 mL 
water and twice with 3 mL methanol. It was then resuspended in 100 µL methanol 




Figure 3.2. Production of phenylboronic acid functionalised silica (method one) 
 
3.2.3 Production of boronic acid functionalised silica – method two 
 
Silica was also modified using the method developed by Li et al. (Li, Zhao et al. 
2006) Silica (0.5 g) was dried overnight at 160 °C, then slurried in 20 mL dried 
dichloromethane. 1 mL GLYMO was added under nitrogen and the mixture stirred 
and refluxed under nitrogen for 24 hours. The silica was filtered off, washed on a 
glass filter-funnel with 25 mL of dichloromethane, acetone, dichloromethane and 
diethyl ether in turn and then dried at 70 °C for 4 hours. 200 mg of APB was 
dissolved in 20 mL of water and sonicated for ten minutes. The pH of this solution 
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was adjusted using aqueous NaOH to 7.5 and 0.5 g of the modified silica was added. 
The mixture was stirred under nitrogen and reflux at 90 °C for 24 hours. The silica 
was finally filtered off again and washed with 25 mL of water and then methanol. 
 
3.2.4 Production of boronic acid functionalised silica – method three 
 
The third method for modification of silica was similar to that above. The method for 
reacting silica with GLYMO was the same as in 3.2.3. However, 200 mg of APB 
was added to 20 mL of chloroform, 0.5 g of silica added to this and the mixture 
stirred under nitrogen at room temperature for 16 hours, before being washed with 
methanol, water, and diethyl ether. 
 
3.2.5 IR Spectroscopy of modified silica 
 
Silica was dried overnight at 110 ºC to remove water, which would prevent effective 
grinding of silica, then ground finely and its total attenuated reflectance measured. 
As controls, unmodified silica and silica which had been directly reacted with APB 
instead of GA were used. Spectroscopic analysis was also carried out on silica taken 
from Bond Elut PBA cartridges. 
 
3.2.6 ICP-MS of modified silica  
 
Mannitol powder was dissolved in 0.1 M HF to obtain a 1% solution and diluted to a 
0.1% mannitol solution with water. About 2 mg of silica modified as in 3.2.2 was 
weighed out accurately to 0.01 mg in a 1 mL polypropylene test tube. The sample 
was soaked with 0.2 mL of 0.1% mannitol solution to suppress boron volatilisation. 
Then, 0.1 mL of concentrated HF was added, and the tube tightly capped. The 
sample was decomposed overnight in an ultrasonic bath until the silica disappeared 
completely, and the solution subsequently evaporated at 70 °C until dry. Then, 1 mL 
of 0.5 M HF was added to the dried samples, and the tube agitated in an ultrasonic 
bath for 30 minutes to recover boron into the HF solution, leaving fluoride deposits. 
The deposits were removed by centrifuge, 100 µL of the supernatant was made up to 
5 mL with water and the resulting solution finally aspirated into the ICP-MS. 
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A standard curve of boron solutions of concentrations from 10 to 1000 ng mL
-1
 was 
also produced. This was aspirated into the ICP-MS, along with unknown samples, to 
enable quantification of samples. The process was also carried out for silica removed 
from Bond Elut PBA cartridges. 
 
3.2.7 Kinetic study of modification of silica 
 
To see how modification of silica proceeded over time, the procedure (3.2.2) above 
was followed but samples of 4 mg of silica were modified, for periods from 0 to 10 
hours. Samples were then digested as in 3.2.6 and analysed using ICP-MS. 
 
3.2.8 Measurement of epoxide functionalisation of silica produced in 3.2.3 and 3.2.4 
 
To measure to the extent of GLYMO functionalisation of silica by methods 3.2.3 and 
3.2.4, silica was reacted with 0.2 N HCl in 1,4-dioxane. This was then titrated 
against 0.1 M NaOH in methanol to determine how much HCl had reacted with the 
epoxide groups on the silica. 
 
3.2.9 Boronic acid functionalised silica extraction of glycopeptides from solution 
 
Horseradish peroxidase (HRP) was used as a model glycoprotein. HRP (1 mg) in 
50 mM ammonium bicarbonate, pH 7.4 (ABC) was mixed with 20 µg trypsin (50:1 
ratio of protein:enzyme) and incubated overnight at 37 ºC. The digest was then 
diluted down to 100 µg/mL with 95:5 ABC:acetonitrile, and 100 µL added to 10 mg 
modified silica (which had been conditioned for 30 minutes with 95:5 
ABC:acetonitrile). This was incubated for 15 minutes at room temperature with 
mixing, centrifuged and the supernatant removed. The silica was washed (twice) 
with 100 µL 95:5 ABC:acetonitrile for 15 minutes, then centrifuged and the 
supernatant removed again. Elution was carried out by incubating for 30 minutes in 
100 µL of 30:70 acetonitrile:water, with 2% formic acid. Samples were centrifuged 
and the supernatant removed. All samples were dried down under nitrogen and 
reconstituted in 95:5 water:acetonitrile. The original solution before and after 
incubation with the silica, the supernatant from the wash steps and the eluent were 
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all analysed using LC-MS/MS. Extractions were also carried out using unmodified 
silica as a control. Each extraction was carried out in duplicate. 
 
LC-MS/MS analysis of samples was carried out using the following gradient, with a 
flow rate of 200 µL/min. 
 
Table 3.3: Gradient used for elution of digest of HRP 
 
Time (mins) % solvent A % solvent B 
0 95 5 
5 95 5 
30 20 80 
34 20 80 
34.5 95 5 
40 95 5 
 
 
10 µL of sample was injected onto the column. The MS conditions were: Sheath gas 
(nitrogen) flow rate (arbitrary units) 40, auxiliary flow rate 4, sweep gas flow rate 4; 
spray voltage was 4 kV, capillary temperature 350 ºC, capillary voltage 14 V and 
tube lens voltage 60 V. 
 
Full scan MS, range 50-2000, and MS/MS scans for theoretical tryptic fragments 
were carried out. Theoretical masses of peptides were calculated using the 
PeptideMass characterisation tool, on the ExPASy Proteomics Server website 
(http://web.expasy.org/peptide_mass) 
 
The three most prominent glycopeptides and non-glycosylated peptides were then 
selected for quantifying recovery of HRP using boronic acid functionalised silica 
The peptides were the tryptic fragments with amino acid sequences TPTIFDNK, 
DTIVNELR and YYVNLEEQK. The 2+ ions for these peptides were detected at 
m/z 468.5, 480.5 and 593.7 respectively. Glycopeptides were tryptic fragments, 
SFANSTQTFFNAFVEAMDR, GLIQSDQELFSSPNATDTIPLVR and 
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LHFHDCFVNGCDASILLDNTTSFR, all of which contained a core-fucosylated and 
core-xylosylated trimannosyl N-glycan. The 3+ ions for these glycopeptides were 
detected at m/z 1119.2, 1225.3 and 1299.4 respectively. Four MRM transitions were 
selected for each glycopeptide/peptide, and the peak area of each summed to give a 
total peak area for each glycopeptide/peptide. Each sample was injected twice, and 
the mean peak area recorded. Recovery was calculated as a percentage of peak area 
in the eluent compared to that in the original digest. 
 
3.2.10 Extraction of mannitol using boronic acid functionalised silica 
 
As a quicker check of the effectiveness of the modified silica at specifically binding 
cis-diol containing compounds in a pH dependent way, mannitol solution 
(100 µg/mL) was made up in a range of buffers at different pH. 100 µL of solution 
was incubated with 10 mg of silica, as detailed in 3.2.9. Samples were then 
centrifuged and the supernatant removed. Solutions were infused at a rate of 
10 µL/min into the mass spectrometer and the average intensity of the signal from 
the mannitol (molecular ion, sodium adduct) measured over 30 seconds. Unmodified 
silica was used as a control, and standard curves of mannitol in the relevant buffer 
used to quantify binding. 
 
3.2.11 Extraction of glycopeptides using Bond Elut PBA silica 
 
Tryptic digests of HRP and fetuin were carried out as in 3.2.9. Solutions of digests 
were made up at 100 µg/mL in buffers with different pH. Extractions were carried 
out as in 3.2.9, except using the different buffers in place of ABC, and using silica 
from the Bond Elut PBA SPE cartridges. Extractions were also carried out using 
fetuin which had been digested with trypsin after being digested with neuraminidase 
to remove sialic acids. LC-MS analysis was carried out using a Waters Acquity LC 
system, connected to a Thermo Exactive Orbitrap mass spectrometer. Peak areas of 
selected peptides and glycopeptides were measured and recovery measured by 
comparing the peak areas to those in the original digest. Accurate masses of peptides 
and glycopeptides were calculated using the PeptideMass characterisation tool and 
glycan mass calculator (http://web.expasy.org/glycanmass/) on the ExPASy 
Proteomics Server website. For HRP, the same peptides and glycopeptides were 
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selected as in 3.2.9. For fetuin, the peptides were HTFSGVASVESSSGEAFHVGK, 
HTLNQIDSVK and TPIVGQPSIPGGPVR. Their 3+, 2+ and 2+ ions were detected 
at m/z 707.7, 577.8 and 737.9 respectively. Glycopeptides were 
RPTGEVYDIEIDTLETTCHVLDPTPLANCSVR with a trisialyated triantennary 
complex glycan, which was detected as a 4+ ion at m/z 1635.2, and 
LCPDCPLLAPLNDSR with a trisialyated triantennary complex glycan which was 
detected as a 3+ ion at m/z 1535.9. 
 
3.2.12 Phenylboronic acid functionalisation of polymeric material 
 
250 mg of 4-aminomethyl phenylboronic acid (HCl salt) was neutralised by reacting 
with 13.3 mL of 0.1 M NaOH dissolved in methanol. 0.266 g of PL-CMS polymeric 
beads was suspended in 12 mL of tetrahydrofuran and this added to the APB 
solution. This was then heated under nitrogen and reflux for 24 hours at 
60 °C. The beads were then washed sequentially with 20 mL 
dichloromethane/acetone/water/tetrahydrofuran, and dried overnight at 40 °C. The 




Figure 3.3: Boronic acid functionalisation of polymeric beads 
 
3.2.13 Binding of mannitol by polymeric beads 
 
As a quick check of the extent of functionalisation of the polymeric beads, modified 
and unmodified beads (about 25 mg, accurately weighed) were incubated with 
250 µL of 50 µg/mL mannitol solution (50:50 methanol:50 mM ammonium 
bicarbonate, pH 7.5) for 30 minutes. Samples were centrifuged and supernatant 
infused into the LTQ-MS. Intensity of m/z 205 (mannitol Na+ adduct) was averaged 
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over 1 minute and compared with a standard curve of mannitol. Recovery from the 
beads was carried out by incubating the beads with 250 µL of either: 
1. 50:50 water/methanol + 1 % formic acid, pH 3.4 
2. 50:50 water/methanol + 10 % formic acid, pH 3.0 
3. 50:50 water/methanol + 1 % TFA, pH 2.2 
4. 50:50 water/methanol + 1 % TFA – sample was then dried down under N2 
and reconstituted in 50:50 water/methanol + 0.1 % formic acid 
 
Recovered solutions were then infused into the LTQ-MS. 
 
The effect of pH on mannitol binding to the beads was investigated by repeating the 
extraction step in buffers at pH 5.0, 6.0 and 8.5. Again, concentration in the solution 
after incubation was measured by centrifugation and infusion of the supernatant. 
 
3.2.14 Extraction of peptides and glycopeptides using polymeric beads 
 
The experiment in 3.2.9 was repeated, using 25 mg of modified polymeric beads 
instead of silica. Extraction was carried out using 50:50 water/methanol + 1 % TFA, 
pH 2.2. Due to the hydrophobic nature of the polymeric beads, extraction from 
purely aqueous samples was not possible. Solutions were therefore made up in 75:25 
water:methanol. All samples were dried down and reconstituted in 95:5 
water:acetonitrile, before analysis by LC-MS/MS. 
 
To try to reduce non-specific binding of HRP peptides to the polymeric beads, an 
attempt was made to block non-specific binding sites with insulin. The HRP 
extraction was carried out as above; however, beads were incubated for 30 minutes 









3.3 Results and discussion 
 
3.3.1 General discussion 
 
Modification of silica by the first method made a noticeable difference to its 
appearance, which changed from white to a pale pink. The other two methods, 
though based on published work, were more problematic. Heating silica at a basic 
pH in an aqueous solution at 90 °C resulted in much of the sample dissolving. In the 
third method, the reaction is carried out in chloroform; however, APB was 
noticeably insoluble in this solvent and suspensions had a marked tendency to 
separate out over time. Although the APB was added in excess and left to react for a 
long time, there was no visible sign that the reaction had occurred. This is reflected 
in the results obtained in experiments using these silicas. 
 
 
3.3.2. IR-spectroscopy of modified silica 
 
Infrared spectra from unmodified silica, silica that had been incubated directly with 
APB (control) and fully modified silica produced as in 3.2.2 are shown below 
(Figure 3.4). The key difference is the appearance of bands in the modified silica at 
1348 and 708 cm
-1
 indicating the existence of B-O bonds, not present in the two 
controls. There are also absorbances at 1572 and 1436 cm
-1 
which can be attributed 
to C-C bonds in the benzene ring and C-H bonds respectively. 
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Figure 3.4: Infrared spectra of unmodified, control and boronic acid functionalised 
silica 
 
Spectra for silica modified by methods two and three showed no difference from the 
control or unmodified silica, indicating that the functionalisation with phenylboronic 
acid had not been successful. 
The spectrum for Bond Elut PBA silica is shown in figure 3.5. It too shows an 
absorbance at about 708 cm
-1
 of about a similar intensity. 
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Figure 3.5: FTIR spectrum of Bond Elut PBA silica 
 
3.3.3 ICP-MS of modified silica 
 
Incubation of the silica produced by method 1 with GLYMO-APB for different 
lengths of time demonstrated an overall increase in boron content of the silica with 
time, below (Table 3.4, Figure 3.6): 
 
Table 3.4: Effect of increasing reaction time on degree of modification of silica 
 
Modification time (hours) Boron (µg/mg silica) Boron (mmol/g silica) 
0 0 0 
1 4.82 0.44 
2 5.78 0.53 
3 9.23 0.84 
4 8.06 0.73 
5 11.75 1.07 
6 10.74 0.98 
7 11.31 1.03 
8 5.64 0.51 
9 12.87 1.17 































Figure 3.6: Effect of increasing reaction time on degree of modification of silica 
 
The samples were individually incubated with magnetic stirrers. It was noted that 
these occasionally stuck in position, and it is possible that this is what happened with 
the sample incubated for 8 hours. It is unfortunate that this time was that used to 
modify silica in practice. However, if this result is ignored, the other results suggest 
that an incubation for 8 hours would give a concentration of boronic acid functional 
groups of about 1 mmol/g silica. ICP-MS of silicas modified by alternate methods 
was not carried out, due to the difficulties experienced in production of the silica, 
combined with the lack of positive results from IR spectroscopy and binding 
experiments with saccharides and glycopeptides. HF digestion of Bond Elut PBA 
silica produced a value for boron of 4.37 µg/mg of silica, or 0.40 mmol/g of silica. 
This is significantly lower than that found in the analysis of the modified silica, 
which perhaps is expected given the much larger particle size of the Agilent material 
(40 µm compared to 5 µm), and smaller pore size (60 Å compared to 300 Å). 
Unfortunately, direct measurements of the modified silica were not made, so the 
exact size of the post-reaction particles is not known. However, it does not seem 
unreasonable to suggest that the surface area:volume ratio of the modified silica 
would be larger than that of the Agilent material, given the large difference in their 
starting sizes. 
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3.3.4 Measurement of epoxide functionalisation of silica produced in 3.2.3 and 3.2.4 
 
Titration results indicated an epoxide functional group concentration of 0.54 mmol/g 
silica. This was about half the concentration of boronic acid functional groups 
detected by the first method, suggesting that the reaction between GLYMO and 
silica takes place more efficiently in an aqueous solution, presumably because the 
water speeds up the hydrolysis of the alkoxy groups. Nonetheless, the concentration 
of epoxide groups detected would still be sufficient to enable efficient binding of 
glycopeptides and saccharides, if the concentration of epoxide groups translated into 
the same concentration of phenylboronic acid functional groups. 
 
3.3.5 Boronic acid functionalised silica extraction of glycopeptides from solution 
 
Mean peak areas of peptides and glycopeptides extracted using modified silica are 
shown in Table 3.5. Mean recovery of peptides was 1.1% with the boronic acid 
functionalised silica, and 0.1% with the control silica. Mean recovery of 
glycopeptides was 3.2% with the boronic acid functionalised silica and 0.1% with 
the control silica. Recovery of both peptides and glycopeptides was better with the 
modified silica, and best for glycopeptides. However, the recovery was still very 
poor. The data shows that this was due to a failure of binding rather than elution. 
Since the ICP-MS data suggests that the total content of boronic acid was not too 
low, this implied that either the boron detected using ICP-MS was not in a boronic 
acid group, or that the glycopeptide binding was not taking place for another reason, 
possibly due to steric hindrance. To examine if this was the case, mannitol binding 











Table 3.5: Recovery of targeted glycopeptides/peptides pre-incubation with 
control/boronic acid functionalised silica, post-incubation, from wash solutions and 
in final elutions 
 
 Mean peak area 
 Peptides Glycopeptides 
m/z 468.5 480.5 593.7 1119.2 1225.3 1299.4 
HRP digest, 
100 µg/mL 








225000 515000 40500 16000 7700 21600 
Control 
wash 1 
46200 83200 3070 7650 2490 10100 
Boronic 
wash 1 
61900 142000 11300 16800 4270 32300 
Control 
wash 2 
8380 14200 233 854 306 1370 
Boronic 
wash 2 
17600 34900 2380 3840 775 4260 
Control 
elution 
678 916 0 80 0 5.5 
Boronic 
elution 
4250 6080 242 836 129 789 
 
 
3.3.6 Extraction of mannitol using boronic acid functionalised silica 
 
The concentration of mannitol in solution before extraction was 100 µg/mL. The 
concentrations after incubation are shown in Table 3.6. 
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Table 3.6: Mannitol concentrations after incubation with control or boronic acid 
functionalised silica 
 
Buffer pH Mean mannitol concentration post incubation (µg/mL), 
n=2 
Boronic acid silica Unmodified silica 
5.0 64.7 49.7 
6.0 85.2 84.5 
7.0 98.2 84.5 
8.0 95.4 94.7 
8.8 98.2 96.6 
 
The binding, counter to expectations, appeared to be higher in weakly acidic 
solutions. However, at all pH values the concentration of mannitol was higher after 
incubation with boronic acid functionalised silica than with unmodified silica. Only 
two repeats were carried out for each pH, so it is possible this result is due to noise. 
However, the results for each set were closely correlated, and for pH 5.0 and 7.0 the 
results for the boronic and unmodified silica were well separated, implying that the 
results are real. This would suggest that either the porosity of the silica was 
significantly reduced by the modification, reducing the surface area available for 
binding, or that the phenylboronic acid group itself bound the mannitol less strongly 
than the bare silica. This latter suggestion would go against all the published 
literature on the subject, so is unlikely to be the case. If the first is true, then binding 
would also be unlikely using Bond Elut PBA silica, which has a larger particle 
diameter than the silica being modified. (40 µm compared to 5 µm) and smaller pore 
size (60 Å compared to 300 Å, before modification). For this reason, extraction using 
Bond Elut PBA silica was attempted. 
 
3.3.7 Extraction of glycopeptides using Bond Elut PBA silica 
 
Tryptic digests of HRP were extracted first using the Bond Elut PBA silica. 
Recovery of three peptides (m/z 468.5, 480.5 and 593.7) was measured, as was 
recovery of three glycopeptides (m/z 1119.2, 1225.3 and 1299.4). Recovery when in 
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buffers of pH 5.5, 7.0 and 8.5 are shown in table 3.7. Although recovery was 
reasonable at both pH 7.0 and pH 8.5 for glycopeptides, contrary to expectations it 
appeared to be better at pH 5.5. Recovery of non-glycosylated peptides was fairly 
low, although it was higher for the peptide with m/z 468.5.  
 
Table 3.7: Recovery of HRP tryptic peptides and glycopeptides using Bond Elut 
PBA silica 
 
Buffer pH Mean % Recovery of Peptide m/z 
(n=3) 
Mean % Recovery of 
Glycopeptide m/z (n=3) 
468.5 480.5 593.7 1119.2 1225.3 1299.4 
5.5 37.5 9.2 13.5 96.2 76.6 88.3 
7.0 29.4 3.1 14.6 63.4 70.1 75.6 
8.5 42.1 2.7 15.2 51.9 59.0 79.7 
 
The same process was then repeated using a tryptic digest of fetuin, which contains 
predominantly sialylated glycopeptides. The results are shown in table 3.8. At 
neutral and basic pH, recovery of glycopeptides was very low, whereas unexpectedly 
recovery of non-glycosylated peptides was comparatively high. Recovery of 
sialylated glycopeptides improved from slightly acidic buffer, but so did recovery of 
non-glycosylated peptides, so improved recovery could be due to binding of the 
peptide portion of the molecule, rather than through the cis-diol groups on the 
glycans. 
 
Table 3.8: Recovery of fetuin tryptic peptides and glycopeptides using Bond Elut 
PBA silica 
 
Buffer pH Mean % Recovery of Peptide 
m/z (n=3) 
Mean % Recovery of Glycopeptide 
m/z (n=3) 
707.7 577.8 737.9 1535.9 1635.2 
5.5 104.4 36.1 105.6 40.3 76.8 
7.0 69.3 18.6 73.7 0.4 2.9 
8.5 34.6 21.6 69.6 1.2 3.8 
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To investigate if it was the different binding characteristics of sialic acids which 
were responsible for altering the way fetuin bound at lower pH, tryptic digests of 
desialylated fetuin were extracted. The results are shown in table 3.9. Although 
recovery of glycopeptides improved it was still no better than the recovery of non-
glycosylated peptides, and was worse at pH 8.5. Curiously, although the peptide 
portion of the fetuin should have been unaltered by digestion with neuraminidase, 
the recovery of the non-glycosylated fragments differed markedly from that observed 
when fetuin was extracted with sialic acids still attached. 
 
Table 3.9: Recovery of fetuin tryptic peptides and desialylated glycopeptides using 
Bond Elut PBA silica 
 
Buffer pH Mean % Recovery of Peptide 
m/z (n=3) 
Mean % Recovery of 
Glycopeptide m/z (n=3) 
707.7 577.8 737.9 1244.8 1416.9 
5.5 59.9 39.3 48.9 48.7 33.3 
7.0 55.1 29.1 68.4 60.1 34.5 
8.5 119.2 30.4 72.4 21.6 35.4 
 
3.3.8 Binding of saccharides by polymeric beads 
 
After incubation with unmodified beads, the concentration of the mannitol solution 
appeared to rise from 25.0 µg/mL to 36.1 µg/mL. After incubation with the modified 
beads, the concentration of the solution fell to 1.9 µg/mL. However, recovery from 










Table 3.10: Recovery of mannitol from modified polymeric beads 
 
Elution method Mean recovery (%), n=2 
50:50 water/methanol + 1% formic 
acid, pH 3.4 
2.9 
50:50 water/methanol + 10% formic 
acid, pH 3.0 
1.8 
50:50 water/methanol + 1% TFA, pH 
2.2 
1.0 
50:50 water/methanol + 1% TFA – 
sample was then dried down under N2 
and reconstituted in 50:50 
water/methanol + 0.1% formic acid 
4.0 
 
The apparent rise in concentration of mannitol when incubated with unmodified 
beads may be attributable to the hydrophobicity of the beads. A high concentration 
of organic solvent is required to prevent the beads separating from the solution. It 
may be that this solvent is forming a layer around the beads, and that the highly 
hydrophilic mannitol is in turn partitioning into the aqueous fraction of the solvent, 
resulting in a rise in its concentration in this part. As shown in Table 3.11, there was 
a small fall in mannitol concentration when the incubation was carried out at pH 5.0. 
Mannitol solutions are mildly acidic and it may be that when in acidic solutions, 
mannitol remains protonated and therefore does not partition into the aqueous 
fraction to the same extent. 
Although mannitol concentration had been shown to fall after incubation with the 
modified beads, recovery was poor. Since the mannitol had been shown to bind 
effectively to the beads, the problem must lie with the elution. Non-specific binding 
had not been seen with the unmodified beads, and could not therefore account for the 
low levels of recovery. However, the low pH values of all the elution buffers suggest 
that binding other than the expected boronic ester formation (which would be 
reversed at low pH) was occurring. It is difficult to see what this could have been. 
This is backed by the data showed in Table 3.11, on mannitol binding at different pH 
values. This shows that binding across the pH range of 5.0 to 8.5 did not appear to 
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differ significantly, which it would be expected to if boronic ester formation was 
responsible for binding.  
 
Table 3.11: Concentration of mannitol solution, originally 25.0 µg/mL, after 
incubation with polymeric beads in different pH buffers (n=1) 
 
Buffer pH Concentration of mannitol, post incubation 
(µg/mL) 
Modified beads Unmodified beads 
5.0 1.1 23.3 
6.0 1.5 32.5 
7.5 1.9 36.1 
8.5 1.4 36.8 
 
3.3.9 Extraction of peptides and glycopeptides using polymeric beads 
 
Despite the failure of the attempt to recover mannitol from polymeric beads, an 
attempt was made to extract glycopeptides from tryptically digested HRP. The 
recovery of peptides and glycopeptides from solution is shown in table 3.12.  
Recovery of glycopeptides was again poor. However, unlike the extraction attempts 
using modified silica, some binding of glycopeptides to the beads was apparent, as 
seen in the falls in peak area of the glycopeptides with m/z 1119.2 and 1225.3. The 
concentration of glycopeptides in wash solutions was also low, indicating that they 
were binding to the modified beads. The low concentrations of (non-glycosylated) 
peptides after incubation and in wash solutions suggested that non-specific binding 
of peptides to the beads was a significant problem however, and may be responsible 
for the binding of glycopeptides as well. This is again also indicated by the poor 
recovery, which suggests that the binding of the glycopeptides and peptides is not 
disrupted by the change to an acidic medium, as would be expected if the binding 
was to a boronic acid group. 
Efforts to prevent this non-specific binding by including a pre-incubation step with 
insulin were not successful at improving recovery of glycopeptides, with results 
from all stages of the extraction process remaining at similar levels. 
 138 
Table 3.12: Recovery of targeted glycopeptides/peptides pre-incubation with boronic 
acid functionalised polymeric beads, post-incubation, from wash solutions and in 
final elutions.  
 
 Mean peak area 
 Peptides Glycopeptides 
m/z 468.5 480.5 593.7 1119.2 1225.3 1299.4 
HRP digest, 
100 µg/mL 
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The experiments attempted in this chapter experienced serious problems. 
Manufacture of working boronic-acid functionalised silica proved harder than 
anticipated. By two (published) methods (3.2.3 and 3.2.4), modification of the silica 
failed comprehensively. Attempts to contact the authors of the methods were also 
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unsuccessful, but it is difficult to understand how they managed to heat silica at 
90 ºC in an alkaline solution, or to react silica with aminophenylboronic acid in 
chloroform. An attempt by the other method (3.2.2) resulted in silica which, when 
analysed using FTIR or ICP-MS after HF digestion, appeared to contain high 
amounts of boron. However, it was distinctly unsuccessful at capturing cis-diol 
containing molecules, whether large glycopeptides or small saccharides. The failure 
to bind simple saccharides suggests that it was not lack of porosity that was 
responsible for the failure of the binding, and leaves only the possibility that the 
boron detected was not present in a boronic acid group, i.e. that a different, as yet 
unknown, reaction was taking place to the one expected. 
Comparison of the self modified silica with commercially available boronic acid 
functionalised silica did not serve to clarify the picture. Examination of the Agilent 
silica detected lower levels of boron than that found in the modified silica. The 
Agilent material also had a smaller pore size, and larger particle size; nonetheless, at 
a neutral pH it bound glycopeptides from a solution of a tryptic digest of HRP, and 
did so more effectively than it bound non-glycosylated peptides. These 
glycopeptides were also recovered when an acidic eluent was used. However, 
extraction of these glycopeptides from an acidic buffered solution (pH 5.5) was more 
effective than extraction from a neutral pH, contrary to expectations. Repeating the 
experiment using a tryptic digest of fetuin threw up more anomalous results, as at pH 
7.0, recovery of glycopeptides was very poor, whereas recovery of non-glycosylated 
peptides was reasonably high. This was also the case at pH 8.5. At pH 5.5 recovery 
of glycopeptides was improved, but recovery of non-glycosylated peptides was also 
improved, suggesting that recovery may not be due to boronic ester formation 
involving the cis-diol groups. 
The formation of such esters between sialic acid and boronic acid has been shown to 
have a different pH dependence to the majority of cis-diol containing molecules. 
Specifically, N-acetylneuraminic acid has been shown to continue to bind strongly to 
phenylboronic acid below neutral pH, and its binding affinity actually increased as 
pH decreased as far as pH 4 (Otsuka, Uchimura et al. 2003). As a result, the fetuin 
extraction was repeated, after using neuraminidase to cleave off terminal sialic acids. 
Although this did increase binding of the glycopeptides at neutral and basic pH, 
surprisingly it also did the same for peptides, which should have been unaffected by 
the presence of the enzyme. Perhaps most importantly, recovery of (at least) one of 
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the non-glycosylated peptides from the digest was higher than recovery of the 
examined glycopeptides, meaning that even after this modification step the silica was 
not useful for specifically extracting fetuin glycopeptides. 
The confusing picture with the modified and commercially available silica was the 
reason an attempt was made to modify polymeric beads instead. Initial results 
showed some promise, with rapid and extensive binding of mannitol from solution, 
which was not seen with unmodified beads. Recovery, however, was poor. Since 
incubation with unmodified beads resulted in an apparent rise in the concentration of 
mannitol (possibly due to partitioning into the aqueous fraction of the incubation 
buffer), it is unlikely that this poor recovery was due to nonspecific binding of the 
mannitol to the beads. However, it is not clear what it is due to; again, modification 
of the beads with a functionality other than the expected boronic acid group could be 
responsible. This might also explain the problems found when trying to specifically 
extract glycopeptides from solution using the beads, which bound both glycosylated 
and non-glycosylated peptides without the desired discrimination. 
In summary, attempts to produced boronic acid functionalised materials for the 
specific extraction and concentration of glycopeptides have not been a success. 
Neither silica nor polymeric beads were able to do so specifically, despite some 
evidence that the silica at least had been modified in the intended manner. It is not 
clear why this is; however, modification with a different boron containing functional 
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Chapter 4: The use of ‘superchargers’ in mass 
spectrometry to improve the charging of difficult to detect 



















Aim: To investigate the use of different ‘superchargers’ to improve the charging in 
electrospray ionisation of species which are difficult to detect in either positive or 




4.1.1 Electrospray ionisation 
 
Electrospray ionisation is a soft ionisation technique for producing gas phase ions 
from a solution. In liquid chromatography – electrospray ionisation (LC-ESI), a 
liquid containing ionised analytes flows through a capillary or needle to which a high 
voltage (typically 1-3 kV) is applied. On leaving the capillary, the stream of liquid is 
deformed and forms a (Taylor) cone with convex sides and a rounded tip. Above a 
certain voltage the tip of the cone inverts and produces a jet of liquid. The unstable 
nature of this jet results in an aerosol spray made up of droplets of solvent containing 
the charged analyte ions. The solvent evaporates from the droplet until its charge 
density becomes too great (the Rayleigh limit) and the repulsive forces between the 
ions cause the original droplet to break up into smaller daughter droplets. 







where zR is the unit charge limit, e is the elementary charge, ε0 is the permittivity of 
the surrounding medium, γ is the surface tension, and R is the droplet radius. 
 
4.1.2 Mechanism of free ion production 
 
There are two theories of how ions are finally produced in the gas phase, shown in 
Figure 4.1. The first, originally proposed in 1968 (Dole, Mack et al. 1968), is known 
as the Charged Residue Model (CRM). It suggested that the subdivision of particles 
at the Rayleigh limit into smaller particles would continue until droplets are formed 
containing a single charged analyte particle, which would then enter the gas phase.  
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An alternative suggestion (the Ion Evaporation Model, or IEM) was put forward by 
Iribarne and Thomson in 1976 (Iribarne and Thomson 1976). They suggested that 
before a droplet containing just a single charged analyte is formed, the charge 
density on its surface would be sufficient to push an ion into the gas phase. As 
evaporation of solvent continued and droplet size shrank, more and more ions would 
be pushed into the gas phase. 
There is evidence that smaller molecules are ionised by the IEM process, (Gamero-
Castaño and Mora 2000; Nguyen and Fenn 2007), whereas larger molecules such as 
proteins are ionised by the CRM process (Nohmi and Fenn 1992).  
 
4.1.3 Ionisation of small molecules 
 
With electrospray, small molecules tend to produce singly charged ions. The charge 
on these ions determines whether negative or positive ion mode is suitable for 
analysis. It in turn is strongly influenced by the choice of solvent and the structure of 
the analyte in question. Acidic solvents promote protonation, and therefore may be 
better for positive ion analysis. Conversely, neutral or basic solvents are often used 
for negative ion analysis. Complicating matters is the fact that such solvents also 
affect chromatographic retention, so choice of solvent pH may not be quite so 
straightforward when LC-ESI is used as when a sample is infused into a mass 
spectrometer. Typically, positive ion mode is used when small molecules contain 
basic functional groups, whereas negative ion mode is used for molecules with a 
pronounced acidic nature. This means that compounds containing amino, amide, 
aldehyde/keto ester or hydroxyl functional groups can be analysed using positive ion 
ESI, while compounds containing carboxylic acids, hydroxyl/phenol or imide 





Figure 4.1: Schematic representation of the possible pathways for ion formation from 
a charged liquid droplet. Upper mechanism is the Charged Residue Model. Bottom 
mechanism is the Ion Evaporation Model. In the latter model the final ion is 
produced by desorption, whereas the ion in the former model it is produced by 
evaporation of solvent from the droplet. (Nguyen and Fenn 2007) 
 
4.1.4 Ionisation of proteins and peptides 
 
Larger molecules such as proteins and peptides tend to form multiply charged 
species in ESI. This is particularly true of peptides produced by tryptic digestion as 
they contain an arginine or lysine residue at their C-terminal, as well as an amino 
group at their N-terminal. A typical spectrum from the ESI of horse myoglobin is 
shown in figure 4.2. One key detail to note here is that a series of multiply charged 
species is created, with total charge distributed across the ‘multi-charge envelope’. 
Since mass spectrometers detect ions based not on their mass but on their 
mass/charge ratio, this has the effect of bringing large molecules into the range 






Figure 4.2: ESI mass spectrum from horse myoglobin (A) distribution showing 
multiple charges (B) spectrum deconvoluted for molecular weight determination 
(Powell, Razunguzwa et al. 2009) 
 
For Fourier transform mass spectrometers, increased charge also improves signal to 
noise, mass accuracy and resolution (Hu, Noll et al. 2005). 
 
Under the CRM, the charge on a protein, peptide or other macromolecule is limited 
by the maximum charge (i.e., the Rayleigh limit) that a droplet of a similar size to 
the macromolecule can contain before fissioning. Excess charge is lost from a 
droplet by the expulsion of small electrolyte and solvent ions, until upon desolvation 
the remaining charge is transferred to the macromolecule. However, this approach 
fails to quantitatively explain some of the multiple charging observed with 
macromolecules. Hogan et al (Hogan, Carroll et al. 2008) have proposed that in 
positive mode for proteins that denature in acidic solutions (or in negative mode for 
proteins that denature in basic solutions), some of the protein may reside not in the 
interior of the droplet but at its charged surface. Although the desorption of the entire 
macromolecule may not be favoured energetically, as desolvation occurs partial 
desorption of the poorly-solvated charged regions of the protein may occur instead of 
emission of charge carriers. The macromolecule would then protrude from the 
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droplet, with the charged segment outside the droplet not contributing to the excess 
surface charge. This would allow such a protein to carry an overall charge greater 
than that of the Rayleigh limit of the droplet. 
 
4.1.5 Improving charging on molecules by derivatisation 
 
From the above information it should be clear that increasing the number of charged 
molecules of an analyte in solution is desirable, as it should increase the signal from 
that analyte in the mass spectrometer. Increasing the number of charges on a 
molecule can also improve signal if movement to the gas phase is through the IEM 
process, as multiply charged ions would be more repelled by surrounding ions of the 
same polarity, and therefore be more likely to be pushed out of the droplet. A non-
polar region is preferable within the analyte, as non-polar ions prefer the air-solvent 
interface and reside at the droplet surface, meaning they more readily enter the gas 
phase (Cech and Enke 2000). When tandem mass spectrometry is being used, a 
move to a higher charge distribution is also desirable, as fragmentation efficiency is 
better for more highly charged species (Smith, Loa et al. 1990). Finally, it may be 
desirable to carry out mass spectrometric analysis in a different mode to that optimal 
for the compound in question, for instance when multiple compounds are being 
analysed at once and switching between polarities is not possible. All these situations 
can be addressed by chemical derivatisation of the original compound. 
 
An example of this is the way that molecules containing carboxylic acids have been 
derivatised to enable their detection in positive ion mode. Butanolic HCl 
derivatisation produces butyl esters which give a characteristic product ion due to the 
loss of C4H8 in CID, and this approach has been used to measure levels of 
methylmalonic acid, a marker for defective vitamin B12 metabolism (Schmedes and 
Brandslund 2006). Similarly, sialic acids are frequently derivatised with l,2-diamino-
4,5-methylenedioxy-benzene (DMB) to improve detection in positive ion mode 
(whilst simultaneously introducing a fluorophore). (Morimoto, Nakano et al. 2001). 





4.1.6 Improving charging through superchargers 
 
The downsides of improving charging through derivatisation are the added time and 
effort involved, the inevitable in-method losses and the likelihood of reduced signal 
if multiple derivatives are possible. An alternative that has been found to improve 
charging on peptides is the introduction into the solvent, either pre- or post-column, 




Figure 4.3:  Structures of ‘superchargers’. From left, dimethyl sulfoxide, sulfolane 
and m-nitrobenzyl alcohol 
 
 The effect of these low volatility, high surface-tension compounds, was first 
reported in a series of papers by Iavarone and Williams (Iavarone, Jurchen et al. 
2000; Iavarone, Jurchen et al. 2001; Iavarone and Williams 2002; Iavarone and 
Williams 2003; Iavarone and Williams 2003b). They found that the addition of 
glycerol or m-nitrobenzyl alcohol (m-NBA) to samples being electrosprayed resulted 
in highly charged protein and peptide ions, with both the maximum charge state 
detected and the average charge state increased. They also found that the overall base 
peak abundance was not affected, meaning that the change in charge distribution was 
not simply due to suppression of lower charge states. The fact that the increase in 
charging occurred with small (4-mer) peptides suggested that conformational 
changes are not responsible. 
Despite the increase in charge for peptides and proteins, Iavarone and Williams 
found that when m-NBA was added to aqueous solutions of dendrimers, the average 
charge state, highest charge state and most common charge state were all reduced. 
The reverse was true for methanolic solutions of dendrimers. Investigation of the 
effect on solutions of diaminoalkanes to eliminate the possibility of conformational 
effects produced the same result 
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A number of different compounds have been found to act as superchargers. The most 
commonly used are m-NBA, dimethylsulfoxide (DMSO) and tetramethylene sulfone 
(sulfolane), but others which have been shown to have an effect include benzyl 
alcohol, m-nitroacetophenone, m-nitrobenzonitrile, o-NBA, p-NBA, m-nitrophenyl 
ethanol and m-(trifluoromethyl)-benzyl alcohol (Lomeli, Peng et al. 2010). These 
compounds all display low solution-phase basicities and relatively low gas-phase 
basicities, and are less volatile than water. 
The effects of superchargers on chromatographic retention and resolution have also 
been examined. Valeja et al. (Valeja, Tipton et al. 2010) found that the addition of 
m-NBA and DMSO to LC solvents reduced retention time for intact proteins on a 
C18 column, and the addition of DMSO also improved chromatographic separation. 
In comparison, Kjeldsen et al. (Kjeldsen, Giessing et al. 2007), found that the 
addition of m-NBA to LC solvents increased the average charge state of tryptic 
peptides, resulting in improved fragmentation efficiency when fragmentation was 
carried out using electron-transfer dissociation (ETD). It also reduced the retention 
time of the peptides on a reversed-phase column, and at the same time increased 
peak width and reduced peak height marginally. The extent to which peptide charge 
increased in the presence of m-NBA varied significantly (mean plus standard 
deviation of 0.25 ± 0.15). This did not appear to be related to peptide length, pI or 
hydrophobicity. They also examined the effect of m-NBA on phosphopeptides. 
Without m-NBA, only one of the nine phosphopeptides examined had a charge state 
of 3+ or greater; with 0.1% m-NBA in the LC solvent, six phosphopeptides were 
charged to that extent. 
Xie et al. (Xie, Shen et al. 2012) demonstrated that superchargers could be used to 
improve proteomic analysis. Specifically, they showed that the addition of m-NBA 
to LC solvent resulted in an increase in signal intensity for a complex sample of 
tryptic peptides from a digest of the AMJ2 cell line. When fragmented using ETD, 
the addition of m-NBA also resulted in an increased success rate of identifications 
using pFind and X!Tandem algorithms. 
Meyer and Komives (Meyer and A. Komives 2012) found a similar result. Using a 
mobile phase with 5% DMSO added and sequencing by both CID and ETD, they 
found significantly improved peptide identification. However, according to Meyer 
and Komives, the increase in identifications was not due to supercharging, which 
was greater when 0.1% m-NBA was used, and not observed when 5% DMSO was an 
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additive. They attributed the improved MS/MS efficiency with the DMSO modified 
mobile phase to charge state coalescence. 
 
4.1.7 Superchargers mode of action 
 
There has been significant discussion about the exact mode of action of 
superchargers. Originally, it was thought that denaturation of proteins and large 
peptides caused by the presence of the superchargers exposed more sites for charging 
and reduced Coulombic repulsion between the sites. However, evidence that the 
same charge enhancement is seen with small peptides means this is unlikely to be the 
sole reason. Iavarone et al. (Iavarone and Williams 2002) said that it appeared to be 
related to the increased surface tension in electrospray droplets. This, they argued, 
meant that a higher surface charge density was needed before the Rayleigh limit 
would be reached, and this in turn would mean peptide and protein ions with higher 
charges would be found at the droplet surface. This is backed up by the work with 
dendrimers, where the addition of m-NBA to aqueous solutions (lowering the surface 
tension) reduced the charge, whereas addition of m-NBA to methanolic solutions 
(raising the surface tension) increased the charge. However, Lomeli at al. (Lomeli, 
Yin et al. 2009) found that addition of m-NBA to solutions of proteins in 20 mM 
ammonium acetate, pH 6.8, also resulted in modest increases in the maximum and 
average charge. The precise importance of surface tension has also been questioned 
by Šamalikova and Grandori, who demonstrated that charge state distributions of 
proteins are not altered by changes in surface tension (Šamalikova and Grandori 
2003; Šamalikova and Grandori 2005), although their method meant it was difficult 
to separate the effect of reducing surface tension from the effect of changing protein 
conformation. They also found that DMSO increased the average and maximum 
charge on myoglobin and cytochrome c when acetic or formic acid was used to 
acidify the solution, but puzzlingly not when HCl was used. 
Miladinović et al. (Miladinović, Fornelli et al. 2012) demonstrated that 
supercharging of proteins and a peptide (substance P) was possible using a dual-
sprayer ESI microchip to introduce the supercharging reagent directly into the Taylor 
cone. This showed that the supercharging process only requires a short period of 
interaction between the supercharger and the analyte, estimated at less than 1–2 ms 
when low flow rate ESI conditions are utilised. They also observed that although 
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both sulfolane and m-NBA increased average charge, DMSO resulted in a reduction 
in average charge. 
Sterling and Williams (Sterling and Williams 2009) found that the increased 
charging of proteins including myoglobin in aqueous solutions caused by the 
addition of m-NBA was mirrored by the effect of heating the solution as it was 
electrosprayed. They argue that surface tension cannot be responsible for the 
increase in charging, as m-NBA has a lower surface tension than water. Instead, they 
suggest that because of its lower volatility electrospray droplets become increasingly 
enriched in m-NBA, but that because of the lower vapour pressure of m-NBA, the 
rate of evaporative cooling of the droplet will be lower. As a result, droplets 
containing m-NBA will be at an elevated temperature and have a longer lifetime than 
those containing just water. This will induce conformational changes in the proteins 
in the droplets, enabling greater charging. This explanation does not, however, 
account for the increase in charging seen on small peptides or already denatured 
proteins. 
The higher charge state ions produced from aqueous solutions when sulfolane or 
m-NBA are present have higher collision cross sections measured using ion mobility, 
consistent with increased protein denaturation (Sterling, Daly et al. 2010; Sterling 
and Williams 2010). 
Evidence that conformational state is important was also provided by Sterling et al. 
in another paper (Sterling, Cassou et al. 2011). They showed that reduction and 
alkylation of cytochrome c and ubiquitin did not affect the maximum or average 
charge states of the proteins in ESI in the absence of m-NBA but that, when m-NBA 
was present, charging increased with decreasing numbers of crosslinks. Similarly, 
addition of m-NBA to native RNAse A solutions increased average and maximum 
charge, but addition to reduced and alkylated RNAse A resulted in a decrease in 
charge, attributed to the reduced surface tension of the electrospray droplets caused 
by the addition of the m-NBA. 
Sterling et al. also used travelling-wave ion mobility-mass spectrometry to 
investigate the effects of superchargers on the solution- and gas-phase structures of 
two protein complexes. (Sterling, Kintzer et al. 2012) They found that low 
concentrations of m-NBA effectively increase the charge of concanavalin A dimers 
and tetramers, but that higher concentrations cause solution-phase dissociation of the 
dimers and up to a ~22% increase in the collision cross section (CCS) of the 
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tetramers. They also found that the anthrax toxin octamer, in the presence of 0.8% 
m-NBA, dissociated to an extent which could not be attributed to Coulombic 
destabilisation in the gas phase as a result of higher charging. They concluded that 
the supercharging of large protein complexes is the result of conformational changes 
induced by enrichment of the supercharging reagent in electrospray droplets. 
The same group in another study (Sterling, Prell et al. 2011) found that the presence 
of low concentrations of DMSO reduced the charge on hen egg white lysozyme and 
equine myoglobin, but that significant increases in charge occurred at higher 
concentrations. They also found that, at low concentration, DMSO caused a 
compaction of these proteins but that unfolding took place at concentrations of ~63% 
and ~43% DMSO for lysozyme and myoglobin, respectively. This is much higher 
than the concentration in the solvent, suggesting that droplets become concentrated 
in the electrospray due to preferential evaporation of water. Using evidence of 
conformational changes obtained using near-UV circular dichroism and solution 
phase hydrogen/deuterium exchange mass spectrometry, Sterling argued that this 
increase in concentration causes denaturation of proteins and is largely responsible 
for the supercharging effect.  
Certainly, the change in supercharging effect with increasing concentration is 
difficult to explain if proton transfer reactivity is responsible. Calculated proton 
affinities for sulfolane, m-NBA and DMSO are shown in Table 4.1. They show that 
all three display greater proton affinity and gas-phase basicity (GB) than water. As 
such, if proton transfer reactivity is important, although proton transfer could occur 
spontaneously from DMSO, sulfolane or m-NBA to analytes with lower GB values, 
such transfer should actually be enhanced when only water is present. 
In summary, it would appear that there are different mechanisms responsible for the 
effects of superchargers in ESI, dependent on the size and type of analyte being 
examined (as there are for ionisation itself). For proteins and large peptides, 
superchargers exert their effect as they become concentrated in electrospray droplets, 
acting as chemical denaturants; in solutions high in organic solvents, they also 
increase surface tension and reduce evaporative cooling, so that thermal denaturation 
also occurs. Reduced Coulombic repulsion and increased availability of chargeable 
sites then result in increased charge. 
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Table 4.1 : Proton affinity (PA) and gas-phase basicity (GB) for water, acetonitrile 
and superchargers 
 
 PA (kJ/mol) GB (kJ/mol) 
Water 697 660 
Acetonitrile 779 748 
Sulfolane 830 801 
DMSO 884 853 
m-NBA 834 800 
 
For small molecules or larger ones which are incapable of conformational change, 
any increase in charging appears to be down to increased surface tension, enabling 
the surface of the droplet to carry greater charge without undergoing Rayleigh limit 
fission. This then results in greater production of analyte ions, via the IEM 
mechanism. 
There are still some results which do not appear to fit this pattern, however; 
specifically, the results of Kjeldsen et al., that the addition of m-NBA increased the 
charging on tryptic peptides and phosphopeptides. These are large molecules, but 
ones which would not be expected to display significant conformational changes to 
expose more charging sites. However, consideration of the problem using Hogan’s 
theory (mentioned in 4.1.4) that peptides can partially protrude from electrospray 
droplets could explain this phenomenon. Thus, electrospray droplets with a high 
organic starting concentration and containing a supercharger would become enriched 
in the supercharger as water evaporates from the droplet, resulting in droplets with 
higher surface tension than are found when the supercharger is not present. This 
results in a greater potential charge on the droplet surface, which can be transferred 
to the protruding portion of the peptide. Then, when the final ion is produced by the 
CRM, it carries a higher charge than if the supercharger had not been present. This 






Figure 4.4: Possible mechanism of supercharging of peptides. Top, without 
supercharger, ion formation by CRM follows loss of charge from droplet in daughter 
droplets. Bottom, with supercharger, ion formation by CRM follows charge 
movement onto parts of peptide located outside the droplet. 
 
4.1.8 Switching ionisation mode 
 
The exact mode, or modes, by which superchargers exert their effects on peptides is 
unknown. However, for small molecules it may be that it at least partially depends 
on the organic content of the solvent when an analyte enters the electrospray. It may 
be that for compounds that elute in higher organic concentrations, the charging on 
droplets, and hence on the analytes themselves, can be improved by the addition of 
superchargers. A possible application of this would be to enable better detection of 
small molecules which are only well ionised in one ionisation mode, when the mass 
spectrometer is operating in the other ionisation mode. This could be useful when 
rapidly switching ionisation mode is not possible. 
Superchargers have also been shown to improve the charging on acidic 
phosphopeptides, which do not usually ionise well in positive ion mode. It is not 
unreasonable to suggest that the same may be true of acidic glycopeptides, which can 
suffer from a similar problem. This has a specific application in nanoflow LC-MS, 
when dealing with large acidic glycopeptides and using a triple quadrupole mass 























ionisation mode, their m/z can lie outside the range of the instrument. In negative 
ionisation mode, it can be extremely difficult to obtain a stable spray when using 
nanoflow LC, especially if a gradient elution is being used. However, the use of 
superchargers to increase charge distribution for these molecules may allow their 
detection at lower concentrations in positive ion mode, whilst using a triple 





4.2.1 Materials and equipment 
  
All water used was purified using an Elgastat Option 3 water purification unit and 
had 18.2 MΩ resisitivity. Trypsin (sequencing grade) was purchased from Promega 
(Southampton, UK). Bendroflumethiazide, canrenone, clopamide and etacrynic acid 
were from the European Pharmacopeia (Strasbourg). Bumetanide was from Leo 
Pharma (Buckinghamshire, UK). Chlorothiazide, furosemide, metolazone were from 
Sanofi-Aventis (Frankfurt, Germany). Xipamide was from Lacer (Barcelona, Spain). 
Mefruside was from Bayer (Brussels, Belgium). Triamterene was from Smith Kline 
Beecham (Brentford, UK). All other chemicals were of analytical grade and were 
purchased from Sigma Aldrich (Poole, UK).  
 
A Hypersil Gold C18 column from Thermo Fisher (Loughborough, UK), 200 mm 
length and 2.1 mm internal diameter with 1.9 µm particles was used for 
chromatographic separations.  
 
LC-MS(MS) was carried out using either a Waters Acquity UPLC system and 
Thermo Exactive Orbitrap mass spectrometer, or a Thermo Accela HPLC pump and 






4.2.2. Effect of superchargers on detection in positive/negative ionisation mode of 
diuretics 
 
A 1 µg/mL solution of the following diuretics was made up (in 95:5 
water:acetonitrile): Acetazolamide; Bendroflumethiazide; Chlorothiazide; 
Bumetanide; Canrenone; Furosemide; Amiloride; Mefruside; Chlorthalidone; 
Pemoline; Clopamide; Metolazone; Xipamide; Triamterene; Hydrochlorthiazide; 
Etacrynic acid (see figure 4.5 for structures).  
The mixture was separated and analysed by LC-MS using the Exactive Orbitrap 
mass spectrometer. Mass spectrometer conditions were (positive/negative ion mode): 
Sheath gas flow 60/70 arbitrary units (a.u.); auxillary gas flow 10 a.u.; Spray voltage 
4.5/3.0 kV; Capillary temperature 250 °C; Capillary voltage 52.5/-95.0 V; Tube lens 
voltage 135/-145 V; Skimmer voltage 20/-32 V; Heater temperature 300 °C. Scans 
were carried out between 100 and 500 m/z.  
The LC starting conditions were 95% Solvent A, 5% Solvent B, and the gradient 
changed linearly to 57% Solvent A, 43% Solvent B at 15 minutes, then linearly to 
20% Solvent A, 80% Solvent B at 20 minutes. Solvent A was water with 0.1% 
formic acid and 1% of either sulfolane or dimethyl sulfoxide, or 0.1% m-NBA (v/v). 
m-NBA concentration was lower than that of sulfolane or DMSO, as at higher 
concentrations of m-NBA back pressure had been observed to rise excessively. 
Solvent B was acetonitrile with the same additives. 
Five microlitres of solution was injected onto the column for each run. Each analysis 
was carried out five times in positive and five in negative mode, and the mean peak 
heights and signal:noise ratios of the extracted ion chromatograms (3 ppm tolerance) 




Figure 4.5: Structures of diuretics used in superchargers experiments 
 
Analysis of the same diuretic mixture was also carried out using an isocratic elution 
(30% A for 45 minutes, other method details the same) to see if differences between 
the responses of diuretics was due to the solvent make up at the time of elution. Each 
isocratic analysis was carried out twice with each of the different supercharger 
additives. 
 
As mentioned in 4.1.7, it has been proposed that some of the effects of superchargers 
could be due to resultant increased heating of electrospray droplets. To see if the two 
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had similar effects on the signal from diuretics, the gradient elution method was 
repeated using water with 0.1% formic acid as solvent A, but with the capillary 
temperature/heater temperature in the HESI source at 250/300 °C, 300/350 °C, 
350/400 °C and 400/450 °C. Each analysis was carried out twice. 
 
4.2.3 Effect of superchargers on detection in positive/negative ionisation mode of 
glycopeptides 
 
Fetuin was denatured, alkylated and digested using the following procedure: ≈1 mg 
of protein was weighed out and dissolved in 100 µL 8M urea/50 mM ammonium 
bicarbonate (ABC) solution, and incubated at room temperature. After 3 hours, 4 µL 
of 500 mM dithiothreitol was added, and the solution then incubated at 37 °C for 
2 hours. The solution was then removed from the incubator, 4 µL of 500 mM 
iodoacetic acid added and the solution incubated for 30 minutes at room temperature 
in the dark. 50 mM ABC was added to make the volume up to 950 µL. Trypsin was 
dissolved to give a 200 µg/mL solution, and 50 µL added to the fetuin solution, to 
give a protein:enzyme ratio of 100:1. The sample was left overnight at 37 °C, and the 
reaction stopped by the addition of 4 µL formic acid. Tryptically digested fetuin was 
then diluted to a concentration of 1 µg/mL (approximately 20 pmol/mL) for analysis 
by LC-MS. 
 
Recombinant EPO was digested in a similar manner. A vial of rEPO (Epiao, 
2,000 IU) was filtered through a 10 kDa Microcon and washed 3 times with 500 µL 
of 50 mM ABC. It was then recovered and made up to 100 µL with 8M urea/50 mM 
ammonium bicarbonate (ABC) solution, after which the same digest process was 
followed as with fetuin. 
 
Acidic glycopeptides were separated and analysed using LC-MS using the Exactive 
Orbitrap mass spectrometer. Mass spectrometer conditions were (positive/negative 
ion mode):  Sheath gas flow 60 arbitrary units (a.u.); auxillary gas flow 10 a.u.; 
Spray voltage 4.0/3.0 kV; Capillary temperature 250 °C; Capillary voltage 92.5/-
95.0 V; Tube lens voltage 165/-145 V; Skimmer voltage 44/-32 V; Heater 
temperature 300 °C. Scans were carried out between 200 and 2,500 m/z. The LC 
starting conditions were 95% Solvent A, 5% Solvent B, and the gradient changed 
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linearly to 57% Solvent A, 43% Solvent B at 40 minutes. Solvents and analysis 
methods were the same as in 4.2.2 for the different glycopeptides, except that scans 
were carried out between 250 and 4,000 m/z. 
Automatic peak detection was carried out using Thermo Excalibur software, using 
the following settings -  
Baseline window (number of scans over which to look for a local minima): 40 
Area noise factor (noise level multiplier used to determine peak edge after location 
of possible peak): 5 
Peak noise factor (noise level multiplier used to determine potential peak signal 
threshold): 10 
Min peak width: 3 scans 
INCOS noise algorithm used to determine noise level 
 
 
4.3 Results and discussion 
 
4.3.1 Effect of superchargers on detection in positive/negative ionisation mode of 
diuretics 
 
Addition of superchargers to LC solvents at the concentrations tested slightly 
affected retention time, though only to a small extent. Peak width was not noticeably 
affected by the presence of superchargers. 
 
One way analysis of variance was carried out (using Minitab 15) to compare the 
peak heights of the diuretics with different superchargers in positive ionisation mode, 
and separately in negative ionisation mode. Dunnett’s test was used to see if the data 
obtained using superchargers was statistically significant at the 5% confidence level 
from that obtained without superchargers in the LC solvents. Those results which 
were statistically significant are written in bold in tables 4.2 and 4.3. 
 
A number of observations are possible. Firstly, the presence of sulfolane, 
dimethylsulfoxide or m-NBA affects the peak height of several of the diuretics. 
These effects were generally significant, especially in positive ion mode and 
especially for sulfolane and m-NBA. However, this is not one way, with some peak 
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heights increased and others decreased for all of the superchargers. Peak heights in 
both positive and negative mode are affected. Also, the effect of the superchargers 
does not change simply with retention time, as may be expected if the effect was 
solely due to the change caused in the surface tension of the electrospray droplets. 
 
In positive ion mode, after the addition of sulfolane, seven diuretics gave an 
increased signal (amiloride, acetazolamide, triamterene, pemoline, clopamide, 
metolazone and bumetanide). Eight compounds gave reduced signal (chlorthiazide, 
chlorthalidone, furosemide, mefruside, bendroflumethiazide, xipamide, etacrynic 
acid and canrenone).  
 
With the addition of dimethyl sulfoxide, only the signals from amiloride, pemoline, 
triamterene and clopamide are increased; all other diuretics display a reduced signal 
in the presence of the supercharger, except metolazone, which is not significantly 
affected. 
 
The addition of m-NBA to the LC solvents resulted in significantly decreased signal 
in positive ion mode only from chlorthiazide, while a significant increase was seen 
for acetazolamide, triamterene, chlorthalidone, clopamide, metolazone, furosemide, 
mefruside, bendroflumethiazide, bumetanide and etacrynic acid. Signal from the 
other diuretics was not significantly different. 
 
The use of sulfolane to increase charging appeared to be slightly more effective in 
negative ionisation mode. Canrenone and triamterene were not detected in negative 
ionisation mode, with or without superchargers present. However, for all the other 
compounds signal was significantly increased in the presence of sulfolane; it was 
significantly increased with eight compounds in the presence of DMSO (amiloride, 
acetazolamide, chlorthiazide, pemoline, chlorthalidone, clopamide, mefruside and 
xipamide) and significantly decreased with none.  For m-NBA, decreases were seen 
with metolazone and mefruside, while the signal from all other compounds was 
significantly increased. 
 
Unfortunately, there is no single treatment that enhances signal for all diuretics either 
in a signal ionisation mode, or if the ionisation mode is switched. However, if 
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canrenone is excluded and switching is possible, the addition of sulfolane to LC 
solvent would increase signal from the remaining diuretics by between 1.16 
(metolazone) and 7.60 (pemoline) times. 
 
Table 4.2 Ratios of mean peak heights of diuretics with superchargers added to 
solvents to those measured without superchargers. Positive ion mode. Figures in bold 
are statistically significant. 
 
Compound Mean peak height 
ratio (Sulfolane) 
+ve 






Amiloride 2.40 1.92 1.48 
Acetazolamide 3.05 0.06 1.55 
Chlorthiazide 0.07 0.02 0.81 
Triamterene 2.75 3.91 1.49 
Pemoline 7.60 2.87 2.21 
Chlorthalidone 0.46 0.01 3.30 
Clopamide 1.99 2.04 6.88 
Metolazone 1.70 1.03 3.66 
Furosemide 0.58 0.03 2.36 
Mefruside 0.04 0.06 1.45 
Bendroflumethiazide 0.32 0.31 1.58 
Xipamide 0.10 0.08 0.84 
Bumetanide 1.81 0.03 1.89 
Etacrynic acid 0.0 0.0 3.70 








Table 4.3 Ratios of mean peak heights of diuretics with superchargers added to 
solvents to those measured without superchargers. Negative ion mode. Figures in 
bold are statistically significant. 
 
 
It is not immediately clear why the interaction with sulfolane, dimethyl sulfoxide or 
m-NBA has the effects seen. There is no obvious pattern relating the effect of the 
superchargers on individual diuretics in positive and negative ionisation mode, with 
increases and decreases in signal not clearly linked. Examination of the polarity of 
the compounds did not suggest any reason why some should produce an increased 
signal, while for others the signal decreased. Similarly, attempts to correlate partition 
coefficient, isoelectric point or molecular polarisability with peak height ratios for 
sulfolane, DMSO or m-NBA were also unsuccessful. R-squared values for these data 
sets are shown in Table 4.4, and demonstrate the lack of an obvious link between 
these characteristics and the effects of superchargers.  
Compound Mean peak height 
ratio (Sulfolane)  
-ve 




height ratio  
(m-NBA) -ve 
Amiloride 4.14 1.55 1.32 
Acetazolamide 3.96 2.38 1.49 
Chlorthiazide 6.83 1.64 2.73 
Triamterene ND ND ND 
Pemoline 3.67 1.72 2.75 
Chlorthalidone 1.92 1.25 1.52 
Clopamide 2.62 1.65 1.63 
Metolazone 1.16 1.04 0.58 
Furosemide 6.11 1.24 4.56 
Mefruside 1.73 1.13 0.77 
Bendroflumethiazide 1.51 0.97 1.25 
Xipamide 3.48 1.16 2.56 
Bumetanide 3.88 0.80 2.62 
Etacrynic acid 4.91 1.42 9.78 
Canrenone ND ND ND 
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Table 4.4 Coefficient of determination (R
2
) values demonstrating lack of correlation 
between physical characteristics of diuretics and effects of superchargers (measured 




Sulfolane DMSO m-NBA 
Log P 0.1250 0.0635 0.0589 
pI 0.1309 0.3761 0.0176 
MP 0.3849 0.1333 0.0282 
 
 
4.3.2 Effect on changing HESI source temperatures on diuretic peak height 
 
One possible explanation is related to the thermal stability of the compounds 
involved. Sterling et al. (Sterling, Daly et al. 2010) suggested that the presence of 
low vapour pressure superchargers during electrospray ionisation results in the 
preferential enrichment of aqueous droplets in these reagents as evaporation occurs. 
Evaporative cooling will occur less after the droplets are substantially enriched in the 
low volatility supercharging reagent, resulting in droplets of a higher temperature. 
They suggested that this higher temperature may cause destabilisation or 
denaturation of the protein complex. With small molecules however, gas phase ion 
production may occur by the ion evaporation model, first proposed by Iribarne and 
Thomson in 1976 (Iribarne and Thomson 1976). This proposes that charged droplets 
would have at their surface charged particles, and that the resulting field would 
become so strong that it would push ions into the gas phase. In this model, multiply 
charged ions would be more likely to escape, while the likelihood of ions escaping 
would also be increased by an increase in droplet temperature. 
 
This would suggest that thermal effects may be partially responsible for the effects 
of superchargers on the peak height of diuretics, with those that are thermally labile 
decomposing in the electrospray when superchargers are present, resulting in 
reduced peak height, while those that are not thermally labile are increasingly 
transferred into the gas phase with a resulting increase in peak height. 
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To examine this possibility, LC-MS analysis of diuretics was carried out with the 
capillary and HESI gas heated to different temperatures. However, the results 
showed that there is no obvious link between the effect of increasing temperature 
and the effect of the presence of superchargers. Examination of the mass spectra 
obtained across the diuretics peaks told a similar story. Increasing fragmentation is 
seen with increasing capillary and HESI gas temperature but this is not mirrored in 
the spectra obtained in the presence of superchargers. Of course, it is possible that 
the effect of heating the capillary and gas in the HESI source does not adequately 
model the effect of heating from superchargers, but it is not unreasonable to expect 
some correlation if it is an important factor. 
 
4.3.3. Effect of isocratic elution on supercharger effects on diuretics 
 
The other proposed way in which superchargers exert their effect on proteins is 
through increasing surface tension in electrospray droplets containing high amounts 
of organic solvents. To see if this was an influencing factor in the effect of 
superchargers on diuretics, isocratic elutions were carried out, with and without 
superchargers in the LC solvent. If, as predicted, superchargers exert their effect by 
changing the surface tension of electrospray droplets, then differences in these 
effects should be seen with an isocratic elution. 
 
There is some evidence that this is the case with sulfolane. Although the differences 
are small, twelve of the 15 compounds examined behaved as predicted. With DMSO 
this was true for six compounds. With m-NBA, ten compounds behaved as predicted. 
For this latter supercharger then, the role of surface tension is perhaps less clear cut, 
while for DMSO it is ambiguous at best. 
 
The difference between the effects of superchargers in positive and negative ion 
mode also provides evidence that surface tension and droplet temperature are not the 
only ways in which superchargers exert their effects, as both of these would be 
expected to be altered in the same way in positive and negative ionisation mode. The 
effect of the presence of superchargers on negative ionisation could be due to their 
greater proton affinity and gas phase basicity than water and acetonitrile, allowing 
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them to accept protons more readily from the analytes and increasing analyte 
negative ion formation. 
 
4.3.4. Effect of superchargers on detection in positive/negative ionisation mode of 
glycopeptides 
 
Glycopeptides were identified by looking for fragment ions corresponding to 
diagnostic sugar oxonium ions of m/z 292, 366 and 657 (Neu5Ac, Hex-HexNAc, 
and Neu5Ac-Hex-HexNac). Total ion chromatograms and extracted ion 
chromatograms for these oxonium ions, with and without superchargers are shown in 
figures 4.6-4.9. Peaks were automatically detected by the software based on its peak-
picking algorithm, and were investigated for the presence of glycopeptides when 
peaks were automatically detected in the EICs of all three oxonium ions. The number 
of peaks detected by the software increased with the addition of either m-NBA or 
sulfolane. In particular, the addition of m-NBA resulted in the detection of a large 
peak at approximately 37.2 minutes which was not picked up in the other 
chromatograms.  
 
The way in which the presence of superchargers affects charging can be seen by 
comparing the mass spectra from the peaks at approximately 17.2 (when the eluent 
was highly aqueous) and 47.5 minutes (when it was mostly organic). The positive 
mass spectra from these peaks are shown in figure 4.10 and 4.11. The negative mass 
spectra are shown in figure 4.12 and 4.13. 
 
The positive ion spectra from the peaks at 17.2 minutes show very little difference 
between the charge states of the ions with or without superchargers in the LC 
solvents. The main ions detected are at m/z 1438.2, 1535.3 and 1632.3. This 
corresponds to the triply charged tryptic fragment containing the N-glycosylation at 
Asn-156. The ions are glycopeptides with triantennary glycans with two, three or 
four sialic acid residues, although given the tendency of sialic acids to be lost in 
electrospray, it is not certain if all these are present originally or are formed by 
fragmentation in the electrospray. There is no great difference in the charge 
distributions, although there is a slightly greater abundance of the quadruply charged 
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ion at m/z 1151.7 when sulfolane was used. The overall intensity of the signal was 
also increased when sulfolane and DMSO were used. 
 
A different picture is seen with the positive ion spectra from 47.5 minutes. With this 
peak, the spectrum obtained without superchargers is again dominated by triply 
charged ions, including ones at m/z 1960.9, 1741.8, and 1863.8. The 1741.8 is an 
Asn-176 glycopeptide with a biantennary structure and two sialic acids. The 1960.9 
could be either the Asn-176, triantennary with three sialic acids, or the Asn-99, 
biantennary with two sialic acids. Similarly, the 1863.8 ion could be either the 
Asn-176 triantennary with two sialic acids, or Asn-99, biantennary with one sialic 
acid. 
With the addition of superchargers, the charge distribution shifts. The addition of 
sulfolane results in an increase in the abundance of the quadruply charged ions at 
m/z 1308.4, 1470.9, 1543.7 and 1635.2. These are from tryptic glycopeptides 
containing the Asn-99 glycosylation site. The increase in charge is not as great with 
DMSO; however, this results in a more condensed charge distribution, with a 
corresponding increase in signal intensity.  
The addition of m-NBA did not result in an obvious move to higher charge states. 
Rather, it appears to have resulted in a reduction in the intensity of the signal from 
the m/z 1960.9 ion only. 
 
A different result is also obtained when negative ion mode was used. Examination of 
the spectra from the peak at 17.2 minutes show that without superchargers, the 
spectrum is dominated by the triply charged  m/z 1533.3 ion, corresponding to the 
Asn-156 glycopeptide, triantennary with three sialic acid residues. There is also a 
small amount of the same glycopeptide with four sialic acids (m/z 1630.3) but not an 
ion at m/z 1436.3, suggesting that the small amount of that glycopeptide found in 
positive ion mode was formed by fragmentation. 
When DMSO is added, there is little change in the spectrum in negative ion mode. 
However, both the addition of sulfolane and m-NBA result in increased charge, with 
a shift with sulfolane to the quadruply charged m/z 1149.7 ion, and a shift with 
m-NBA to both quadruply charged m/z 1149.7 and 1222.7 as well as to the quintuply 
charged m/z 979.9 ion. 
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TIC F: FTMS {1,1}  + p ESI 
Full ms [250.00-4000.00]  
MS 0259
NL: 3.68E4
Base Peak m/z= 
292.1001-292.1037 F: 
FTMS {1,1}  + p ESI Full ms 
[250.00-4000.00]  MS  
Genesis 0259
NL: 1.73E5
Base Peak m/z= 
657.2290-657.2368 F: 
FTMS {1,1}  + p ESI Full ms 
[250.00-4000.00]  MS  
Genesis 0259
NL: 6.70E4
Base Peak m/z= 
366.1361-366.1405 F: 
FTMS {1,1}  + p ESI Full ms 
[250.00-4000.00]  MS  
Genesis 0259
 
Figure 4.6: (from top) Fetuin tryptic digest. Total ion chromatogram and extracted ion chromatograms for m/z 292.1019, 657.2329 and 
366.1383. No superchargers in solvents 
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FTMS {1,1}  + p ESI Full ms 
[250.00-4000.00]  MS  
Genesis 0254
NL: 2.45E5
Base Peak m/z= 
657.2290-657.2368 F: 
FTMS {1,1}  + p ESI Full ms 
[250.00-4000.00]  MS  
Genesis 0254
NL: 8.40E4
Base Peak m/z= 
366.1361-366.1405 F: 
FTMS {1,1}  + p ESI Full ms 
[250.00-4000.00]  MS  
Genesis 0254
 
Figure 4.7: (from top) Fetuin tryptic digest. Total ion chromatogram and extracted ion chromatograms for m/z 292.1019, 657.2329 and 
366.1383. 1% sulfolane in solvents 
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FTMS {1,1}  + p ESI Full ms 
[250.00-4000.00]  MS  
Genesis 0256
NL: 4.09E4
Base Peak m/z= 
366.1361-366.1405 F: 
FTMS {1,1}  + p ESI Full ms 
[250.00-4000.00]  MS  
Genesis 0256
 
Figure 4.8: (from top) Fetuin tryptic digest. Total ion chromatogram and extracted ion chromatograms for m/z 292.1019, 657.2329 and 
366.1383. 1% DMSO in solvents 
 174 
RT: 0.00 - 60.01
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RT: 16.65 RT: 47.46
RT: 50.82RT: 20.26
NL: 3.05E8
TIC F: FTMS {1,1}  + p ESI 
Full ms [250.00-4000.00]  
MS 0252
NL: 1.61E5
Base Peak m/z= 
292.1001-292.1037 F: 
FTMS {1,1}  + p ESI Full ms 
[250.00-4000.00]  MS  
Genesis 0252
NL: 3.73E5
Base Peak m/z= 
657.2290-657.2368 F: 
FTMS {1,1}  + p ESI Full ms 
[250.00-4000.00]  MS  
Genesis 0252
NL: 1.83E5
Base Peak m/z= 
366.1361-366.1405 F: 
FTMS {1,1}  + p ESI Full ms 
[250.00-4000.00]  MS  
Genesis 0252
 
Figure 4.9: (from top) Fetuin tryptic digest. Total ion chromatogram and extracted ion chromatograms for m/z 292.1019, 657.2329 and 
366.1383. 0.1% m-NBA in solvents 
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0259#2125-2141  RT: 
17.10-17.22  AV: 17 T: 
FTMS {1,1}  + p ESI Full 
ms [250.00-4000.00] 
NL: 1.10E5
0254#2036-2055  RT: 
16.38-16.53  AV: 20 T: 
FTMS {1,1}  + p ESI Full 
ms [250.00-4000.00] 
NL: 3.92E5
0256#2132-2154  RT: 
17.15-17.33  AV: 23 T: 
FTMS {1,1}  + p ESI Full 
ms [250.00-4000.00] 
NL: 5.82E4
0252#2060-2077  RT: 
16.57-16.71  AV: 18 T: 
FTMS {1,1}  + p ESI Full 
ms [250.00-4000.00] 
 
Figure 4.10: Positive ion mass spectra from 17.10 to 17.35 minutes. From top – no superchargers; 1% sulfolane; 1% DMSO; 0.1% m-NBA. Inset 









































































0259#5904-5915  RT: 
47.46-47.55  AV: 12 T: 
FTMS {1,1}  + p ESI Full 
ms [250.00-4000.00] 
NL: 5.15E4
0254#5918-5949  RT: 
47.47-47.72  AV: 32 T: 
FTMS {1,1}  + p ESI Full 
ms [250.00-4000.00] 
NL: 4.99E5
0256#5924-5949  RT: 
47.55-47.75  AV: 26 T: 
FTMS {1,1}  + p ESI Full 
ms [250.00-4000.00] 
NL: 2.62E4
0252#6034-6048  RT: 
47.36-47.47  AV: 15 T: 
FTMS {1,1}  + p ESI Full 
ms [250.00-4000.00] 
 
Figure 4.11: Positive ion mass spectra from 47.40 to 47.75 minutes. From top – no superchargers; 1% sulfolane; 1% DMSO; 0.1% m-NBA. Inset 












































































0261#2124-2140  RT: 
17.09-17.22  AV: 17 T: 
FTMS {1,1}  - p ESI Full 
ms [250.00-4000.00] 
NL: 1.75E5
0255#2040-2060  RT: 
16.38-16.53  AV: 21 T: 
FTMS {1,1}  - p ESI Full 
ms [250.00-4000.00] 
NL: 2.19E4
0257#2135-2155  RT: 
17.17-17.33  AV: 21 T: 
FTMS {1,1}  - p ESI Full 
ms [250.00-4000.00] 
NL: 2.15E4
0253#2060-2076  RT: 
16.57-16.70  AV: 17 T: 
FTMS {1,1}  - p ESI Full 
ms [250.00-4000.00] 
  
Figure 4.12: Negative ion mass spectra from 17.10 to 17.35 minutes. From top – no superchargers; 1% sulfolane; 1% DMSO; 0.1% m-NBA. 










































































1980.8303 2960.07152675.50751786.9757 2310.91192155.7901 2433.9497
NL: 5.92E4
0261#5897-5909  RT: 
47.46-47.55  AV: 13 T: 
FTMS {1,1}  - p ESI Full 
ms [250.00-4000.00] 
NL: 6.46E4
0255#6084-6115  RT: 
47.47-47.72  AV: 32 T: 
FTMS {1,1}  - p ESI Full 
ms [250.00-4000.00] 
NL: 2.62E4
0257#5916-5941  RT: 
47.55-47.75  AV: 26 T: 
FTMS {1,1}  - p ESI Full 
ms [250.00-4000.00] 
NL: 2.04E4
0253#5897-5911  RT: 
47.36-47.47  AV: 15 T: 
FTMS {1,1}  - p ESI Full 
ms [250.00-4000.00] 
 
Figure 4.13: Negative ion mass spectra from 47.40 to 47.75 minutes. From top – no superchargers; 1% sulfolane; 1% DMSO; 0.1% m-NBA. 







With the peak at 47.5 minutes, a similar pattern is observed. Without superchargers, the 
spectrum is dominated by the (3+) m/z 1958.8 ion. The addition of sulfolane causes an 
increase in charge, with a shift to ions at m/z of 1088.8 (5+), 1233.1 (5+), 1306.3 (5+), 
1541.7 (4+) and 1633.2 (4+). The addition of DMSO causes a smaller increase in 
charge, and also allows the ion at m/z 2177.9 to be detected, whereas it was not when 
superchargers were not used. The addition of m-NBA to the LC solvent does not have a 
huge effect on charging either. Although the distribution moves so that the predominant 
ion is that of m/z 1468.9, signal intensity also falls, so this shift is caused more by a drop 
in the intensity of the 1958.8 ion than an increase in more highly charged species. 
 
Peaks detected automatically by the peak picking software in all three of the extracted 
ion chromatograms for oxonium ions were analysed, and the detected glycopeptides are 
listed in tables 4.5 and 4.6. They show that the total number of glycopeptides 
automatically detected increased when superchargers were used compared to when they 
were absent, except when DMSO was used in negative ion mode. This is particularly 
true for glycosylations at the Asn-99 site, none of which were automatically detected 
when superchargers were not present, but at least one variation of which was detected in 
the presence of all three superchargers. The improvement in detection can be attributed 
directly to an increase in average charge. Detection of expected glycopeptides of known 
mass can obviously be more effectively and sensitively carried out by searching for that 
specific mass. However, when it is desirable to identify all the glycan variants present, 
identification of peaks by the detection of oxonium ions from in-source fragmentation is 
a common approach. Since fragmentation efficiency is increased as charge increases, an 
increase in charge (as is seen in the presence of superchargers) has the added effect of 
increasing the detection of oxonium ions. This, in turn, results in more glycopeptide 






Table 4.5 Fetuin N-glycans detected in positive ionisation mode, with and without 
superchargers present. Notation indicates antennae number and sialic acid residues 
 
N-glycan site 
Glycans detected with 
No 
supercharger 
Sulfolane DMSO m-NBA 
















176 Tri-3S Bi-2S, Tri-2S, 
Tri-3S, Tri-4S 
None detected Bi-1S, Tri-3S, 
Tri-4S 
 
Table 4.6 Fetuin N-glycans detected in negative ionisation mode, with and without 
superchargers present. Notation indicates antennae number and sialic acid residues 
 
N-glycan site 
Glycans detected with 
No 
supercharger 
Sulfolane DMSO m-NBA 
99 None detected None detected Bi-2S Bi-1S, Bi-3S, 
Tri-3S, Tri-4S 
156 Tri-3S, Tri-4S Tri-3S, Tri-4S Tri-3S, Tri-4S Tri-3S, Tri-4S 
176 Tri-3S Bi-2S, Tri-3S, 
Tri-4S 
None detected Tri-3S, Tri-4S 
 
The greatest number of glycan variants was detected when 0.1% m-NBA was added to 
the LC solvent. The biggest difference between detection without superchargers present 
and with m-NBA present is seen with glycosylations at Asn-176 and Asn-99. These are 
the later eluting glycopeptides, which would fit with m-NBA exerting its effect through 
increasing the surface tension on electrospray droplets. This also fits with the proposal 
that glycopeptides are partially desorbed from electrospray droplets before ionisation, as 
this would be most likely when glycopeptides have a hydrophobic portion which would 
sit at the surface of the droplet. Such glycopeptides, due to their increased hydrophobic 
nature, would also elute later in the chromatographic conditions used here. The validity 
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of this could be examined using isocratic elution conditions, but time was not available 
for this. 
 
It is still not clear what causes the differences in the effects of the different 
superchargers. Although the addition of m-NBA improved the detection of all 
glycopeptides, the addition of DMSO and sulfolane reduced the detection of at least one 
glycopeptide. Further work to investigate this could be useful, and would involve 
isocratic elutions to remove the influence of changing solvent concentrations. It may 
also be useful to examine how mixtures of superchargers influence charging and signal 
from these compounds, as there appear to be qualitative and not just quantitative 
differences in their effects. 
 
Somewhat different results were obtained when the same approach was taken with 
tryptically digested rEPO. The digest results in four glycosylated peptides; one 
containing the O-glycan, one with the N-glycan at Asn83 and one containing the two N-
glycans at Asn24 and Asn38. The complexity of the latter glycopeptide meant that it was 
not examined in these experiments. O-glycans were better identified when analysed with 
sulfolane in the LC solvent than when it was absent. Figure 4.14 shows the EIC obtained 
for m/z 1207.748, the disialylated O-glycan, with and without sulfolane present in the 
LC solvent. The peak intensity of the O-glycan with the sulfolane present is much 
higher than the peak intensity without it. A similar effect is seen in the EIC of m/z 
1062.119, the O-glycan with a single sialic acid attached (Figure 4.15). Again the peak 
with the sulfolane in the LC solvent is about 5 times higher than the peak without 
superchargers present.  
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RT: 0.00 - 60.02 SM: 3G



















































Base Peak m/z= 
1207.5460-1207.5508 
F: FTMS {1,1}  + p ESI 
Full ms 
[250.00-4000.00]  MS 
1632
NL: 1.32E5
Base Peak m/z= 
1207.5456-1207.5504 
F: FTMS {1,1}  + p ESI 
Full ms 
[250.00-4000.00]  MS 
03
 
Figure 4.14: EIC for m/z 1207.748, glycopeptide containing disialylated O-glycan. Top, 
with 1% sulfolane in LC solvent; bottom, no supercharger added. 
 
RT: 0.00 - 60.02 SM: 3G













































Base Peak m/z= 
1061.9999-1062.0021 
F: FTMS {1,1}  + p ESI 
Full ms 
[250.00-4000.00]  MS 
1632
NL: 2.39E5
Base Peak m/z= 
1061.9999-1062.0021 
F: FTMS {1,1}  + p ESI 
Full ms 
[250.00-4000.00]  MS 
03
 
Figure 4.15: EIC for m/z 1062.119, glycopeptide containing singly sialylated O-glycan. 
Top, with 1% sulfolane in LC solvent; bottom, no supercharger added 
Peak height  = 8.29 x 10
5
 
Peak height  = 1.32 x 10
5
 
Peak height = 1.22 x 10
6
 




This is a different effect to that demonstrated with fetuin, and shows that the use of 
superchargers can increase the peak height of acidic glycopeptides, as well as improving 
the ability to identify glycopeptide peaks. This latter approach was also taken with 
rEPO. Table 4.7 shows the peaks identified with and without the various superchargers 
present. As mentioned earlier, the increased acetylation of sialic acids and the presence 
of N-glycolyl neuraminic acid in rEPO have both been suggested as possible methods to 
distinguish between rEPO and huEPO. In these experiments, however, only one glycan 
containing an acetylated sialic acid residue was detected, and none were detected 
containing any Neu5Gc. It is not known if this is due to the specific rEPO chosen, or if 
the sensitivity of the approach was too poor to detect these glycoforms, but it is a 
weakness in the approach for anti-doping purposes.  
Unlike with fetuin, the greatest increase in peak identification was seen with sulfolane, 
whereas the other superchargers did not have such a strong effect. Again, it is not clear 
what causes the difference between the effects of the different superchargers, or why 
they should have different effects on different glycopeptides. The clear improvement in 
glycopeptide detection when they are used, however, suggests that this may be 
something worth further investigation. 
 
Table 4.7 rEPO glycans detected in positive ionisation mode, with and without 
superchargers present. Notation indicates antennae number (nA), N-acetyl lactosamine 
repeat units (nR), N-acetylneuraminic acid residues and acetylations (nS(n)), and N-
glycolylneuraminic acid residues (nG) 
 
Glycan site 
Glycans detected with 
No 
supercharger 
Sulfolane DMSO m-NBA 



























The addition of sulfolane, DMSO or m-NBA to LC solvents did not significantly affect 
the retention time or peak width of diuretics. However, they did affect the peak height of 
these compounds. In particular, sulfolane enhanced signal in negative ionisation mode. 
It is not clear what this effect is due to. Proposals that superchargers exert their effect 
through effects on electrospray droplet surface tension and temperature were examined, 
but the two did not appear to be directly correlated with peak height. This is not to say 
that they have no effect, however. It is possible that they are relevant in determining 
response, but any effects are likely to be complex and multifactorial, involving 
(potentially) surface tension, evaporative cooling of electrospray droplets, ionisation 
mode and electrospray current, and the effects of the superchargers on analyte 
ionisation. Despite this lack of clarity however, it appears that the addition of 
superchargers to LC solvents for the analysis of small molecules can result in (analyte-
specific) signal enhancement, with very little additional cost or effort. 
 
The analysis by LC-MS of glycopeptides from a tryptic digest of fetuin using LC 
solvents containing superchargers showed that the average charge state of acidic 
glycopeptides was increased in the presence of superchargers, although the extent to 
which this was true varied through the elution. The extent to which it occurred varied 
also with supercharger, but it was found that the addition of m-NBA to LC solvents 
increased the number of glycopeptides detected when peaks were automatically detected 
by searching for fragments corresponding to oxonium ions, diagnostic for glycopeptides, 
as a direct result of the increase in average charge caused by the presence of the 
supercharger.  
With a similar analysis of rEPO, similar effects were seen, except that the most effective 
supercharger was sulfolane. Its addition to the LC solvent resulted in six N-glycans 
being detected at Asn83 compared to two N-glycans detected in its absence. The addition 
of sulfolane was also observed to increase the peak height of individual glycopeptides in 
EICs. Conformational changes, which have been suggested as responsible for the effect 
of superchargers on protein charging, are less likely to be responsible for their effects on 
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glycopeptides due to their smaller size. It is not clear what the effect is due to, although 
surface tension effects may play a part, and more work is needed to elucidate the 
mechanism involved.  As with small molecules, however, it seems that the use of 
superchargers could be a simple and effective way to improve acidic glycopeptide 
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Chapter 5: Cleavage, digestion and derivatisation of 
N-glycans to identify bisected and non-bisected structures as a 






















Aim: To develop a method that would allow discrimination between endogenous and 
recombinant erythropoietin, based on the absence in rEPO of N-glycans containing 





5.1.1 The N-glycan structures of rEPO and huEPO 
 
The structures found in the glycan groups on rEPO and huEPO were discussed in the 
introduction (1.10), and are shown in figure 5.1. To reiterate, they are bi-, tri- and 
tetra-antennary structures with differing degrees of sialylation and N-acetyl lactosamine 
repeats. They are nearly all core fucosylated. The glycans of rEPO tend to be less acidic 
than those of huEPO, probably due to their content of fewer sialic acid residues, 
although it is not certain that this is the sole reason. The glycan groups on rEPO contain 
more N-acetyl lactosamine repeat units than those of huEPO, and tend to contain more 
tri- and tetra-antennary structures, explaining its greater molecular weight.  
 
Christian Reichel has recently proposed (Reichel 2011) that there is a fundamental 
qualitative difference between endogenous human EPO and rEPO. He has suggested 
that endogenous EPO contains a bisecting N-acetyl glucosamine (GlcNAc) moiety not 
found in any rEPO. This difference could provide a target for discrimination between 








Figure 5.1: Summary diagram of N-glycans found on rEPO and endogenous EPO, 
including possible positions of sulfate and bisecting N-acetylglucosamine moieties. 
After Varki et al. (Varki, Cummings et al. 2009) 
 
5.1.2 Exoglycosidase digestion of EPO N-glycans 
 
Detection of this difference when glycans are intact is difficult, as the difference is 
small, meaning that separation (by LC, CE, or gel electrophoresis) is not easy while 
identification of positional isomers through (single stage) mass spectrometry is not 
possible. Differential binding of the different glycans to lectins may provide a route 
towards discrimination, but Reichel also demonstrated that the presence or absence of 
the bisecting GlcNAc can be key in affecting exoglycosidase digestion. 
Figure 5.2 shows the effect of sequential exoglycosidase digestion on the size of rEPO 
and huEPO, as measured by SDS-PAGE. As expected, rEPO starts off larger and 
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treatment with sialidase reduces the size of both rEPO and huEPO, although the 
decrease is greater for huEPO, due its greater sialic acid content. Addition of 
β-galactosidase resulted in further decreases in size for both, although this time the drop 
was greatest for rEPO, possibly because of its greater number of highly branched 
glycans. After digestion with sialidase, β-galactosidase and β-N-acetylglucosaminidase, 
however, the huEPO product was larger; this, it was proposed, is because the 
β-N-acetylglucosaminidase is sterically hindered by the presence of the bisecting 




Figure 5.2 Effect of digestion of rEPO and huEPO with different exoglycosidase 
combinations. Digestion with β-N-acetylglucosaminidase and α-mannosidase did not 
have the same effect on huEPO as it did on rEPO, possibly because of enzymatic 
inhibition due to the presence of a bisecting GlcNAc on huEPO (from Reichel 2011) 
 
Backing for this proposal is provided by the further addition of α-mannosidase to the 
digestion enzyme mix. Since the mannose residues cannot be cleaved with the GlcNAc 
residues in place, this had little effect on huEPO. However, the mannose residues on 
rEPO were cleaved, resulting in a further decrease in the size of the artificial form. 
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5.1.3 Ovine IgG as a model for huEPO 
 
The only commercially available standard for human urinary EPO, that available from 
the National Institute for Biological Standards and Controls (NIBSC), is currently in 
very short supply. As of November 8 2012, their website carried a message stating 
‘Users should be aware that stocks of this standard are running low and it is unlikely to 
be possible to replace it.’ (NIBSC 2012). Even when they are in stock, vials of the 
standard contain only 10 IU (approximately 100 ng). 
 
However, other glycoproteins exist with similar glycan structures to that purported to be 
found on huEPO. In particular, a study by Raju et al. (Raju, Briggs et al. 2000) found the 
glycosylation found in the CH2 domain of the heavy chain of the Fc region of ovine IgG 
was predominantly bi-antennary, as shown in figure 5.3. Although there are variations in 
the glycans found, 74.8 % of the glycans found in positive ion mode MALDI were 
fucosylated, and 97.3 % of those detected in negative mode. They also found that 
66.5 % of those detected in positive ion mode contained a bisecting GlcNAc residue, 
and 60.1 % of those detected in negative ion mode. This suggests that ovine IgG glycans 











Figure 5.3: Basic structures of glycans found on ovine IgG. Structures found can include 
fewer sialic acid, galactose, N-acetyl glucosamine and fucose residues, as indicated by 
dotted lines. Minor amounts of high mannose glycans are also found. 
 
5.1.4 Capillary electrophoresis-mass spectrometry analysis of glycans 
 
Mass spectrometry can provide structural information on glycans released from 
glycoproteins, but cannot discriminate between structural isomers without multiple order 
mass spectrometry (MS
n
), not possible at the levels at which glycoproteins are typically 
found. Separation of isomers using an alternative technique prior to analysis by mass 
spectrometry is therefore required. This has been demonstrated using high-pH 
anion-exchange chromatography, hydrophilic interaction chromatography and GC 
(Galuska, Geyer et al. 2012). 
However, HILIC separations are generally very time consuming and only provide partial 
resolution of isomers, although this problem has been somewhat addressed recently by 
the development of micro- and nanofluidic HILIC approaches (Staples, Bowman et al. 
2009; Huang, Shi et al. 2011). Graphitized carbon as a stationary phase has also been 
shown to be highly selective, allowing resolution of positional isomers of permethylated 
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glycans (Costell, Contado-Miller et al. 2007), and linkage (Pabst, Bondili et al. 2007) 
and positional isomers (Pabst, Grass et al. 2012) of native glycans. 
Improved resolution is obtained using high performance anion-exchange 
chromatography with pulsed amperometric detection (Townsend, Hardy et al. 1989), but 
this too suffers from long analysis time, poor reproducibility and low sensitivity (Lee 
1996). Although more recently the approach has been used to carry out analysis of 
monosaccharides in short time frames (Hurum and Rohrer 2011; Zhang, Khan et al. 
2012), it has not yet been fully explored for the analysis of larger oligosaccharides or 
intact N-glycans. 
Analysis of glycans using GC, meanwhile, firstly requires extensive and time 
consuming derivatisation. 
Excellent resolution of similar glycans has been achieved using capillary 
electrophoresis, with capillary zone electrophoresis (Boucher, Kane et al. 2012) and 
capillary gel electrophoresis (Guttman and Pritchett 1995; Guttman, Chen et al. 1996) 
producing the best separation efficiency and resolution of isomeric glycans. 
This efficient resolution of isomers means that coupling of CE to MS theoretically 
provides a powerful technique for the identification of all the glycans present in a 
complex mixture, such as may be found in a glycoprotein digest. 
However, this coupling is not without its complications. These include the proper 
grounding of the CE electrical circuit, the fact that CE flow rates are of the order of 
1-100 nL/min, compared to 200 µL/min or more with traditional LC flow rates, and the 
need for volatile electrolytes in the CE buffer to enable stable spray formation. 
Nanoelectrospray systems have meant that flow rates are no longer such a problem; 
however, much of the CE separation work being done is carried out in buffers which are 
unsuitable for analysis using ESI-MS. More recent studies demonstrated the use of 
CE-LIF-MS for the successful analysis of APTS-labelled glycans from monoclonal 
antibodies (Gennaro and Salas-Solano 2008) and APTS-labelled human milk 
oligosaccharides (Albrecht, Schols et al. 2010), but studies suffered from the limited 
comparability of detector traces, due to the differences in analyte response in the 
different detectors and the physical distance between the detectors. These problems have 
also been partially addressed recently (Huhn, Ruhaak et al. 2012). 
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5.1.5 Capillary electrophoresis – laser induced fluorescence (CE-LIF) for separation and 
detection of oligosaccharides 
 
Analysis of glycans using CE-LIF was first demonstrated in 1991 using 
3-(4-carboxybenzoyl)-2-quinolinecarboxaldehyde (CBQCA) as a fluorescent labelling 
compound (Liu, Shirota et al. 1991). The technique allowed the detection of N-glycans 
derived from fetuin at subattomole levels. 
Chen and Evangelista (Chen and Evangelista 1998) demonstrated the cleavage of 
N-glycans from glycoproteins using PNGase F, before derivatisation with 
8-aminopyrene-1,3,6-trisulfonate (APTS) under mild reductive amination conditions to 
minimize the cleavage of sialic acid and fucose residues. APTS derivatised sugars have 
an absorbance maximum at 455 nm with significant amount of absorption at 488 nm, 
while APTS itself has an absorbance maximum at 424 nm with a relatively low 
absorptivity at 488 nm. Excitation with a 488 nm argon-ion laser causes APTS-sugar 
complexes to fluoresce with significantly higher intensity, (em λmax = 512 nm) than the 
APTS emission (em λmax = 501 nm). Chen and Evangelista demonstrated that this 
derivatisation, combined with separation using capillary electrophoresis, was suitable 
for producing profiles of the N-glycans from glycoproteins including fetuin, kallikrein 
and rEPO. However, the profile obtained for rEPO was unsurprisingly very complex, 
and analysis was only carried out using 50 μg/mL solutions. 
More recently, Ijiri et al. (Ijiri, Todoroki et al. 2011) demonstrated that CE-LIF could be 
used for the analysis of N-glycans after derivatisation with rhodamine 110. They 
performed a separation in a fused silica capillary using a neutral buffer to separate acidic 
glycans by the number of sialic acids present, and a second separation using an acidic 
buffer which separated asialo-oligosaccharides according to their size. 
Rhodamine 110 was used as a fluorescent derivatising agent on the grounds that it has a 





), and an absorption maximum wavelength very close to 488 nm. 
The approach was used to profile N-glycans released from rEPO. Solutions were made 
up using 10 μg of rEPO in a volume of 3 mL. Although the sialylated glycans could not 
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be fully separated, they migrated in the order of their charge-to-mass ratio in the 
electropherogram and were also influenced by their branching pattern. Desialylated 
glycans were well separated using a 150 mM phosphate buffer (pH 2.5), migrating in the 
order of their charge-to-mass ratio in the electropherogram. 
 
5.1.6 Digestion, derivatisation and detection of N-glycans from rEPO and huEPO. 
 
The suggested difference between rEPO and huEPO could provide a target for 
discriminating between the two. Exoglycosidase digestion of the N-glycans should, in 
theory, produce core glycans with different structures. However, due to vagaries in the 
effectiveness of enzymes, it is necessary to have a method capable of distinguishing 
between glycans that contain a bisecting GlcNAc and their structural isomers. Because 
of the excellent resolution of CE it was decided that this approach would be tried, with 
derivatisation with a fluorophore allowing highly sensitive LIF as a detection method, as 




5.2.1 Materials and equipment 
 
All water used was purified using an Elgastat Option 3 water purification unit and had 
18.2 MΩ resisitivity. β-N-acetylglucosaminidase and β-galactosidase were purchased 
from New England Biolabs UK (Hitchin, UK). Human urinary erythropoietin standard 
(67/343) was purchased from the National Institute for Biological Standards and 
Controls (Hertfordshire, UK). Recombinant EPO Epiao (α-erythropoietin) was from 
Shenyang Sunshine Pharmaceutical Co (Shenyang, China). Reference standard rEPO 
(BRP-EPO batch 3) was purchased from the European Directorate for the Quality of 
Medicines (Strasbourg, France). Aminopyrene trisulfonic acid (APTS) was purchased 
from Invitrogen (Inchinnan, UK). Glycan standards were purchased from Europa 
Bioproducts (Cambridgeshire, UK). CE-LIF equipment and materials were from 
Beckman Coulter (High Wycombe, UK). Centrifugal filters were purchased from 
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Millipore (Watford, UK). Kits for the extraction of EPO using monolithic cartridges 
were purchased from MAIIA Diagnostics (Uppsala, Sweden). All other chemicals and 
products were purchased from Sigma Aldrich (Poole, UK).  
 
A Hypersil Gold C18 column from Thermo Fisher (Loughborough, UK), 200 mm 
length and 2.1 mm internal diameter with 1.9 µm particles was used for 
chromatographic separations.  
 
Chromatography was carried out using either a Waters Acquity UPLC system,  a 
Thermo Accela HPLC pump and autosampler, or a Thermo UltiMate 3000 UHPLC 
pump and autosampler. The first two were used with a Thermo Exactive Orbitrap mass 
spectrometer, while the latter was used with a Thermo Q-Exactive Orbitrap mass 
spectrometer. 
 
5.2.2 N-glycan cleavage and exoglycosidase digestion 
 
One vial of Epiao, containing 2000 IU of EPO (approximately 20 μg) was spun through 
an Ultra-10 Amicon centrifugal filter (10 kDa nominal cut off) at 14,000 g for 10 
minutes. The solution was then made up to 500 μL with 50 mM ammonium bicarbonate, 
pH 7.6 (ABC), and the process repeated twice more. The final retentate was recovered 
by inverting the filter and spinning for five minutes at 2,000 g. The retentate was 
recovered into a low-bind microfuge tube and made up to 50 μL with ABC. 
 
Ovine IgG was dissolved in ABC and adjusted to 120 μg in 50 μL ABC, to give an 
approximately equal molar concentration of glycans as in the rEPO solution. 
 
To each solution, 5 μL of PNGase solution (2.5 IU, in ABC) was added. Samples were 
briefly vortexed, then incubated at 37 °C for 24 hours. 
 
Samples were dried down under nitrogen, then to each tube was added: 
 0.5 μL bovine serum albumin solution (10 mg/mL) 
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 10 μL (100 mIU) Neuraminidase from Clostridium perfringens (C. welchii) in 
10 mM phosphate buffer (pH 5.5) 
 2 μL (16 IU) β1-4 galactosidase solution 
 2 μL (8 IU) β-N-acetylglucosaminidase solution 
 30.5 μL water 
 5 μL G4 buffer (50 mM sodium citrate, pH 6.0, 100 mM NaCl) 
 
Samples were briefly vortexed, then incubated at 37 °C for 24 hours. An additional 5 μL 
of sialidase, 1 μL β1-4 galactosidase of and 1 μL of β-N-acetylglucosaminidase solution 
was then added, and samples incubated for either 12 hours or 20 hours. 
 
The progress of the digest over time was also examined. To do this, 50 μL solutions of 
IgG and rEPO were made up in ABC at 2 μg/mL (100 ng total). Purified glycan 
standard NGA2FB containing a bisecting N-acetylglucosamine residue (see Figure 5.4) 
was also made up in ABC at 1 μg/mL. 
 
To each solution, 5 μL of PNGase solution (2.5 IU, in ABC) was added. Samples were 
briefly vortexed, then incubated at 37 °C for 24 hours. 
 
Samples were dried down under nitrogen, then to each tube was added: 
 0.5 μL bovine serum albumin solution (10 mg/mL) 
 10 μL (100 mIU) Neuraminidase from Clostridium perfringens (C. welchii) in 
10 mM phosphate buffer (pH 5.5) 
 2 μL (16 IU) β1-4 galactosidase solution 
 2 μL (8 IU) β-N-acetylglucosaminidase solution 
 50.5 μL water 
 5 μL G4 buffer (50 mM sodium citrate, pH 6.0, 100 mM NaCl) 
 
Aliquots of the digests (10 μL) were taken at 0, 1, 3, 6, 12 and 24 hours. These were 
frozen at -80 °C, then recovered and derivatised with Rhodamine 110 as in 5.2.4 below. 
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A vial of huEPO standard (10 IU, approximately 100 ng) was also dissolved in ABC 
and digested in the same way as these latter samples of IgG and rEPO, but it was 
digested for the full 24 hours, then the whole digest was recovered and derivatised with 
Rhodamine 110 as below. 
 
Purified standards of glycans NGA2F and M3N2F (see Figure 5.4) were derivatised 
with Rhodamine 110, as in 5.2.4 below. 
 
 
Figure 5.4: Structures of glycan standards 
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5.2.3 Glycan recovery 
 
Samples were allowed to cool to room temperature, then 300 μL of ice-cold ethanol was 
added and the samples vortexed then cooled at -20 °C for one hour. Samples were then 
centrifuged for 20 minutes at 6,000 g and the supernatant transferred to a low bind tube. 
Samples were then dried down under nitrogen, and stored at -80 °C until derivatised. 
 
5.2.4 Derivatisation of glycans – Rhodamine 110 
 
To a microfuge tube containing cleaved, digested and extracted glycans, 10 μL of 
Rhodamine 110 solution (5 mM, 1:19 acetic acid:methanol) and 10 μL sodium 
cyanoborohydride solution (0.1 M in methanol) was added. Samples were vortexed to 
reconstitute dried down glycans, then incubated overnight at 37 °C. Samples were 
cooled to room temperature, then 10 μL potassium hexacyanoferrate (III) solution 
(0.2 M in water) was added and allowed to react for 30 minutes at room temperature. 
Samples were dried down under nitrogen, then reconstituted in 50 μL water for analysis 
by LC-MS. The derivatisation reaction is shown in figure 5.5. 
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Figure 5.5: Reductive amination of N-acetylglucosamine with rhodamine 110, and 
restoration to a fluorescent product with potassium hexacyanoferrate (III) 
 
5.2.5 Derivatisation of glycans – APTS 
 
To a microfuge tube containing cleaved, digested and extracted glycans, 10 μL of 
sodium cyanoborohydride (0.2 M in THF) and 10 μL of APTS (40 mM in 15% acetic 
acid) were added. Samples were vortexed to reconstitute dried down glycans, then 
incubated in the dark at room temperature overnight. Samples were dried down under 
nitrogen, then reconstituted in 50 μL water for analysis by LC-MS. The derivatisation 




Figure 5.6: Reductive amination of N-acetylglucosamine with APTS. 
 
5.2.6. LC-MS analysis of derivatised glycans 
 
Recombinant EPO and IgG which had been digested for 12 hours after a second addition 
of enzymes were analysed using an Acquity UPLC system and Orbitrap mass 
spectrometer. Recombinant EPO and IgG which had been digested for 20 hours after the 
second addition of enzymes were, due to machine availability, analysed using a Thermo 
Accela HPLC system and Orbitrap.  
 
HPLC solvents were A: water and 0.1% formic acid and B: acetonitrile and 0.1% formic 
acid. LC was carried out at a flow rate of 200 μL/minute. A gradient elution was carried 
out, starting at 95% A, and increasing linearly to 57% A at 15 minutes. 10 μL of sample 
was injected on column. 
 
Mass spectrometer conditions were (positive/negative ion mode):  Sheath gas flow 
60 arbitrary units (a.u.); auxillary gas flow 10 a.u.; Spray voltage 4.0/3.0 kV; Capillary 
temperature 250 °C; Capillary voltage 92.5/-95.0 V; Tube lens voltage 165/-145 V; 
Skimmer voltage 44/-32 V; Heater temperature 300 °C. Scans were carried out between 
350 and 2,000 m/z. 
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Rhodamine derivatised samples were analysed in positive ion mode. APTS derivatised 
samples were analysed in both positive and negative ion mode. 
 
Samples from the time series digest of IgG and rEPO, and the digested huEPO standard, 
were analysed using a Q-Exactive mass spectrometer. HPLC was carried out using the 
same column, solvents and flow rates as previously. The mass spectrometer was 
operated in the positive mode, using the following conditions: 
Resolution 35,000; Number of microscans 1; Maximum inject time 30; Sheath gas flow 
rate (arbitrary units) 70; auxillary gas flow rate 10 A.U.; sweep gas flow rate 0 A.U; 
spray voltage 3.75 kV; capillary temperature 320 °C; S-lens RF level 55.0; heater 
temperature 350 °C. 
Samples were injected three times, to ensure that any detected differences in retention 
time were not down to method variability. 
 
5.2.7 Use of superchargers to enhance detection of derivatised glycans 
 
Rhodamine 110 derivatised glycans from rEPO were analysed as in 5.2.6, except that 
1% sulfolane (v/v) was added to the LC solvents. 
 
5.2.8 CE-LIF analysis of derivatised glycans 
 
APTS-labelled glycans from long and short digests of IgG and rEPO were analysed 
using CE-LIF. Analysis was carried out using a Beckman Coulter PA 800 Plus 
Pharmaceutical Analysis System. A 488 nm laser (Ar
+
) was used for fluorescent 
excitation, with a 520 nm emission filter. Samples were separated in a 100 mM acetate 
buffer, pH 4.75 using a Beckman Coulter N-CHO coated capillary, 60 cm total length, 
effective length 50 cm, 75 μm internal diameter. Samples were pressure injected for 10 
seconds and were kept at 10 °C in the sample tray. Separation was carried out over 15 
minutes, in reverse polarity at a maximum voltage of 30 kV. Capillary was conditioned 
between each sample injection by washing for 1 minute with 0.1 N NaOH (aq). An 
APTS-labelled glucose ladder was used to evaluate the size of glycans detected. 
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5.2.9 Extraction, digestion and derivatisation of EPO from urine samples 
 
Extraction of EPO from blank urine samples (20 mL) was carried out using MAIIA 
immunoaffiity monolithic cartridges, according to the kit instructions. Positive and 
negative control urines were also made up, by filtering urine samples through a 30 kDa 
centrifugal filter, and then spiking samples with huEPO (standard 67/343) or rEPO 
(BRP-EPO batch 3) at a concentration of 1 mIU/mL, and these were extracted in the 
same way. Final elution from the columns was into a volume of 50 μL. Samples were 
then transferred to an Ultra-10 Amicon centrifugal filter and dialysed and recovered in 
the same manner as Epiao EPO in 5.2.2. 
Cleavage of glycans with PNGase, exoglycosidase digestion, recovery of glycans and 
derivatisation with Rhodamine 110 was carried out as in 5.2.2, 5.2.3 and 5.2.4. Samples 
were analysed using an Acquity UPLC system and Orbitrap mass spectrometer. 
 
5.3 Results and discussion 
 
5.3.1 Rhodamine 110 derivatisation of glycans from standards 
 
Glycans digested for 24 hours and then for 12 further hours after addition of more 
enzymes were derivatised with rhodamine 110. Extracted ion chromatograms (EICs) for 
m/z 366.1389, produced to identify glycan containing regions, are shown in figure 5.7. 
 
 206 
RT: 0.00 - 15.00 SM: 7B











































































Base Peak m/z= 
366.1371-366.1407 F: 
FTMS {1,1}  + p ESI 
Full ms 
[350.00-2000.00]  MS 
00020
NL: 2.36E4
Base Peak m/z= 
366.1371-366.1407 F: 
FTMS {1,1}  + p ESI 
Full ms 
[350.00-2000.00]  MS 
00021
 
Figure 5.7 EIC of m/z 366.1389 from IgG (top) and rEPO derivatised glycan digests 
 
Two main regions of glycan elution are seen. The first, between approximately 
2 minutes and 2.7 minutes, consists of underivatised glycans. Spectra from these 
regions, shown in figure 5.8, show that the glycans found are fucosylated 
pentasaccharide core glycans, with none (m/z 1,057.39), one (m/z/ 1,260.47) or two 
(m/z 1,463.37) GlcNAc attached. 
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00020#260-351  RT: 
2.00-2.70  AV: 92 T: 




00021#260-351  RT: 
2.00-2.70  AV: 92 T: 




Figure 5.8 Mass spectra from early eluting glycan region of chromatogram, 
demonstrating presence of underivatised glycans. Spectra also contains several peaks 
approximately 100 m/z apart from instrument calibration solution. Top – IgG, 
bottom - rEPO. 
 
The intensity of the signal from these peaks suggests that a significant amount of 
glycans remain underivatised by the current method. In turn, this would mean that 
sensitivity gains could be made by improving the efficiency of the derivatisation. 
 
Mass spectra from the time 9.3 minutes to 11.5 minutes are shown in figure 5.9.  
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RT: 9.41-11.59  AV: 
284 T: FTMS {1,1}  + p 




RT: 9.32-11.51  AV: 
285 T: FTMS {1,1}  + p 
ESI Full ms 
[350.00-2000.00] 
 
Figure 5.9 Mass spectra from 9.3 minutes to 11.5 minutes of chromatograms in figure 5.6. Top – IgG, bottom - rEPO
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The derivatised glycans found match the underivatised glycans which elute earlier. 
Again, they consist of fucosylated pentasaccharide core glycans, with no (m/z 1,371.49), 
one (m/z 1,574.57) and two (m/z 1,777.65) GlcNAc residues attached. Glycans without 
fucose attached are also detected, at m/z 1,225.4345 and 1,428.52, corresponding to 
pentasaccharide core glycans with none and one GlcNAc residues. 
 
LC-MS analysis resulted in double peaks in extracted ion chromatograms which 
corresponded in mass to either the rhodamine 110 derivative, or to the 
dihydrorhodamine derivative, if the glycan ring, shown open in figure 5.4, subsequently 
closed again. If it was the latter, this failure of the derivatisation method would prevent 
analysis using CE-LIF. To check that the oxidation with potassium hexacyanoferrate 
(III) was successful, the derivatisation process was repeated without glycans. The 
results, shown in figure 5.10, show that rhodamine 110 does indeed form 
dihydrorhodamine when incubated with sodium cyanoborohydride, but that this reaction 
is reversed when potassium hexacyanoferrate (III) is added. Furthermore, only one peak 
is seen with either rhodamine 110 or dihydrorhodamine.  Therefore, it is likely that the 
double peaks correspond to glycan isomers, derivatised with rhodamine 110, although it 
is not clear what isomers these would be. Alternatively, the oxidation step may not be as 
effective once the rhodamine 110 is attached to the glycan; the double peak could then 
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0347#1849-1873  RT: 
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0348#1495-1518  RT: 
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Figure 5.10 Base peak chromatograms from rhodamine 110 (top), rhodamine 110 
reduced with sodium cyanoborohydride to give dihydrorhodamine (middle) and 
rhodamine 110 reduced and then oxidised with potassium hexacyanoferrate (III) 
(bottom) 
 
Extracted ion chromatograms for the derivatised oligosaccharides showed that they had 
the same retention times regardless of whether they came from IgG or rEPO, with one 
exception, that for m/z 1,574.57. This corresponds to the fucosylated pentasaccharide 
core with one GlcNAc attached. The retention time for this glycan from rEPO was 
slightly shorter than that for the glycan from IgG, as shown in figure 5.11. Mixing the 
two derivatised digests confirmed that two sets of peaks were present. Since IgG 
consists largely of glycans containing a bisecting GlcNAc, and since 
β-N-acetylglucosaminidase is much less active in cleaving bisecting sugars, it is a 
reasonable hypothesis that the separation of the peaks is due to the position of this sugar. 
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Figure 5.11: Extracted ion chromatograms of of m/z 1,574.57 - Rhodamine 110 
derivatised sugars, Exoglycosidase digested. From top: IgG, rEPO, IgG/rEPO.  
 
Digestion of glycans for an additional 20 hours after the addition of extra enzymes 
resulted in different glycan profiles. Extracted ion chromatograms of m/z 1,574.57 
showed that very little was detected in the rEPO digest, although it was still easily 
detected in the IgG digest, as shown in figure 5.12.  
Extracted ion chromatograms of m/z 1,371.49, shown in figure 5.13, show that in rEPO, 
after 20 hours the glycans have been nearly entirely digested back to the fucosylated 
pentasaccharide core. With IgG, although this peak is large, a significant amount is still 
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Base Peak m/z= 
1574.5664-1574.5724 F: 
FTMS {1,1}  + p ESI Full 
ms [350.00-2000.00]  
MS  ICIS 0275
NL: 9.28E2
Base Peak m/z= 
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Figure 5.12 EICs of m/z 1,574.57 from rhodamine 110 derivatised IgG (top) and rEPO 
digests, 20 hours after addition of extra exoglycosidase enzymes 
RT: 6.91 - 11.13 SM: 7B


























































Base Peak m/z= 
1371.4882-1371.4942 F: 
FTMS {1,1}  + p ESI Full 
ms [350.00-2000.00]  
MS  ICIS 0275
NL: 4.05E4
Base Peak m/z= 
1371.4882-1371.4942 F: 
FTMS {1,1}  + p ESI Full 
ms [350.00-2000.00]  
MS  ICIS 0276
 
Figure 5.13 EICs of m/z 1,371.49 from rhodamine 110 derivatised IgG (top) and rEPO 
digests, 20 hours after addition of extra exoglycosidase enzymes 
Intensity = 9.28 E2 
Intensity = 1.07 E5 
Intensity = 4.05 E4 
Intensity = 6.77 E5 
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With IgG, the ratio of peak areas for glycans with a single GlcNAc attached to the 
pentasaccharide core to those without the residue is approximately 1:5.7. For rEPO, the 
ratio is about 1:47. If oligosaccharides with two GlcNAc residues attached to the 
pentasaccharide core are included with those with one attached, the difference is even 
more pronounced. None were detected in the rEPO digest, but the ratio in the IgG digest 
changes to 1:3.9. 
 
5.3.2 APTS derivatisation of glycans from standards 
 
In comparison with the good LC-MS results observed with the rhodamine 110 
derivatised N-glycans, those from APTS derivatised glycans were poor. Although EICs 
for m/z 366.1389 detected only very small peaks from underivatised glycans in the IgG 
and rEPO digests, suggesting the derivatisation is more efficient than with rhodamine 
110, peaks from derivatised glycans were also hard to detect. Figures 5.14 and 5.15 
show the EICs for glycans with no, one and two remaining N-acetylglucosamines for the 
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Figure 5.14 EICs from APTS derivatised IgG digest for (from top) m/z 747.67, 849.21, 
and 950.75 , corresponding to no, one and two remaining GlcNAc residues. 
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Figure 5.15 EICs from APTS derivatised rEPO digest for (from top) m/z 747.67, 849.21, 
and 950.75, corresponding to no, one and two remaining N-acetylglucosamine residues.  
Intensity = 3.25 E3 
Intensity = 4.85 E3 
Intensity = 1.56 E4 
Intensity = 3.50 E2 
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Retention was much reduced with APTS derivatisation, and the separation of different 
glycans seen with rhodamine 110 derivatisation did not occur. Since peaks co-eluted, 
accurate quantitative analysis of peak areas is not possible. However, the peak area ratio 
for IgG of glycans with and without GlcNAc residues attached to the pentasaccharide 
core was 1: 2.2, so it is in the same region as that obtained with rhodamine 110. With 
rEPO, only the pentasaccharide core structure was detected. It is not clear why the peak 
seen for this glycan was so much smaller in the rEPO digest than in that of IgG with 




5.3.3 Comparison of digests from rEPO, IgG and huEPO with glycan standards at 
different time points 
 
Glycan standards NGA2FB, NGA2F and M3N2F were derivatised with Rhodamine 110, 
and analysed using LC-MS. EICs from these samples are shown in figure 5.16.  
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RT: 8.00 - 10.94 SM: 5G










































Base Peak m/z= 
990.8660-990.8760 F: 
FTMS + p ESI Full ms 
[350.00-3000.00]  MS  
Genesis 18oct2013_03
NL: 4.64E8
Base Peak m/z= 
889.3277-889.3365 F: 
FTMS + p ESI Full ms 
[350.00-3000.00]  MS  
Genesis 18oct2013_04
NL: 2.04E9
Base Peak m/z= 
1371.4893-1371.5031 F: 
FTMS + p ESI Full ms 
[350.00-3000.00]  MS  
Genesis 18Oct2013_05
 
Figure 5.16 EICs of Rhodamine 110 derivatised glycan standards. From top, glycans are 
NGA2FB, NGA2F and M3N2F 
 
The reduction in the hydrophilic nature of the derivatised glycans as the size of the 
glycans is reduced results in an increasing retention time. Mass spectra from these peaks 
are shown in figures 5.17-5.19. 
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18Oct2013_03 #2177-2190 RT: 9.71-9.77 AV: 14 NL: 4.16E7
T: FTMS + p ESI Full ms [350.00-3000.00]








































































Figure 5.17 – Mass spectrum from NGA2FB peak in figure 5.16 
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18Oct2013_04 #2195-2218 RT: 9.79-9.89 AV: 24 NL: 1.33E8
T: FTMS + p ESI Full ms [350.00-3000.00]




































































Figure 5.18 – Mass spectrum from NGA2F peak in figure 5.16 
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18Oct2013_05 #2213-2256 RT: 9.87-10.06 AV: 44 NL: 9.21E8
T: FTMS + p ESI Full ms [350.00-3000.00]





































Figure 5.19 – Mass spectrum from M3N2F peak in figure 5.16 
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EICs of m/z 366.1384 (used to identify glycan containing peaks) from the rEPO digest at 
0, 3, 6, 12 and 24 hours are shown in Figure 5.20. The inital chromatogram shows a very 
broad peak, presumably due to the large variety in glycans present at the start. Over 
time, this broad peak resolves itself into more distinct peaks, presumably as this variety 
is reduced by sequential cleavage of sugar residues by exoglycosidases. The final 
chromatogram shows only a few overlapping, but partially resolved peaks. 
 
RT: 0.00 - 20.01 SM: 7G

































Base Peak m/z= 
366.1377-366.1413 F: 
FTMS + p ESI Full ms 
[350.00-3000.00]  MS  
Genesis 18Oct2013_13
 
RT: 0.00 - 20.01 SM: 7G



































Base Peak m/z= 
366.1377-366.1413 F: 
FTMS + p ESI Full ms 
[350.00-3000.00]  MS  
Genesis 18Oct2013_15
 
RT: 0.00 - 20.01 SM: 7G




































Base Peak m/z= 
366.1377-366.1413 F: 
FTMS + p ESI Full ms 
[350.00-3000.00]  MS  
Genesis 18Oct2013_16
 
A: 0 hours 
B: 3 hours 
C: 6 hours 
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RT: 0.00 - 20.01 SM: 7G




































Base Peak m/z= 
366.1377-366.1413 F: 
FTMS + p ESI Full ms 
[350.00-3000.00]  MS  
Genesis 18Oct2013_18
 
RT: 0.00 - 20.01 SM: 7G






































Base Peak m/z= 
366.1377-366.1413 F: 
FTMS + p ESI Full ms 
[350.00-3000.00]  MS  
Genesis 18Oct2013_19
 
Figure 5.20: EICs of m/z 366.1384 from rEPO digest at – A: 0 hours, B: 3 hours, C: 6 
hours, D: 12 hours, E: 24 hours 
 
The mass spectrum from this final chromatogram between 9 and 10 minutes is shown in 
figure 5.21. This shows that after 24 hour digestion glycans consisting of the fucosylated 
pentasaccharide core with one (m/z 1574.58), two (m/z 1777.66 or 889.33) and three 
(m/z 990.87) GlcNAc residues attached are detected, but the predominant glycan 
detected is the fucosylated pentasaccharide core with no other residues attached (m/z 
1371.49). 
 
D: 12 hours 
E: 24 hours 
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18Oct2013_19 #2128-2171 RT: 9.49-9.68 AV: 44 NL: 1.05E6
T: FTMS + p ESI Full ms [350.00-3000.00]

















































2182.0316 2707.9203 2938.82872313.09441703.8248 2444.6325
 
Figure 5.21 Mass spectrum from 9 to 9.5 minutes from chromatogram E, figure 5.20 
 
For reference, the spectrum from the same time in the chromatogram from the starting 
point of the digest (A in figure 5.20) is shown in figure 5.22, below. Interestingly, there 
is evidence of a glycan with m/z 1574.58 in this sample, although it is possible this is 
formed by in-source fragmentation. 
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18oct2013_13 #2053-2230 RT: 9.15-9.94 AV: 178 NL: 1.01E5
T: FTMS + p ESI Full ms [350.00-3000.00]







































































Figure 5.22 Mass spectra from 9 to 9.5 minutes from chromatogram A, figure 5.20 
 
Comparison of the digest of IgG, rEPO and the glycan standard of NGA2FB showed 
that in the rEPO and IgG digest after 24 hours, a glycan corresponding in mass to a 
fucosylated pentasaccharide core with one attached GlcNAc residue was present, but 
that it had a different retention time in the two digests (see Figure 5.23) The retention 
time of the glycan present in IgG matched that of the same glycan in NGA2FB, the 
bisected standard. This was true for all three injections of the samples. This adds more 




RT: 7.47 - 12.38 SM: 7G







































































Base Peak m/z= 
1574.5686-1574.5844 F: 
FTMS + p ESI Full ms 
[350.00-3000.00]  MS  
Genesis 18oct2013_02
NL: 3.37E6
Base Peak m/z= 
1574.5686-1574.5844 F: 
FTMS + p ESI Full ms 
[350.00-3000.00]  MS  
Genesis 18oct2013_11
NL: 1.32E6
Base Peak m/z= 
1574.5686-1574.5844 F: 
FTMS + p ESI Full ms 
[350.00-3000.00]  MS  
Genesis 18oct2013_16
 
Figure 5.23 EICs of m/z 1574.57 from digests after 24 hours. From top: IgG, NGA2FB, 
rEPO 
 
Unfortunately, attempts to see if the retention time of the same glycan from the digest of 
huEPO matched that from the digest of IgG or rEPO were not successful, as no glycan 
with this m/z was detected in the huEPO digest. However, a peak was found in the 
huEPO electropherogram with an m/z the same as that of the intact glycan standard 
NGA2FB. EICs of this m/z from LC analysis of this standard as well as 24 hour digests 
of rEPO, IgG, huEPO (all derivatised with Rhodamine 110) are shown in figure 5.24. 
They show that there is partial resolution of the peaks found with NGA2FB, IgG and 
huEPO from those found in rEPO. This was especially true of the first of the two peaks 
in the chromatogram, where there is near baseline resolution. This resolution was seen in 
all three repeat injections of the samples. 
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RT: 7.82 - 10.99 SM: 7G






























































































Base Peak m/z= 
990.8674-990.8774 F: 
FTMS + p ESI Full ms 
[350.00-3000.00]  MS  
Genesis 18Oct2013_25
NL: 3.05E8
Base Peak m/z= 
990.8674-990.8774 F: 
FTMS + p ESI Full ms 
[350.00-3000.00]  MS  
Genesis 18oct2013_03
NL: 4.64E6
Base Peak m/z= 
990.8674-990.8774 F: 
FTMS + p ESI Full ms 
[350.00-3000.00]  MS  
Genesis 18oct2013_16
NL: 2.35E6
Base Peak m/z= 
990.8674-990.8774 F: 
FTMS + p ESI Full ms 
[350.00-3000.00]  MS  
Genesis 18oct2013_29
 
Figure 5.24 EICs of m/z 990.87 (2+ ion). From top, 24 hour digest of IgG, NGA2FB 
standard, 24 hour digest of rEPO, 24 hour digest of huEPO 
 
These results suggest that there is a real and detectable difference in the core structures 
of glycans from IgG, rEPO and the huEPO standard. Specifically, it suggests that the 
bisected glycan NGA2FB is the same structure found at the core of glycans from IgG (as 
has been previously reported) and also at the core of glycans from the huEPO standard 
(as suggested by Christian Reichel). This glycan structure is not, however, found in 
rEPO. As such, glycans with the same mass found in rEPO digests must consist of the 
fucosylated pentasaccharide core with three GlcNAc residues, all of which are attached 
to the α-linked mannose residues. As shown in the chromatograms in Figure 5.24, these 





5.3.4. Use of superchargers to enhance detection of derivatised glycans  
 
Extracted ion chromatograms for m/z 1,574.57 from samples of derivatised glycans from 
rEPO analysed with and without sulfolane in the LC solvent are shown in figure 5.25.  
 
RT: 6.98 - 13.68 SM: 7B













































Base Peak m/z= 
1574.5679-1574.5773  
MS  ICIS 00084
NL: 1.46E5
Base Peak m/z= 
1574.5679-1574.5773 F: 
FTMS {1,1}  + p ESI Full 
ms [350.00-2000.00]  MS 
 ICIS 00088
 
Figure 5.25 EIC of m/z 1574.57 from analysis of derivatised glycans from rEPO, with 
(bottom) and without addition of 1% sulfolane to the LC solvent 
 
The addition of sulfolane causes a (very slight) increase in retention time. As can be 
seen in the mass spectra from these chromatograms (figure 5.26), it also causes an 
increase in peak height. Samples were run twice, and mean increase in peak height for 
the 1,574.57 ion was 2.2 times. 
EICs for m/z 1,371.49 and mass spectra focusing on this m/z are shown in figures 5.27 
and 5.28. Again, as well as a slight increase in retention time, an increase in signal is 
seen; mean increase this time was 2.7 times. 
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RT: 10.17-10.74  AV: 
75 T: FTMS {1,1}  + p 




RT: 10.23-10.88  AV: 
85 T: FTMS {1,1}  + p 
ESI Full ms 
[350.00-2000.00] 






















































RT: 10.17-10.74  AV: 
75 T: FTMS {1,1}  + p 




RT: 10.23-10.88  AV: 
85 T: FTMS {1,1}  + p 
ESI Full ms 
[350.00-2000.00] 
 
Figure 5.26 Mass spectra from peaks in EICs in figure 5.25. Top, without sulfolane; 
bottom, with 1% sulfolane in LC solvent  
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RT: 6.98 - 13.68 SM: 7B













































Base Peak m/z= 
1371.4897-1371.4979 F: 
FTMS {1,1}  + p ESI Full 
ms [350.00-2000.00]  MS 
 ICIS 00084
NL: 3.70E5
Base Peak m/z= 
1371.4897-1371.4979 F: 
FTMS {1,1}  + p ESI Full 
ms [350.00-2000.00]  MS 
 ICIS 00088
 
Figure 5.27 EIC of m/z 1,371.49 from analysis of derivatised glycans from rEPO, with 
(bottom) and without addition of 1% sulfolane to the LC solvent 
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RT: 10.17-10.74  AV: 
75 T: FTMS {1,1}  + p 




RT: 10.23-10.88  AV: 
85 T: FTMS {1,1}  + p 
ESI Full ms 
[350.00-2000.00] 




















































1385.5 11376.5086 1378.32401368.4614 1384.04781380.3459 1382.78261366.6709
NL: 3.85E4
00084#1354-1435  
RT: 10.44-11.06  AV: 
82 T: FTMS {1,1}  + p 




RT: 10.58-11.24  AV: 
87 T: FTMS {1,1}  + p 
ESI Full ms 
[350.00-2000.00] 
 
Figure 5.28 Mass spectra from peaks in EICs in figure 5.27. Top, without sulfolane; 
bottom, with 1% sulfolane in LC solvent  
 
5.3.5 CE-LIF analysis of glycans 
 
CE-LIF analysis of APTS labelled glycans was less suggestive of a difference between 
rEPO and IgG after short digestion. Figure 5.29 shows the electropherogram of the 
shorter digests of rEPO and IgG, zoomed in on the region between 4 and 10 on the 
glucose ladder. The only major peak for rEPO is at approximately 11.6 minutes, which 
is about 6 glucose units in size and probably corresponds to the fucosylated 
pentasaccharide core. There is no obvious peak which would correspond to this core 
plus a single (non-bisecting) GlcNAc. In the IgG electropherogram, as well as this core 
structure, other peaks are seen which could correspond to the core plus one, two and 




Figure 5.29 Electropherogram of APTS labelled glycans from rEPO (black) and IgG (green) after the shorter digestion. Pink peaks are 
from glucose ladder, 4-10 residues long 
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Figure 5.30 shows the electropherograms from CE-LIF analysis of the longer digests.  
At about five glucose units long, there are two peaks found in both digests, 
corresponding to the positional isomers of the fucosylated pentasaccharide core with one 
mannose removed. It is not clear how this is formed, since no mannosidases were 
present in the digest. It could be that some of the enzymes used have some secondary 
mannosidase activity, and that as a result of the longer digest, some of this glycan is 
formed. A small third peak is also seen in the IgG digest; potentially, this could be the 
pentasaccharide core with two mannose residues removed and a bisecting GlcNAc 
present, although this has not been confirmed.  
At six glucose residues long, the large fucosylated pentasaccharide peak is again 
observed. This peak seems to be split in the IgG trace; again, it is not clear why this is. 
Then, at seven residues long, there are two peaks seen in both IgG and rEPO digests; 
one peak (at approximately 12.7 minutes) is seen in both; however, a peak is present in 
the IgG electropherogram at 12.4 minutes, and at 12.5 minutes in the rEPO 
electropherogram. It is possible that the peak present in IgG is the fucosylated 
pentasaccharide core with a bisecting GlcNAc residue. Certainly, at eight residues long, 
there are three peaks present in the digest of IgG, and one (or possibly two) present in 
the digest of rEPO, which corresponds to the positional isomers possible respectively 
with and without a bisecting GlcNAc residue present. 
If the peaks from 7-residue long glycans are those from the fucosylated core structure 
with bisecting or non-bisecting GlcNAc residues, then the ratios of the peaks may 
provide a way to discriminate between endogenous and recombinant EPO. However, the 
sensitivity of this approach still needs to be determined. Due to time constraints, it was 
not possible to run a dilution series to estimate the limit of detection of this method. This 










Figure 5.30 Electropherogram of APTS labelled glycans from IgG (black) and rEPO (green) after the longer digestion. Pink peaks are 
from glucose ladder, 4-10 residues long. 
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5.3.6 Extraction, digestion and derivatisation of EPO from urine samples 
 
The method presented here does not have the sensitivity to detect glycans from EPO at 
the level it is found in urine. However, samples were nonetheless extracted using MAIIA 
cartridges, digested and derivatised and then analysed in the same manner as standards. 
EICs for m/z 1,574.57 and 1,371.49 did not detect any peaks in these samples. This does 
at least demonstrate that there are not compounds present at much higher levels than 
EPO which could give false positive results, although obviously it does not preclude 




There is evidence that IgG and rEPO behave differently when digested at approximately 
equimolar concentrations (of glycans) by exoglycosidases. IgG, which has been reported 
to consist mostly of glycans carrying a bisecting GlcNAc, was digested by the 
combination of enzymes used here to two main structures after 36 hours: a fucosylated 
pentasaccharide core, and the same core structure with a single GlcNAc residue 
attached.  
These are also the structures detected when rEPO is digested by the same process for the 
same length of time. However, there are two key differences, depending on the length of 
the digestion. With a shorter digest time, both structures were detected in significant 
amounts. EICs of the mass corresponding to the glycan with the single GlcNAc residue 
attached showed that peaks from rEPO eluted in a shorter time than peaks from IgG. 
This suggests that the peaks are isomers. Since IgG is predominantly bisected, it is 
reasonable to suggest that the peaks seen could be from glycans with a single bisecting 
GlcNAc residue remaining, whereas those seen in rEPO (which is not thought to contain 
a bisecting GlcNAc) have a remaining GlcNAc attached to the α3 or α6 linked mannose 
residues. The detection in sufficient quantities of this latter glycan may provide a way of 
detecting rEPO in the presence of endogenous EPO. 
A second difference is seen when the digestion is carried on for longer. After 20 hours, 
the glycans from the rEPO digest had been digested almost entirely to the fucosylated 
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pentasaccharide core. This was not the case with the glycans from IgG, which still 
contained a large amount of the glycan containing an additional GlcNAc. This would 
tally with this residue being bisecting; the N-acetylglucosaminidase used in the digests 
shows less activity at cleaving bisecting residues. As a result, after 20 hours, there was 
still a relatively large amount of it left. This could provide a second approach for 
discriminating between endogenous and rEPO; after a sufficiently lengthy digest, the 
ratio of m/z 1,574.57 to 1,371.49 ions would be higher with endogenous EPO than with 
rEPO; in the digests carried out here, the ratios were 1:5.7 for IgG, and 1:47 for rEPO. 
Experiments using a purified standard of glycan NGA2FB provided additional evidence 
for the idea that the presence of a bisecting GlcNAc can enable glycans to be separated 
on a C18 column after derivatisation with Rhodamine 110. As stated, glycans from 
digested rEPO could be separated from isobaric glycans from IgG. Exoglycosidase 
digestion of the NGA2FB standard showed that the retention time of glycans from IgG 
was the same as the retention time of glycans from the bisected standard. 
Unfortunately, this difference was not able to provide a way to distinguish between 
huEPO and rEPO, as the glycan with m/z 1,574.57 was not detected in the digest of the 
huEPO standard. However, a glycan corresponding in mass to the bisected standard 
NGA2FB (m/z 990.87, 2+ ion) was detected in this digest. A glycan with this mass was 
also detected in 24 hour digests of rEPO and IgG. The retention time of this glycan was 
the same in the digests of IgG and huEPO, and matched the retention time of the 
NGA2FB standard. However, the retention time in rEPO of this glycan was different. 
This could be because in the three former glycans, one of the GlcNAc residues is 
bisecting; in the latter, it is not.  
At present this approach has not been demonstrated with sufficient sensitivity to be 
tested on real antidoping samples. However, the technology may already exist to provide 
sufficient sensitivity. Digests of rEPO (which were split to enable derivatisation with 
both rhodamine 110 and APTS) were run at a final concentration of 200 μg/mL on the 
Exactive, and had a signal:noise ratio of 223, which increased to 687 when sulfolane 
was added to the LC solvent. Using a minimum signal:noise ratio of 3:1, this would 
imply a limit of detection of 291 ng/mL. Assuming a not unreasonable 50% recovery 
from the MAIIA cartridges and reconstituting in 20 μL after derivatisation, real doping 
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samples would be expected to have a concentration in the region of 5 ng/mL. Although 
this would appear to be a long way from the limit of detection of the method presented 
here, a change from a 2.1 mm column to a 75 μm capillary column would theoretically 
increase sensitivity by up to 784 times. Changing to the more sensitive Q-Exactive 
improved detection; samples were made up at 2 μg/mL, but still displayed high 
signal:noise values. It is worth mentioning, however, that although at relatively low 
concentrations, 100 ng of huEPO was still used in the digest; this is the amount found in 
10 litres of urine, and dropping down to lower absolute amounts may result in much 
higher proportional losses. 
It also needs pointing out that even if the difference in the chromatograms of digested 
and derivatised rEPO and huEPO standards is due to the absence and presence 
respectively of a glycan containing bisecting GlcNAc, it does not necessarily follow that 
this bisected glycan is present in huEPO, only that it is present in the standard. It is 
possible that the standard also contains other glycoproteins, which may themselves 
contain a glycan with a bisecting GlcNAc. Tryptic digest of the huEPO standard 
followed by LC-MS/MS identification of the peptides present may enable this to be 
checked. 
CE-LIF analysis was only carried out on APTS labelled glycans, due to time and 
equipment constraints. It may be valuable to check the sensitivity and separation seen 
with CE-LIF analysis of rhodamine 110 labelled glycans as well.  
The data that was obtained did not entirely tally with that from the LC-MS analysis, 
although the two analyses were carried out on differently derivatised samples. The long 
digests of rEPO and IgG resulted in electropherograms in which peaks were present 
which could correspond to 7-residue glycans without and with bisecting GlcNAc 
residues. The equivalent peaks from LC-MS analysis of rhodamine 110 labelled glycans 
were very small, if present, in the long rEPO digest. 
The short digest of rEPO did not result in detectable peaks in CE-LIF that would 
correspond to glycans of this size, although they were detected in LC-MS analysis of 
this digest. Glycans of this size were detected in both the CE-LIF analysis and LC-MS 
analysis of the short digest of IgG. It is not clear where this discrepancy in the data 
comes from. It is possible that the derivatisation process causes some changes to the 
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glycan structures found, although this would not necessarily be a problem if any effects 
are reproducible and affect different glycan structures equally. However, the CE-LIF 
work was severely time constrained. Although it perhaps provides complementary data 
to that obtained by LC-MS, it needs to be repeated before too much weight should be 
attached to it.  
It would also be useful to provide more time points through the digest than just two. In 
particular, a profile of the digest at, or near, time zero could be helpful. Analysis of a 
digestion progression may better demonstrate how the glycans from the two 
glycoproteins are sequentially digested, and the differences that arise between the two 
profiles as a result. In this way, digestion could be optimised to maximise the detectable 
differences. As mentioned above, this work was partly carried out using LC-MS; it 
suggested that after 24 hours, the digests of rEPO and IgG could be distinguished by the 
retention times of glycans consisting of the fucosylated pentasaccharide core with 3 
GlcNAc residues attached. The retention time of this glycan from a huEPO digest 
matched that from IgG and differed from that from rEPO. Unfortunately, machine 
availability issues meant that analysis of the samples gathered at different time points 
through a digest could not be carried out using CE-LIF; there was also no opportunity to 
examine digested huEPO. Since improved resolution might be expected with capillary 
electrophoresis, use of this approach may provide further evidence of the structural 
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Erythropoietins (EPOs) are available as the original Amgen recombinant material and, 
since the expiration of the patent, as a plethora of biosimilars produced in laboratories 
around the world with differing post-translational isoform structures.  
The current methods for identification of the misuse of EPOs and related drugs 
(isoelectric focusing or SDS/Sarcosyl-PAGE and immunoblotting) abused for 
performance enhancing purposes are both time and labour intensive, albeit that they can 
detect very small concentrations of epoietins. The results they produce are subjective 
and it is suspected that they result in a large number of false negatives, as their lack of 
specificity means that the criteria for a positive test need to be set more tightly than is 
perhaps desirable. 
Alternative methods developed with the intention of tackling this problem either fail to 
identify all the isoforms, lack sufficient sensitivity to be used in anti-doping tests, or 
have not been validated with real anti-doping samples. 
 
The original aim of this PhD was to develop a mass spectrometry-based method for the 
detection of rEPO in anti-doping samples. Mass spectrometry based methods which had 
been previously tried had failed due to a lack of sensitivity; this in turn was due to the 
low levels at which EPO is present in urine (~10 ng/L), combined with the extensive 
variation in the glycosylation found. At the start of the PhD, recently published research 
(Groleau, Desharnais et al. 2008) had been able to detect and identify the three most 
prominent glycoforms of Asn24 and Asn38  using 100 ng of rEPO after desialylation, at a 
concentration of 500 μg/mL. Partial assignment of the glycan structures on these 
glycopeptides was possible, including the identification of N-acetyl lactosamine repeat 
units. With the fully sialylated glycopeptides, detection of the three most abundant 
isoforms of Asn24 was possible with 100 ng of material, but identification of repeat units 
and therefore structural assignment was not. 
 
Efforts to improve on these results and enable the use of mass spectrometry as a 
detection method at endogenous EPO levels were split broadly into two approaches. 
Firstly, there were attempts to improve the recovery of EPO from urine and to do so in a 
method amenable to analysis by LC-MS. Secondly, efforts were focused on improving 
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detection in LC-MS; specifically, on improving the signal from sialylated glycopeptides 
from enzymatically digested EPO, and on detecting differences in the glycosylation 
which could enable endogenous EPO and rEPO to be distinguished. 
 
The first method investigated for the extraction of EPO from urine samples was the use 
of antibody activated magnetic beads. At the time, the only WADA approved method for 
the extraction of EPO was the use of repeated ultrafiltration. This required several time 
consuming steps, and resulted in an end product which was viscous, difficult to apply to 
the IEF gels used for analysis, and not suitable for analysis by LC-MS. Experience with 
antibody activated magnetic beads had shown that they could efficiently and rapidly 
bind proteins from biological samples. Their use had been demonstrated previously for 
the extraction of EPO from blood using polyclonal antibodies and tosyl activated beads 
(Skibeli, Nissen-Lie et al. 2001). The use of protein G coated beads to bind monoclonal 
antibodies promised a more efficient and rapid way of producing beads with more 
uniform and reproducible extraction results.  
Initial results were disappointing. Modification of beads with anti-EPO clone AE7A5 
did not result in any binding of EPO from solution, even in buffer. This, it is suspected, 
is because when this antibody is used to bind EPO on an IEF gel, the EPO has 
previously been denatured. However, modification of the beads with anti-EPO clone 
9C21D11 produced beads which rapidly and effectively bound EPO from buffered 
solution. Analysis using mass spectrometry found a mean recovery of approximately 
69% from urine which had been filtered to remove all naturally occurring EPO, then 
spiked at a known concentration. Analysis using IEF and immunoblotting showed that 
although some isoform selectivity may be seen, it would not be enough to confuse 
results.  
 
Unfortunately, attempts to extract EPO from real urine samples did not succeed. 
Extraction of EPO by ultrafiltration following incubation with magnetic beads showed 
that in complete urine samples, the beads failed to bind EPO. Spiking urine samples 
after ultrafiltration and then extracting them showed that the inhibiting substance was 
likely to be a large compound, possibly a protein to which the 9C21D11 clone showed 
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cross-reactivity. Work could be done to try to elucidate what this protein (or proteins) is. 
Elution of the bound protein from the beads, followed by tryptic digest and sequencing 
of proteins by LC-MS/MS could provide an answer. However, this is of limited value, as 
since the work was started, monolithic antibody activated cartridges which bind EPO 
from urine have become commercially available from MAIIA Diagnostics. These are 
easy to use, efficient and bind EPO rapidly from solution. They were initially expensive, 
so that the magnetic bead approach could have been better at least in terms of cost. 
However, their price has now come down to a competitive one. As such, although a 
useful technique for the rapid extraction of proteins from biological fluids, the use of 
immunomagnetic beads to bind EPO from urine does not appear to be a valuable path to 
continue down.  
 
One key aspect of the development of this new tool from MAIIA Diagnostics is the time 
it took them to come to market; the product was in development for several years. 
Although it is not known for sure what aspect of the development process took so long, 
the results presented here demonstrate the necessity and difficulty of finding the right 
antibody, with sufficient affinity, avidity and specificity to effectively bind EPO from a 
complex matrix.  
 
Attempts were also made to produce modified silica with phenylboronic acid 
functionality. This functional group has been shown in the past to reversibly bind 
cis-diol groups, such as are found in saccharides and therefore in glycoproteins. Binding 
and release are pH dependent, which suggested a theoretically simple and efficient way 
of selectively binding glycoproteins and glycopeptides from complex solutions before 
releasing them for analysis. 
 
Again, however, results were not as hoped. None of the silicas produced, by three 
different (published) methods, was successful at binding saccharides, glycopeptides or 
glycoproteins. Replication of two of these methods was problematic, and did not appear 
to result in a functionalised product; the third method, although analysis by FTIR and 
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ICP-MS suggested it resulted in silica modified with phenylboronic acid, still did not 
result in silica capable of binding glycan groups in solution. 
 
It is not entirely clear why these results were obtained. Efforts to contact the authors of 
the original papers were not successful. Similarly, attempts to obtain some of the (self-
produced) silica as was used by the authors failed, and the authors themselves have 
published nothing else utilising the same methods since.  
 
It is also possible that there were problems elsewhere in the methods. To check if non-
specific binding to the microfuge tubes used in the experiments was distorting the 
results, experiments were carried out at different pH transferring a glycoprotein digest 
between multiple tubes, and seeing how the peak heights of different glycopeptides were 
affected. However, at the concentrations involved, only one glycopeptide was 
significantly affected by non-specific binding, and this was excluded from the assay as a 
result. 
 
Measurements of the surface area, and perhaps most importantly, pore size of the silica 
used before and after modification were not carried out. As stated above, analysis by 
ICP-MS of HF digests of the modified silica demonstrated an increase in boron 
concentration, which was also suggested by the FTIR data. However, the location of 
these boronic acid groups is not determined by these methods. Measurement of the pore 
size (and particle size) could potentially show if modification is primarily confined to 
the inside of the pores, which could be out of reach of the large glycopeptides, providing 
an explanation for their failure to bind. However, binding was seen with commercially 
available boronic acid functionalised material, which had much smaller pores than those 
on the unmodified silica, suggesting that steric hindrance should not be a problem. 
 
Modification of polymeric beads resulted in another hard-to-explain phenomenon. The 
beads were shown to bind both mannitol and glycopeptides from solution; however, 
recovery from these beads by adjustment to an acidic pH was unsuccessful, and the 
beads seemed to bind both glycosylated and non-glycosylated peptides. This continued 
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to be the case even after an attempt was made to block the non-specific binding by 
incubation with insulin. 
 
In short, it is not clear why the production and use of boronic acid functionalised 
materials was not successful. There is also the question of the usefulness of the 
technique, when combined with LC-MS. When MALDI is used as the ionisation 
method, the presence of non-glycosylated proteins or peptides significantly suppresses 
ionisation of glycosylated ones. This is also seen when a mixture of glycosylated and 
non-glycosylated compounds is infused into a mass spectrometer via ESI. However, 
although boronic acid functionalised silica, had it behaved as had been hoped, could 
have been useful as a trapping column, the separation of glycosylated and non-
glycosylated compounds can also be carried out by efficient LC; HILIC stationary 
phases in particular are very effective at separating the two types of compound. 
 
Enhancement of MS signal by the introduction of ‘superchargers’ into LC solvents was 
investigated. This was shown to be effective with small molecules, particularly in 
negative ion mode. Although superchargers have generally been shown to increase the 
average charge on large molecules, the results here showed that they could also increase 
(and decrease) the signal from small, singly charged molecules. The results obtained did 
not provide a full picture on what caused this effect. Signal intensity was not directly 
correlated with the effect of superchargers on electrospray droplet surface tension or 
temperature. Further work could look at isolating these factors further, as well as other 
potential influencing factors such as gas phase basicity, to try to elucidate the exact 
method of their effect. Since different superchargers appear to have different effects on 
different analytes, a proper understanding of the mechanism of their action may enable a 
better selection of additives for improved signal strength. 
 
The use of superchargers as an LC additive for the analysis of sialylated glycopeptides 
was also examined. An increase in average charge was seen, and it is probable that this 
is responsible for an increase in the detection of oxonium ions from in-source 
fragmentation of glycopeptides. As a result, the addition of superchargers resulted in 
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improved identification of glycopeptides from a digest of fetuin. The mechanism which 
results in the increase in charging is also yet to be fully identified. A proposed 
mechanism, which involves the partial desorption of large molecules from electrospray 
droplets, could be involved. The validity of this mechanism could be examined 
relatively easily, as it should mean that glycopeptides with more hydrophobic peptide 
portions would be more affected by the presence of superchargers. Isocratic elutions of 
glycopeptides such as those from tryptically digested HRP, which vary in peptide 
sequence but are fairly uniform in glycosylation could provide useful information. 
 
Finally, the cleavage, digestion and derivatisation of N-glycans to identify bisected and 
non-bisected structures as a way to discriminate between rEPO and huEPO was 
examined. Ovine IgG, which has been reported to be mostly bisected, was used as a 
model for huEPO, due to the shortage of analytical standards for the latter glycopeptide. 
Its suitability as a model has yet to be demonstrated. Since the bisecting N-acetyl 
glucosamine (GlcNAc) in huEPO was proposed as a result of data obtained by 
SDS-PAGE analysis of sequential exoglycosidase digestions of huEPO, it would be 
logical to repeat this work with ovine IgG, to demonstrate that it follows the same 
pattern of digestion. 
 
LC-MS analysis of exoglycosidase digests of cleaved N-glycans from ovine IgG and 
rEPO suggested that the presence or absence of a bisecting GlcNAc results in a 
detectable difference. After a short digest period, both digests were found to contain 
glycans containing a fucosylated pentasaccharide core structure, with a single GlcNAc 
residue attached. However, these structures were resolved by LC, suggesting they are 
positional isomers of each other. It is suggested that the glycan predominantly found in 
the IgG digest is that with a bisecting residue. If this is so, and the same is found in 
huEPO, it could provide a way of distinguishing the presence of rEPO in urine. 
 
After a longer digest, the levels of this glycan in rEPO digests became nearly 
undetectable; however, in the IgG digest they remained high, due to the much lower 
activity of the N-acetylglucosaminidase enzyme used in cleaving bisecting residues. In 
 246 
the rEPO digest, nearly all the glycans found had been digested back to the fucosylated 
pentasaccharide core. As such, an alternative method for distinguishing rEPO and 
huEPO could rely on the ratio of the fucosylated pentasaccharide core to the same 
glycan with an extra GlcNAc residue. 
 
CE-LIF analysis of the same digests (though derivatised by a different process), 
however, gave slightly different results. They seemed to suggest that a detectable 
difference, that of the presence or absence of the bisecting GlcNAc, was detectable after 
the longer digest process, but not after the short one. However, these results still need to 
be repeated to check their accuracy and rule out any derivatisation specific effects. Even 
so, although the results from the CE-LIF analysis do not fully tally with those from LC-
MS, they do suggest that a detectable difference can be found, but that optimisation of 
the digest process may be key. 
 
The use of a still shorter digest process found that the presence of a bisecting GlcNAc 
may also enable those glycans with the residue to be distinguished from those without. 
After a 24 hour incubation with exoglycosidases, a fucosylated pentasaccharide core 
glycan with 3 GlcNAc residues attached was detected in digests of IgG, rEPO and 
huEPO standard. The retention time of this glycan in the IgG and huEPO digests 
matched that of the bisected glycan standard, NGA2FB. The retention time of the glycan 
found in the rEPO digest, however, was different. This provides further backing for the 
proposal that huEPO contains a bisecting GlcNAc residue, although it is possible that 
the glycan is found on another glycoprotein also present in the standard.  
 
There is still a significant amount of work to do to fully develop this method. 
Optimisation of the enzyme digest to reduce reaction time is necessary to make the 
method a viable alternative to the current testing process. This is also necessary to 
optimise the extent of digestion, enabling the difference between the glycans of rEPO 
and huEPO to be most easily distinguished. It would be useful to carry out analysis of a 
huEPO digest at different time points, including at time zero, to understand how the 
glycan profiles change through the digestion.  
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It is not yet known what the limit of sensitivity is of the analysis by CE-LIF. This needs 
to be checked, and it would also be useful to analyse samples labelled with rhodamine 
110, not only to check if the data tallies with that obtained by LC-MS, but also to see 
what the limits of detection found with that approach are. 
 
As stated in Chapter 5, the development of a nanoflow LC method, coupled to a 
sensitive mass spectrometer, is needed to provide the sensitivity required to work at the 
concentrations and amounts found in anti-doping samples. If this is achieved, it will also 
be necessary to check that there are no other compounds present in urine which would 
interfere with the results. This would have to be carried out with a large range of normal 
blank urines, ideally from athletes from different disciplines and different ethnic 
backgrounds. It would also have to be carried out with so-called ‘effort’ and ‘active’ 
urines, both of which have proved problematic under the current testing process. The 
experiments presented here would also need to be repeated with other rEPOs, including 
biosimilars, and ideally with NESP and CERA as well to demonstrate that the glycans of 
these drugs can also be distinguished from those of endogenous EPO. 
 
However, despite the volume of work still to be done, at present the results obtained 
suggest that the method may provide an alternative way of detecting the use of rEPO as 
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